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Introduction
HIV Ireland, and the Gay Health Network have been to the forefront of 
Irelands response to HIV over the past 30 years. The importance of our 
work, past and present, cannot be underestimated, especially now with 
new HIV diagnoses in Ireland increasing to their highest level on record. 
Since 2011, Ireland has experienced a 35% increase in new HIV diagnoses. 
In 2017, there are on average 10 new HIV diagnoses every week.
Against this backdrop, HIV Ireland and the Gay Health Network play 
a key role in supporting people who live with HIV, and crucially, an 
increasingly important role in HIV prevention. We believe this policy 
options paper will play a key part in the widening conversation around 
HIV prevention, and the crucial role PrEP can play in reducing new HIV 
infections.
We would like to sincerely thank Dr. Ann Nolan for producing this 
important document. We would equally like to thank all participants in 
the research who gave of their time and expertise. The richness of the 
document reflects the breadth of knowledge and expertise that exists 
within Ireland when it comes to HIV and sexual health.
HIV is a highly stigmatised, chronic illness. The impact it can have on 
a person’s health and wellbeing is profound. We believe that PrEP can 
significantly contribute to negating that potential reality for many people 
in the future. 
To quote Dr. Nolan, ‘PrEP promises to be one of the most important 
innovations in the global response to HIV, and Ireland's escalating 
epidemic suggests that we cannot afford to be left behind.’ 
We wholeheartedly endorse that view.
Niall Mulligan
Executive Director
HIV Ireland
15th June 2017 – Irish AIDS Day
Noel Sutton
Chairperson
Gay Health Network
Executive Summary
This policy options review and evidence-scoping of Pre-Exposure 
Prophylaxis (PrEP) for HIV prevention has been commissioned by HIV Ireland 
Ltd (HIVI) and the Gay Health Network (GHN). The primary aim of this paper 
is to provide evidence-based guidance on PrEP efficacy, while establishing 
the views of key populations affected by HIV, and stakeholders directly and 
indirectly involved in the provision of HIV services throughout Ireland.
This study relies significantly on existing evidence for PrEP particularly 
reviews conducted by the World Health Organisation (WHO), the 
National Institutes for Health and Care Excellence (NICE), the National 
Health Service (Wales), the United States Centre for Disease Control 
and Prevention (CDC), and the British HIV Association (BHIVA) to reach 
conclusions about policy options for PrEP in Ireland. 
PrEP is a biomedical HIV prevention strategy meaning that it uses 
antiretroviral drugs to protect HIV-negative people from HIV infection. In 
August 2016, the European Commission  granted marketing authorisation 
for once-daily Truvada® (emtricitabine 200 mg/tenofovir disoproxil 245 
mg; FTC/TDF) in combination with safer-sex practices to reduce the risk 
of sexually acquired HIV-1 infection among uninfected adults at high risk, 
which means that once-daily Truvada® is licensed for PrEP in Ireland.
The Evidence-base for PrEP Efficacy
The World Health Organisation’s (WHO) Consolidated guidelines on the 
use of antiretroviral drugs for treating and preventing HIV infection, 
Recommendations for a public health approach - Second edition (2016) 
recommends that oral PrEP should be offered as an additional prevention 
choice for people at substantial risk of HIV. WHO’s systematic review 
and meta-analysis of PrEP trials demonstrated that PrEP is effective in 
reducing the risk of acquiring HIV infection. It was found that the level of 
protection did not differ by age, sex, regimen (TDF versus FTC + TDF) or 
mode of acquiring HIV (rectal, penile or vaginal exposure) but detectable 
drug levels in the blood are strongly correlated with the prophylactic 
effect, emphasising the importance of adherence to PrEP.
The sources upon which this study relies - WHO; European Centre 
for Disease Prevention and Control (ECDC); the European AIDS Clinical 
Society; British HIV Association (BHIVA); the National Institute for Health 
and Care Excellence (NICE); the United States Centre for Disease Control 
(CDC); the Scottish HIV Pre-Exposure Prophylaxis Short Life Working 
Group and the National Health Service (NHS) Wales - conclude that the 
quality of the evidence base for PrEP efficacy is robust.[1]. Trials with 
potentially transferable findings include:
1.  WHO, Consolidated Guidelines, 2016; Nandwani R and Valiotis G, on behalf of the Scottish HIV Pre-Exposure 
Prophylaxis Short Life Working Group. PrEP in Scotland. Scottish Health Protection Network (SHPN) October 2016; 
NICE, Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil), 2016; 
BHIVA–BASHH Position Statement on PrEP in the UK: Update 2016; Center for Disease Control, US Public Health 
Service, Pre-exposure Prophylaxis for the Prevention of HIV Infection in the United States, 2014; ECDC GUIDANCE HIV 
and STI prevention among men who have sex with men, 2015; Jones, A., Couzins, Z., Preparing for PrEP? – A Review 
of the Current Evidence for Pre-exposure Prophylaxis (PrEP) to prevent HIV infection in Wales, NHS Wales, 2017; 
European AIDS Clinical Society.
1. The iPrEx study was a double-blind RCT evaluating once-daily 
Truvada® or placebo in 2,499 HIV-negative men or transgender 
women who have sex with men with evidence of high-risk behaviour 
for HIV infection. Once daily Truvada® reduced the relative risk of 
acquiring HIV infection by 44% compared with placebo;
2. The Partners PrEP study was a double-blind RCT evaluating once-
daily single agent tenofovir disoproxil or Truvada® or placebo in 4,747 
HIV-negative individuals in a heterosexual partnership with a person 
already infected with HIV in Kenya and Uganda. Once-daily Truvada® 
reduced the relative risk of acquiring HIV infection by 75% compared 
with placebo;
3. The PROUD study was an open-label trial of once-daily Truvada® in 
544 HIV-negative men or transgender women who have sex with men 
in England. Participants were randomised to start PrEP with Truvada 
immediately on study entry or after a deferral period. Once-daily 
Truvada reduced the relative risk of acquiring HIV infection by 86% 
compared with no prophylaxis;
4. The IPERGAY study was a double-blind RCT evaluating Truvada® or 
placebo taken ‘on demand’ before and after sexual activity in 414 
high-risk MSM in France and Canada. Participants took a median of 
15 tablets per month and reduced the relative risk of acquiring HIV 
infection by 86% compared with placebo.
The Bangkok Tenofovir Study is the only large-scale study conducted with 
people who inject drugs (PWID). Over 2, 400 PWID were enrolled and with 
optimal adherence a 70% reduction in HIV incidence was reported but 
in general, this RCT reported a 48.9% reduction in HIV using once daily 
Tenofovir disoproxil fumarate (TDF) without Emtricitabine (FTC) among 
PWID. The policy context for this study differs significantly from the Irish 
context and as such, the high levels of adherence may not be relied upon.
While these population trials provide generally unbiased indicators 
of the effect of PrEP on HIV incidence rates, they do not provide 
insight into the effectiveness of PrEP in real-world clinical care settings. 
Implementation research is needed in diverse settings not least in terms 
of supporting adherence and the capacity of already over-stretched 
health systems to respond effectively to increased demand. It is also 
largely unknown how PrEP may affect behavioural and social outcomes in 
the medium to long term. The RCTs described here noted few changes in 
terms of sexual behaviours but trials provide a high level of psycho-social 
support that may not be replicated in real-world settings. 
The cost-effectiveness of PrEP is frequently cited as a key barrier to 
PrEP implementation and Gilead Science’s application for a Supplementary 
Protection Certificate for once-daily Truvada® is a significant threat to 
taking PrEP to scale in Europe. Cost effectiveness analysis appears to 
be particularly sensitive to key variables such as HIV incidence, levels of 
adherence, demand for PrEP, risk behaviours, the cost of drugs and other 
clinical interventions required to support PrEP programmes: as such cost-
effectiveness studies conducted in other jurisdictions are of limited value 
to the Irish context. While France is the only country in Europe currently 
providing PrEP through the public health service, a number of countries 
are implementing or planning to implement PrEP demonstration projects.
National and International PrEP Policy Context
The national and international policy architecture for PrEP is well 
established. The transnational dimensions of health are facilitated through 
governance structures which foregrounds global and local connectivity. 
Ireland emphasises an all-of-government approach with policy coherence 
prioritised between the Health Service Executive and Irish Aid’s global 
health and HIV partnership portfolio, illustrating the extent to which 
health policy is increasingly perceived to be international in scope. 
PrEP is already governed – directly and indirectly - by international 
policy instruments that have been ratified by Ireland. The most recent 
of these, the 2016 United Nations Political Declaration on HIV and AIDS: 
On the Fast-Track to Accelerate the Fight against HIV and to End the 
AIDS Epidemic by 2030, was adopted at the United Nations General 
Assembly High-Level Meeting on AIDS in June 2016, and includes explicit 
commitment to the adoption of evidence-based prevention measures 
including PrEP. Furthermore, UNAIDS is a key partner in Ireland’s Global 
Health and HIV Portfolio to which overseas development assistance 
commits €2.7 million per annum.[2] To fast track actions to achieve 
2020 targets, the new Action plan for the health sector response to 
HIV in the WHO European Region 2017-2022 emphasises the need for 
member states to optimise prevention efforts through the prioritisation 
of evidence-based HIV prevention urging a particular focus on key 
populations, ‘with inclusion of novel approaches such as pre-exposure 
prophylaxis (PrEP) for populations at substantial risk of HIV acquisition’[3] 
Also of continuing relevance, the Dublin Declaration, 2004 commits 
member states in Europe and Central Asia to act collectively in tackling 
the HIV/AIDS epidemic, setting out a number of actions to accelerate 
the achievement of this commitment. The most recent special report 
under the Dublin Declaration 2016 particularly emphasised the need to 
reduce HIV infections in Europe using a range of prevention interventions 
including PrEP. Finally, at national level, policy provision for PrEP is 
contained in the National Sexual Health Strategy 2015-2020 which urges 
the implementation of guidelines for the appropriate use of antiretroviral 
therapy in HIV prevention.
2. 2015 budget allocation
3. WHO Europe, Action plan for the health sector response to HIV in the WHO European Region, 2017-2022, Geneva
An Overview of Findings and Recommendations
Following careful consideration of the evidence-base for PrEP, this study 
conducted a wide range of key informant interviews with stakeholders in 
Ireland including civil society activists, policy makers, health care providers 
and researchers, pharmaco-economists, international development 
specialists, with two focus group discussions (FGD) undertaken with MSM 
and people living with HIV. Given the paucity of data available on the 
potential or rationale for introducing PrEP in Ireland, opportunities to 
verify or triangulate information were limited. In order to present a clearer 
picture of the Irish-specific landscape, data from this research was collated 
with pre-existing Irish-specific grey literature and academic sources, 
with outlier issues and/or data corresponding to ToR requirements 
not previously considered. The primary findings and recommendations 
resulting from this process are presented here in summary:
1. Policy options for the introduction of PrEP into Ireland as indicated 
by the evidence base governing PrEP efficacy; the global, regional 
and national policy context; the high risk profile of most at-risk 
populations; the epidemiology of HIV in Ireland, which reflects 
broader European trends; the views of health care providers and 
key stakeholders working directly and indirectly in HIV, and the views 
of potential end users, point to one option: This review identified 
overwhelming support for the introduction of PrEP for populations at 
substantial risk of HIV in Ireland as part of a comprehensive package 
of HIV prevention interventions.
2. An albeit limited level of self-administered PrEP use among MSM 
appears evident in Ireland, but which nonetheless requires urgent 
intervention by statutory services in collaboration with civil society 
who may be well placed to provide immediate information, education 
and guidance for PrEP users. It is recommended as a first step, 
that the safety concerns posed by the online purchase and self-
administration of PrEP in Ireland must immediately prompt the 
funding and establishment, within existing specialist sexual health 
clinics, of information, advice and clinical monitoring services until 
such time as PrEP is made available through the HSE. 
3. The evidence base, while currently dependent on RCTs and a 
small number of implementation studies, which are increasing in 
number, clearly demonstrates PrEP efficacy particularly for MSM 
and transsexual women. Notwithstanding the absence of context-
transferable evidence for key populations other than MSM and trans 
women, the World Health Organisation recommends that oral PrEP 
should be offered as an additional prevention choice for all people 
at substantial risk of HIV as part of a combination of prevention 
approaches, which is widely supported by contributors to this review, 
while recognising that the primary beneficiaries of potential PrEP 
introduction are likely to be MSM in practice.
4. PrEP in practice is marked by a number of unknowns with regard 
to adherence levels, the potential for risk compensation, and of 
particular concern to health care providers interviewed in this study, 
the capacity of an already over-stretched sexual health service to 
absorb a cohort of HIV-negative clients. Implementation research is 
needed in diverse settings not least in terms of supporting adherence 
and the capacity of already over-stretched health systems to 
respond effectively to increased demand. It is also largely unknown 
how PrEP may affect behavioural and social outcomes in the medium 
to long term. The vast majority of contributors to this review favoured 
an implementation or demonstration study as a first step not least 
because the budget impact may be contained, any unintended 
consequences more easily offset and issues resolved before PrEP is 
taken to scale. Concerns about the cost of PrEP were frequently cited 
as a perceived barrier to PrEP implementation: this is a Europe-wide 
concern, not just an Irish one. Clinical interventions are not cost-
neutral and the actual cost of once-daily Truvada® for PrEP is likely 
to impact significantly on the budget for HIV and sexual health. An 
implementation trial would facilitate cost-containment until such time 
as generic substitutions are licensed for PrEP in Europe. As a first 
step, it is recommended that GHN and HIVI support the introduction 
of an implementation study, which may be more easily and speedily 
sanctioned, until such time as PrEP may be taken to scale.
5. The cost-effectiveness of PrEP appears to be particularly sensitive to 
key variables such as HIV incidence, levels of adherence, willingness 
to use PrEP, risk behaviours, the cost of drugs and other clinical 
interventions required to support PrEP programmes: as such cost-
effectiveness studies conducted in other jurisdictions are of limited 
value to the Irish context. The potential cost of PrEP is perceived 
to be a barrier to implementation in Ireland. In the medium to long 
term, there is a role for advocacy in challenging the HSE to explore 
the cost-saving potential of generic substitution of ARVs which 
have been found to be acceptable to patients and HIV health care 
providers, while Return on Investment analysis should be considered 
in conjunction with budget impact and cost effectiveness analysis 
which may prove to be a more propitious cost benefit benchmark for 
PrEP implementation in Ireland.
6. Coupled with concerns about the cost of PrEP and the capacity of 
the health system to respond to the clinical requirements of PrEP 
introduction, some participants raised questions as to whether PrEP 
should be made available to non-Irish citizens. This is problematic in 
public health terms given that at least 55% of HIV cases diagnosed 
in Ireland originate from other countries. [4] Additionally, 35% 
(n=94) of people testing HIV+ in Ireland in 2015 were born in sub-
Saharan Africa, and over half (53%) of female cases were born in 
sub-Saharan Africa. To fail to provide PrEP to non-Irish citizens 
4. Geographic origin is unknown in 15% of cases (HPSC, 2015, p.12-13)
may potentially offset any HIV prevention gains and institute non-
coherence between Ireland’s national and international health policy 
commitments. It is recommended that policy advocacy must ensure 
that PrEP implementation does not operate eligibility on the basis of 
citizenship but works to ensure inclusiveness on public health terms 
and in the interests of a ‘whole-of-government’ approach. 
7. Europe’s Action plan for the health sector response to HIV in the WHO 
European Region, 2017-2022 urges member states to “collect and 
analyse timely and high-quality epidemiological data to understand 
how, where and among whom new HIV infections are occurring, 
develop HIV estimates, monitor risk behaviours and estimate the size 
of key populations in need of services.”[5] Ireland’s failure to prioritise 
and invest in the collection of epidemiological data is a significant 
risk to cost-effectiveness, budget impact and service planning 
estimates for PrEP and other interventions, while also precluding 
full engagement and reporting against high profile international 
commitments, including 90-90-90 targets. A number of participants 
in this study raised the need for increased behavioural surveillance 
investment to help identify and better off-set risk by early 
intervention. There is a role for civil society to champion improved 
surveillance systems in Ireland so that new technologies (like PrEP) are 
supported by robust epidemiological data and evidence.
8. Civil society advocacy is central to the realisation of particularly 
contested policy issues, and plays a key role in holding government 
and statutory service providers to account. While advocates for 
PrEP implementation are an important part of the process, Ireland’s 
relatively conservative political culture points to a generally cautious 
approach to policy change for sexual health. Views were divided on 
the best approach to policy advocacy for PrEP but it is suggested 
that advocacy platforms for PrEP might be best served by campaigns 
targeting key policy makers, while mobilising political champions to 
engage stakeholders in dialogue to help remove some of the barriers 
to PrEP implementation. Civil society representatives need to be 
prepared for media interest in PrEP with a factually based public 
health narrative that is devoid of emotive arguments and rests on 
sound science. 
9. Finally, it is a flawed rationale that renders the statutory services ever 
the subject of complaint when private interests like Gilead Science Inc 
are the primary reason why PrEP affordability and cost effectiveness 
is questionable. Gilead’s application for an SPC for Truvada® is the 
single most significant threat to taking PrEP to scale in Europe not just 
in Ireland and this issue requires strong civil society engagement.
5. WHO Europe, 2016, p.8
Conclusion
A combination of the evidence for PrEP efficacy coupled with the 
risk profile of key populations in Ireland, increasing incidence of HIV 
reflecting broader European trends, PrEP’s policy coherence with 
Ireland’s international policy position, and a high level of support for 
PrEP implementation among key stakeholders and potential end-users, 
points to the need for immediate steps to be taken to make PrEP 
available to key populations at substantial risk of HIV acquisition as part 
of a comprehensive package of HIV prevention measures. At an absolute 
minimum, the failure to provide HIV testing and clinical monitoring to MSM 
who are self-purchasing and administering PrEP is a risk to the individual 
and broader public health. While multidrug resistance levels are generally 
low, the risks are increased if people with an undiagnosed HIV infection 
are acquiring PrEP online. The global, regional and national policy context 
actively advocates PrEP implementation and the requirements to prioritise 
HIV prevention in member states of the European Union where sexually 
acquired HIV incidence rates are raising exponentially must render PrEP a 
policy priority in Ireland. 
Limitations of the Review
This policy options review and evidence-scoping of PrEP for HIV 
prevention was time-limited with parameters and scope clearly 
determined by the Terms of Reference. It relies significantly on existing 
evidence for PrEP particularly reviews conducted by a range of multilateral, 
national and international institutes for health to reach conclusions about 
policy options for PrEP in Ireland. Much of the information synthesised 
and presented in this paper was provided by those with direct or indirect 
involvement in HIV and sexual health in Ireland and is consequently not 
free of bias. The reviewer has endeavoured to critique key informant 
responses where possible but the paucity of grey or academic sources 
relating to PrEP in Ireland limited the robustness of this exercise. The 
limitations imposed by time and the breadth of ToR requirements; the 
paucity of the Irish-specific evidence base; the poor participation of 
stakeholders from outside Dublin and stakeholder bias necessitates some 
generalised findings. As such, the findings and conclusions presented 
herein must be interpreted with caution.
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This policy options review of Pre-Exposure Prophylaxis (PrEP) for HIV 
prevention has been commissioned by HIV Ireland Ltd (HIVI) and the Gay 
Health Network (GHN). It provides a time-limited scoping of the evidence 
base underscoring PrEP efficacy while examining the Irish context, and real 
and perceived barriers to PrEP implementation. The primary aim of this 
policy options review is to provide evidence-based guidance to both HIVI 
and the GHN while establishing the views of key populations affected by 
HIV, and stakeholders directly and indirectly involved in the provision of 
HIV services throughout Ireland, to enable informed policy dialogue and an 
advocacy platform for PrEP.
The author wishes to emphasise that this paper is not a comprehensive 
review of the evidence for PrEP and should not be read as such. 
Systematic reviews of the evidence base have been effectively undertaken 
by better resourced multilateral and national institutions for health in 
other jurisdictions. This study draws on existing evidence for PrEP, relying 
in part on reviews conducted by the World Health Organisation (WHO), 
the National Institutes for Health and Care Excellence (NICE), the National 
Health Service (Wales), the United States Centre for Disease Control 
and Prevention (CDC), and the British HIV Association (BHIVA) to reach 
conclusions about policy options for PrEP in Ireland. There is no scope 
to revisit or critique that evidence base here other than as background 
against which PrEP efficacy may support and provide reference for the 
primary data collected through key informant interviews with stakeholders 
throughout Ireland.
PrEP is a biomedical HIV prevention strategy meaning that it uses 
antiretroviral drugs to protect HIV-negative people from HIV infection. 
Antiretrovirals (ARVs) are currently used in multiple ways to prevent the 
transmission of HIV in Ireland and internationally: 
1. from mother-to-child during pregnancy and childbirth (prevention of 
mother-to-child transmission, PMTCT); 
2. post-exposure to HIV by a person who is HIV-negative (Post-exposure 
Prophylaxis, PEP); and 
3. in the treatment of HIV-positive people, ARVs suppress the viral 
load to decrease the risk of onward transmission of the virus. This is 
known as Treatment-as-Prevention (TasP).
PrEP represents an additional intervention for use of ARVs in 
the prevention of new HIV infections in Ireland, though this is not 
without some challenges in terms of feasibility, cost and its place in 
the competition for health priorities. In August 2016, the European 
Commission  granted marketing authorisation for once-daily 
Truvada®(emtricitabine 200 mg/tenofovir disoproxil 245 mg; FTC/TDF) 
in combination with safer-sex practices to reduce the risk of sexually 
acquired HIV-1 infection among uninfected adults at high risk, which 
means that once-daily Truvada® is licensed for PrEP in Ireland. However, 
while PrEP is currently available to buy on prescription from the pharmacy 
0
3
-
0
4
in St. James’s Hospital, Dublin, it is not available through the Health 
Service Executive. This policy options review, involving a scoping[6] of 
the evidence base supported by key informant (KI) interviews with a wide 
range of stakeholders, will provide evidence-based guidance to both HIV 
Ireland Ltd and the Gay Health Network in accordance with the Terms of 
Reference (see Appendix A) on the potential of PrEP to enhance current 
HIV prevention efforts and inform advocacy and policy dialogue in Ireland.
1.1 A Global, Regional & National Overview of HIV: Incidence and 
Prevalence in Ireland
In 2015 there were 2.1 million new HIV infections worldwide, and while 
AIDS-related deaths have declined in almost all regions of the world 
between 2010 and 2015, the number of newly acquired HIV infections 
has barely declined or remained static during the same period.[7] UNAIDS 
reports that key populations at increased risk of HIV infection include 
gay men and other men who have sex with men (MSM), sex workers, 
people who inject drugs (PWID), transgender people, and prisoners. 
Analysis of data available to UNAIDS suggests that more than 90% of new 
HIV infections in central Asia, Europe, North America, the Middle East 
and North Africa in 2014 were among people from key populations and 
their sexual partners[8]. Notwithstanding continuing prevention efforts, 
there has been only a minimal decline in the number of HIV diagnoses 
per 100,000 population over the last decade in the EU/EEA area, with a 
rate of 6.6 per 100,000 in 2006 (29,156 cases) compared with 6.3 per 
100,000 (32,483 cases) in 2015[9]. In the 31 countries of the EU/EEA, the 
highest proportion of HIV diagnoses was reported to be in MSM (42%) in 
2015, with heterosexual contact the second most common transmission 
mode (32%). Transmission arising from injecting drug use accounted for 
4% of HIV diagnoses[10]. The European Centre for Disease Prevention and 
Control (ECDC) and the WHO Regional Office for Europe report that one 
third (37%) of the total number of people diagnosed were not born in the 
reporting country. 
The epidemic in Ireland reflects both global and regional trends 
reporting relatively stable rates of HIV diagnoses between 2010 and 
2014 with a notable increase of 30% between 2014 and 2015[11]. In 
2015, there were 485 cases of HIV notified in Ireland - a rate of 10.6 per 
100,000 population compared to an EU/EEA average incidence rate of 
6.3 per 100,000 - which the Health Protection Surveillance Centre (HPSC) 
reports is ‘the highest rate ever reported in Ireland’[12]. While epidemic 
patterns and trends vary significantly across European countries, sustained 
increases in the number of infections among MSM are particularly 
6.  Defined as an exercise which due to time and resource limitations aims to rapidly map the key concepts underpinning 
a research area and the main sources and types of evidence available – see Mays, N., Roberts, E., & Popay, J. (2001). 
Synthesising research evidence. In N. Fulop, P. Allen, A. Clarke, & N. Black (Eds.), Studying the organisation and 
delivery of health services: Research methods (pp. 188-219). London: Routledge
7. UNAIDS, Global AIDS Update, 2016: Geneva, Switzerland, p. 2-3
8. Ibid, p.8-9
9. Ibid, p.X
10.  European Centre for Disease Prevention and Control/ WHO Regional Office for Europe. HIV/AIDS surveillance in 
Europe 2015. Stockholm: ECDC; 2016.
11. Health Protection Surveillance Centre (HPSC), HIV in Ireland - 2015 Report: Dublin, Ireland, 5th October 2016
12. Ibid, p. 4
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noteworthy. Ireland is one of only 15 countries in the region where sex 
between men constituted over 50% of new HIV diagnoses in 2015[13] 
and one of only 4 countries - Bulgaria, Cyprus, Malta – where substantial 
increases in MSM transmission is noted between the period 2005-2015.[14] 
Sex between men and women is the second most commonly reported 
mode of transmission in the EU/EEA region, accounting for 32% (9,545) of 
HIV diagnoses and 27% (130) of cases notified in Ireland. More than one-
third (37%; 2,494) of heterosexually acquired HIV in the EU/EEA originate 
from countries with generalised epidemics. The highest proportions of 
these were observed in Germany (60%), France (49%) and Ireland (58%) in 
2015. The HPSC reports that in excess of one third (34%) of MSM diagnosed 
with HIV in Ireland were born in Latin America, 33% in Ireland and 17% in 
Europe, while at least 55% of cases originate from other countries.[15]
Transmission through injecting drug use has decreased in many countries 
in East Europe. However, in 2015 injecting drug use accounted for one 
third of new diagnoses reported with more than half of those new cases 
diagnosed in Russia. Ireland experienced an 81% increase in the number of 
people who inject drugs (PWID) testing positive for HIV in 2015 compared 
to 2014. The HPSC reports that this increase was due to an outbreak of 
recently acquired HIV infection among PWID living in Dublin in 2014/2015, 
primarily among homeless chaotic polydrug users, many of whom were 
injecting snow blow, a synthetic cathinone or short-acting stimulant[16]. 
Patterns of needle and syringe re-use and having a sexual partner who was 
also injecting drugs were also risk factors within this group.
The ECDC and WHO Regional Office for Europe point to an alarmingly 
high number – 48% - of late diagnoses in the European Region which 
contributes to ill-health, early death and increases the risk of onward HIV 
transmission. Again Ireland broadly reflects this trend with 45% of all HIV 
diagnoses presenting late in 2015. The HPSC emphasise, however, that the 
proportion of people who presented late was much lower (31%) among 
those who had a previous HIV diagnosis abroad compared to those who 
did not self-report a previous diagnosis abroad (52%)[17]. Demographic 
data points to a 3:2 male to female ratio with 76% of all HIV cases notified 
in Ireland in 2015 male and 24% female with a median age at diagnosis of 
34 years, broadly reflecting EU/EEA age and gender characteristics. Eight 
per cent of diagnoses notified in Ireland were young people between the 
ages of 15 and 24 years, while 9.3% were over 50 years when diagnosed. 
The HPSC collates data on newly diagnosed cases of HIV and AIDS in 
Ireland annually but a study of the demographics and clinical status of 
all people living with HIV infection in Ireland has not been undertaken. 
This data is available in other jurisdictions: for example, the HIV and AIDS 
Reporting System (HARS) in the United Kingdom (UK) is a consultation 
based, disaggregate dataset which is submitted on a quarterly basis, 
13.  European Centre for Disease Prevention and Control/ WHO Regional Office for Europe. HIV/AIDS surveillance in 
Europe 2015. Stockholm: ECDC; 2016, p.1
14. Ibid, p.3
15. Geographic origin is unknown in 15% of cases (HPSC, 2015, p.12-13)
16. Health Protection Surveillance Centre (HPSC), HIV in Ireland - 2015 Report: Dublin, Ireland, 5th October 2016, p28
17. Ibid, p.18
0
5
-
0
6
and reported by all outpatient HIV service providers. The HARS dataset 
conducts an annual survey of HIV prevalence which serves to support 
commissioning services and enhance surveillance outputs.[18] Using 
data from six adult hospitals caring for HIV positive patients in Ireland, 
Tuite et al retrospectively identified the number of patients accessing 
specialist care for HIV over a 12-month period from July 2009 to June 
2010 to estimate diagnosed prevalence rates for people living with 
HIV in Ireland by region.[19] Using data from the 2011 Census for ages 
15-59 (international age-range requirement) the authors estimated 
that Ireland’s HIV prevalence rate is 1.09/1000 for 15-59 year olds with 
prevalence estimated at 2.25/1000 in the Dublin region.[20] The relatively 
high prevalence estimate in the Dublin region prompted the authors 
to conclude that routine opt out testing for HIV in healthcare settings 
should be considered, a finding that is supported by a follow on study in 
an Emergency Department in Dublin in which an opt-out blood borne 
virus screening programme was piloted over a 10-month period in 2015 
resulting in 7 new late HIV diagnoses not all of whom were representative 
of high risk key populations[21].
1.2 Scope of the Policy Options Review of Pre-Exposure Prophylaxis (PrEP)
The scope of this time-limited policy options review of PrEP commenced 
with an initial scoping of the evidence base within parameters that were 
defined by HIV Ireland and the Gay Health Network: these included the pros 
and cons underscoring PrEP as a biomedical HIV prevention intervention; 
real and perceived barriers to PrEP implementation, and an assessment 
of PrEP efficacy in terms of key populations.  The paucity of data available 
on the Irish context was a limiting factor in Phase 1, Desk Review/ Scoping 
of Academic and Grey Literature Sources and this gap was somewhat 
addressed by Phase 2, key informant (KI) interviews which were conducted 
with a wide range of stakeholders. The primary aim of this project is to 
provide evidence-based policy guidance to both HIV Ireland Ltd and the 
Gay Health Network in accordance with the Terms of Reference (see 
Appendix A) and inform advocacy and policy dialogue.
The combined assessment requirements are grouped under three 
headings, presented in Figure 1.2:
18.  Public Health England, HIV Surveillance Systems, https://www.gov.uk/guidance/hiv-surveillance-systems [accessed 
30th March 2017]
19.  Helen Tuite, M Horgan, PWG Mallon, SJ McConkey, Busi Mooka, Fiona Mulcahy, Cathal Walsh, A O’Hora, Darina 
O’Flanagan, Colm Bergin, Catherine Fleming, Patients accessing ambulatory care for HIV-infection: epidemiology and 
prevalence assessment - Irish Medical Journal, Volume 108, Number 7, July/August 2015
20. Ibid
21.  O’Connell S, Lillis D, Cotter A, O’Dea S, Tuite H, Fleming C, et al. (2016) Opt-Out Panel Testing for HIV, Hepatitis B 
and Hepatitis C in an Urban Emergency Department: A Pilot Study. PLoS ONE 11(3): e0150546. doi:10.1371/journal.
pone.0150546
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Figure 1.2: Scope of the Policy Options Review 
 
 
Assessment of Criteria and review 
questions
Source of Evidence 
Pros & cons of PrEP/
experiences in other 
jurisdictions
PrEP efficacy as 
established  
by clinical trials
Desk review/scoping 
exercise
Implementation research 
in other jurisdictions
Desk review/Interviews
Real and perceived 
barriers to PrEP 
implementation
Desk review/Interviews
PrEP in an Irish context Policy, feasibility, cost 
effectiveness
Interviews with limited 
document review
Prevalence of high 
risk behaviours & 
perspectives of  
potential end-users  
(key populations)
Interviews/FGDs[22]
Policy/advocacy 
guidance
Effective advocacy for 
PrEP implementation in 
Ireland
Interviews
Transnational dimensions 
of policy transfer for 
PrEP
Document review
Ability to influence Document review / 
interview
[22]
22.  Focus Group Discussion
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2. Methodology
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three phases: Phase 1 - document review & scoping the evidence base; 
Phase 2 - schedule of interviews, and Phase 3 - data analysis and report 
production.
2.1 Phase 1: Desk Review[23]
This review applied qualitative research methods in the social sciences.[24] 
The development of the research instrument was primarily informed by 
the core aims defining the review as indicated by HIVI and the GHN in 
Appendix A. Phase 1 commenced with a scoping of the evidence base for 
PrEP to which 8 contract days were initially allocated and to a wide range 
of grey literature sources provided by HIVI and the GHN. While parameters 
for inclusion were quite wide, the sheer breadth of the evidence base 
and the project time limitation prompted a more focused and narrowed 
search which included articles and documents published from 2015 only. 
The initial stages of Phase 1 aimed to fulfil the requirements of the ToR by 
assessing recurring themes in the literature in order to focus the document 
search and identity key issues for inclusion in key informant interviews: 
WHO’s Consolidated guidelines on the use of antiretroviral drugs for 
treating and preventing HIV infection, Recommendations for a public health 
approach - Second edition (2016) served to direct the initial thematic 
scoping in conjunction with parameters defined by HIVI and the GHN. 
Databases and HIV/AIDS-specific journals included in Phase 1: 
document review and scoping of the evidence base, were: PubMed; 
Science Direct; Cochrane Database; British Medical Journal (BMJ); the 
Lancet; Journal of the International Association of Providers in AIDS 
Care; Journal of the International Association of Physicians in AIDS Care; 
International Journal of STD and AIDS; Journal of AIDS Policy and Law, 
and the Journal of Addiction. A document review synthesis collapsed 
all data gathered in Phase 1 against the requirements of the ToR under 
four primary thematic headings as dictated by desk review findings (see 
Appendix B). These were public health effectiveness of PrEP; adherence to 
PrEP; feasibility of PrEP; risk compensation/disinhibition arising as a result 
of PrEP, and the cost effectiveness of PrEP. 
The questions posed by the ToR and the primary themes arising from 
the desk review informed the development of the research instrument 
developed to gather data on the Irish context, which was the primary  
data gap evident from the literature review. 
23.  The complete desk review matrix is an extremely large document – too unwieldy to include in Appendices – but is 
available on request from the author.
24.  Bryman, A., Social Research Methods: 4th Edition. 2012, Oxford: Oxford University Press; Creswell, J.W., Qualitative 
Inquiry and Research Design: Choosing Among Five Traditions. 1998, Thousand Oaks, CA: Sage; Rubin, H.J., Rubin, 
I.S., Qualitative Interviewing: The Art of Hearing Data. Second Edition. 2005, Thousand Oaks, CA: Sage Publications; 
Gomm, R., Social research methodology: a critical introduction, (2008) Palgrave Macmillan 2nd Edition
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2.2 Phase 2: Interviews with key informants and stakeholders
The desk review phase was followed by 17 semi-structured key-informant 
interviews; two focus group discussions (FGDs) and a number of email 
submissions (see Appendix C). Thirty-two invitations to interview were 
issued, with 17 accepted resulting in a response rate of 53%. The 
remaining 47% were either unavailable for interview or did not respond 
to the initial invitation to interview or follow-up. Email submissions were 
received by four informants or in response to follow-up queries. Key 
stakeholders were either centrally or peripherally involved in the clinical 
or psychosocial support of people living with HIV in Ireland or involved in 
the PrEP debate in other jurisdictions. The sample included health care 
providers, pharmaco-economists, health researchers, epidemiologists, 
pharmacists, civil society activists, and international actors. The first FGD 
included 11 MSM who were potential end-users of PrEP and the second 
FGD was held with 6 people living with HIV including women from sub-
Saharan Africa and MSM. The research methodology employs a generic 
purposive participant sample but snowball sampling - a method in which 
selected participants propose other key informants – provided five 
additional key informants to the review, not all of whom were available 
to participate when invited to do so. The timeframe identified for 
completion of the review process – 20 days – necessitated review by 
both synchronous and asynchronous methods. Six key stakeholders, 
some of whom are not resident in Ireland, were interviewed by telephone 
(asynchronous of place), while the remaining were interviewed by face-
to-face (synchronous) methods. E-mail contact to verify data or clarify 
issues arising in FGD was also employed. The interview schedules while 
encompassing the measures indicated by the ToR and reflecting the 
5 themes arising from scoping the literature and document review, 
were adapted to reflect the various specialisations of KIs, and in some 
instances, focused specifically on one or two areas of expertise. 
2.3 Phase 3: Analysis of evidence and recommendations
This final phase aggregated data from various sources in an assessment 
matrix to support triangulation and analyses of all information and data 
collected. This report will present the findings in Chapter 4 in accordance 
with the criteria specified by the ToR, while reflecting themes arising in 
interview. The final chapter will combine the evidence base presented 
in Chapter 3 with Irish context data presented in Chapter 4 to arrive 
at clear recommendations for PrEP advocacy and policy dialogue. The 
final chapter will further outline a global, regional and national policy 
framework for PrEP.
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W 2.4 Limitations of the Review
This policy options review was capacity (one person) and time-limited 
to 20 days with a 5-day extension authorised at write-up to facilitate 
inclusion of all data collected by the process. The capacity of the 
researcher to follow-up with key stakeholders and incorporate the 
enormous volume of additional data submitted throughout the process 
for inclusion in analysis is also limited and as such all data presented here 
must be interpreted in that context. 
As PrEP, while licensed, is currently not available via the health 
system in Ireland, interviews focusing on the Irish context were primarily 
theoretical as there is no hard evidence upon which claims about PrEP 
may be made. As such, this research is not unbiased as it draws heavily 
on the perspectives of sector insiders including sexual health clinical and 
technical specialists; civil society HIV service providers; epidemiologists; 
pharmaco-economists; policy makers and potential end-users. A number 
of senior civil servants, arguably the health policy decision makers, 
declined to be interviewed and/or did not respond to invitations to 
interview. Hence, any clear indications as to whether or not PrEP is likely 
to be introduced in Ireland cannot be definitively answered here. The 
relatively low response rate (53%) despite follow-up with all those invited 
to participate, would appear to suggest some reluctance to engage, at 
least publicly, in the PrEP debate in Ireland. 
The research is weakened by the poor participation of stakeholders 
from outside Dublin. While invitations to interview were issued to clinical 
and psychosocial services providers in Cork, Galway and Limerick, only 
the Sexual Health Centre in Cork opted to participate. As such, regional 
perspectives are not well represented in the findings. It is equally 
problematic that KIs selected for interview and willing to participate were 
primarily sector insiders and more likely to support the introduction of 
PrEP. Consequently, it has not been possible to address stakeholder 
bias or adequately address the reasons why some may not support the 
introduction of PrEP into Ireland. As such, the findings herein must be 
interpreted with caution.
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3.  Overview of the  
Evidence-base for PrEP
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W This chapter will summarise some of the key issues arising from 
a scoping of the evidence base for PrEP efficacy and will include 
examination of issues around product safety. An assessment of the 
evidence base for key populations in terms of adherence, efficacy and 
the phenomenon of risk compensation will be considered, followed by 
the evidence for cost effectiveness including the risks associated with 
Gilead Science Inc.’s recent application for a Supplementary Protection 
Certificate (SPC) for once-daily Truvada®.  This chapter will conclude with 
a review of multilateral and national guidelines for PrEP with the status of 
implementation in other jurisdictions. 
3.1 The Evidence Base for PrEP Efficacy
The World Health Organisation’s Consolidated guidelines on the 
use of antiretroviral drugs for treating and preventing HIV infection, 
Recommendations for a public health approach - Second edition (2016) 
recommends that oral PrEP should be offered as an additional prevention 
choice for people at substantial risk[25] of HIV replacing previous guidance 
advocating PrEP for MSM. In preparing the updated guidelines, WHO 
embarked a systematic review and meta-analysis of PrEP trials containing 
TDF, which demonstrated that PrEP is effective in reducing the risk of 
acquiring HIV infection. It was found that the level of protection did not 
differ by age, sex, regimen (TDF versus FTC + TDF) or mode of sexual 
acquisition (rectal, penile or vaginal exposure) but detectable drug 
levels in the blood are strongly correlated with the prophylactic effect, 
emphasising the importance of adherence to PrEP.[26] WHO announced 
that it will publish comprehensive implementation guidance for PrEP in 
2016 but this has not been published at time of writing.
As indicated at the outset, the scope of this review does not provide 
for an objective assessment of randomised controlled trials (RCTs) which 
have found PrEP to be effective in reducing the sexual transmission of HIV 
in both men and women. While large-scale population trials are important 
and generally unbiased indicators of an effect, they operate some 
limitations not least in terms of the applicability of results in real-world 
scenarios. The background incidence in the PROUD study was so high, 
for example, that the same effect may not be replicable in practice. That 
said PROUD was a UK-based study that was conducted in a routine clinical 
practice and as such its lessons are transferable to the Irish context but 
both clinicians and study participants were aware of the allocation of 
treatment thus introducing the risk of bias. A number of RCTs included 
in WHO’s meta-analysis were conducted in sub-Saharan Africa where 
the epidemiology of the HIV epidemic is vastly different, and social and 
cultural characteristics too divergent to assume transferability to people 
living in Ireland. Some modelling studies have suggested that the public 
health impact of PrEP may be hampered by slow uptake, poor adherence, 
25.  Substantial risk of HIV infection is provisionally defined as HIV incidence around 3 per 100 person-years or higher 
in the absence of PrEP. HIV incidence higher than 3 per 100 person-years has been identified among some groups 
of men who have sex with men, transgender women in many settings, and heterosexual men and women who have 
sexual partners with undiagnosed or untreated HIV infection (WHO, Consolidated Guidelines, 2016, p.53)
26.  Ibid, p.52
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or increases in risk behaviour (risk compensation/disinhibition)[27]  
To address these issues, more than 20 demonstration projects and Open 
Label Extensions (OLE)[28] of PrEP RCTs are currently planned or ongoing 
and will contribute to our understanding of PrEP uptake and delivery 
beyond the RCT setting.[29]
The time and resource limitations of this policy options study precluded 
an in-depth review or critique of the evidence base for PrEP and relies 
on better resourced and well established expertise as emphasised in 
the introduction. The sources upon which much of section 3.1 is based 
conclude that the quality of the evidence base for PrEP efficacy is robust. 
These sources include the WHO; European Centre for Disease Prevention 
and Control (ECDC); the European AIDS Clinical Society; British HIV 
Association (BHIVA); the National Institute for Health and Care Excellence 
(NICE); the United States Centre for Disease Control (CDC); the Scottish 
HIV Pre-Exposure Prophylaxis Short Life Working Group and the National 
Health Service (NHS) Wales.[30] The evidence summary provided by NICE 
and reinforced by NHS Wales and the Scottish Short Life Working Group 
on PrEP, reviews four main trials considered most appropriate to the 
potential provision of PrEP in a UK setting: these are iPrEX study[31]; the 
Partners PrEP study[32]; the PROUD study[33], and the IPERGAY study.[34] 
While significant differences exist between the national insurance 
model of healthcare service delivery in the UK and the Irish two-tier 
hybrid system of private and public services, the epidemiology and 
characteristics of HIV infection in the two jurisdictions is similar. Summary 
highlights from these trials are replicated for information purposes here as 
arguably trial results are transferable to the Irish context:
1. The iPrEx study was a double-blind RCT evaluating once-daily 
Truvada®® or placebo in 2,499 HIV-negative men or transgender 
women who have sex with men with evidence of high-risk behaviour 
for HIV infection. It was conducted in Peru, Ecuador, Brazil, the US, 
Thailand and South Africa. Once daily Truvada® reduced the relative 
risk of acquiring HIV infection by 44% compared with placebo. Self-
27.  Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre-
exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med. 
2013;10(3):e1001401.
28.  An open-label trial or extension is a clinical trial in which both the researchers and participants know which 
treatment is being administered.
29.  Wilton J, Senn H, Sharma M, Tan DHS, Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review, 
28 April 2015 Volume 2015:7 Pages 125—136
30.  WHO, Consolidated Guidelines, 2016; Nandwani R and Valiotis G, on behalf of the Scottish HIV Pre-Exposure 
Prophylaxis Short Life Working Group. PrEP in Scotland. Scottish Health Protection Network (SHPN) October 2016; 
NICE, Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil), 2016; 
BHIVA–BASHH Position Statement on PrEP in the UK: Update 2016; Center for Disease Control, US Public Health 
Service, Pre-exposure Prophylaxis for the Prevention of HIV Infection in the United States, 2014; ECDC GUIDANCE HIV 
and STI prevention among men who have sex with men, 2015; Jones, A., Couzins, Z., Preparing for PrEP? – A Review 
of the Current Evidence for Pre-exposure Prophylaxis (PrEP) to prevent HIV infection in Wales, NHS Wales, 2017; 
European AIDS Clinical Society.
31.  Grant RM, Lama JR, Anderson PL et al. for the iPrEx study team (2010) Preexposure chemoprophylaxis for HIV 
prevention in men who have sex with men. New England Journal of Medicine 30; 363: 2587–99
32.  Baeten JM, Donnell D, Ndase P et al. for the Partners PrEP study team (2012) Antiretroviral prophylaxis for HIV 
prevention in heterosexual men and women. New England Journal of Medicine 367:399–410; Baeten JM, Donnell D, 
Mugo NR et al. for the Partners PrEP study team (2014) Single-agent tenofovir versus combination emtricitabine plus 
tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, 
phase 3 trial. Lancet Infectious Diseases 14: 1055–64
33.  McCormack S, Dunn DT, Desai M et al. (2016) Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection 
(PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 387: 53–60
34.  Molina JM, Capitant C, Spire B et al. for the ANRS IPERGAY study group (2015) On-demand preexposure prophylaxis 
in men at high risk for HIV-1 infection. New England Journal of Medicine 373: 2237–46
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which found emtricitabine or tenofovir in only 9% of people with HIV 
infection and 51% of people who were HIV-negative, while 3 people 
had an emtricitabine-resistant infection and no one reported a 
tenofovir-resistant infection; 
2. The Partners PrEP study was a double-blind RCT evaluating once-
daily single agent tenofovir disoproxil or Truvada® or placebo in 4,747 
HIV-negative individuals in a heterosexual partnership with a person 
already infected with HIV (i.e. serodiscordant heterosexual couples) 
in Kenya and Uganda. Once-daily Truvada® reduced the relative risk 
of acquiring HIV infection by 75% compared with placebo, while 1 
person had an emtricitabine-resistant infection and 1 person had a 
tenofovir-resistant infection;
3. The PROUD study was an open-label trial of once-daily Truvada® 
in 544 HIV-negative men or transgender women who have sex with 
men in England. Participants were randomised to start PrEP with 
Truvada® immediately on study entry or after a deferral period. 
Once-daily Truvada® reduced the relative risk of acquiring HIV 
infection by 86% compared with no prophylaxis; adherence levels 
were high and while 2 people in the immediate Truvada® group 
who had HIV infection at baseline or at the 4-week visit developed 
an emtricitabine-resistant mutation, no participants developed a 
tenofovir-resistant mutation;
4. The IPERGAY study was a double-blind RCT evaluating Truvada® 
or placebo taken ‘on demand’ before and after sexual activity in 
414 high-risk men who have sex with men in France and Canada. 
Participants took a median of 15 tablets per month and reduced 
the relative risk of acquiring HIV infection by 86% compared with 
placebo; adherence varied throughout the course of the trial with 
rates of detection for tenofovir diphosphate and emtricitabine 86% 
and 82% respectively and none of the 16 people who developed HIV 
infection after enrolment had resistant mutations to tenofovir or 
emtricitabine.
The Bangkok Tenofovir Study[35] is the only large-scale study conducted 
with people who inject drugs (PWID). Over 2, 400 PWID were enrolled 
and provided regular HIV testing and risk reduction counselling. With 
optimal adherence a 70% reduction in HIV incidence was reported but 
in general, this RCT reported a 48.9% reduction in HIV using once daily 
Tenofovir disoproxil fumarate (TDF) without Emtricitabine (FTC) among 
PWID. The policy context for this study differs significantly from the Irish 
context and as such, the high levels of adherence may not be relied upon. 
This trial which was funded by the US CDC, was overshadowed by ethical 
35.  Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, 
Natrujirote P, Kittimunkong S, Chuachoowong R. Antiretroviral prophylaxis for HIV infection in injecting drug users in 
Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. The 
Lancet. 2013 Jun 21;381(9883):2083-90. Available from: https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/
archive/prep-idu-factsheet- 508.pdf [accessed 4th April 2017]
O
V
E
R
V
I
E
W
 
O
F
 
T
H
E
 
E
V
I
D
E
N
C
E
-
B
A
S
E
D
 
F
O
R
 
P
R
E
P
1
9
-
2
0
and methodological controversy[36]. Trial findings, however, led the U.S. 
Centers for Disease Control and Prevention to recommend that PrEP be 
considered “as one of several prevention options for persons at very high 
risk for HIV acquisition through the injection of illicit drugs”[37]
As emphasised above, while these population trials provide generally 
unbiased indicators of the effect of PrEP on HIV incidence rates, they do 
not provide insight into the effectiveness of PrEP in real-world clinical 
care settings. Implementation research is needed in diverse settings 
not least in terms of supporting adherence and the capacity of already 
over-stretched health systems to respond effectively to increased 
demand. It is also largely unknown how PrEP may affect behavioural and 
social outcomes in the medium to long term. The RCTs described here 
noted few changes in terms of sexual behaviours but trials provide a high 
level of psycho-social support that may not be replicated in real-world 
settings. WHO notes that while daily dosing was the preferred choice for 
the majority of users, implementation research is required to establish 
how best to adapt PrEP to diverse and changing sexual practices. It is also 
required to establish whether frequent HIV and renal monitoring could be 
reduced; how best to maximise support for PrEP users while minimising 
cost, while integrating PrEP into existing services. 
3.1.1 PrEP Safety [38]
While Truvada® has long been licensed for use as treatment for people 
who are HIV positive, the adverse effects when used for PrEP is less well 
understood. The summary of product characteristics (SPC) provides an 
indication of potential side effects, which need to be factored into its use 
as PrEP:
1. Renal (kidney) failure, renal impairment, elevated creatinine[39], 
hypophosphataemia[40] and proximal tubulopathy[41] have 
been reported with the use of tenofovir disoproxil for treating 
HIV infection. The SPC recommends that creatinine clearance 
is calculated in all people before starting Truvada® for either 
treatment or prevention and renal function should also be monitored 
during use. In the iPrEx study, elevated creatinine levels were seen 
in 2% of the Truvada® group and 1% of the placebo group but this 
reversed when the drug was stopped. Elevated creatinine levels were 
also seen in 18% of the Truvada® group and 10% of the placebo 
group (p=0.03) in the IPERGAY study, but none led to discontinuation 
of the study drug. In PROUD, 3/275 people in the immediate 
Truvada® group interrupted treatment because of high creatinine 
36.  Wolfe, Daniel. 2013. “Beyond the Hype: PrEP for People Who Inject Drugs.” http://www.huffi ngtonpost.com/
daniel-wolfe/beyond-the-hype-prep-for-_b_3437910.html [Accessed 5 April 2017]; Mathers, B.M. et al. 2010. “HIV 
prevention, treatment and care services for people who inject drugs: a systematic review of global, regional, and 
national coverage.” Lancet 375: 1014-1028.
37.  Caitlin Kennedy and Virginia Fonner, Pre-exposure prophylaxis for people who inject drugs: A systematic review, 
WHO, 2014, p. 3
38.  Adapted from NICE, Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir 
disoproxil), 2016, p. 8
39.  A chemical waste molecule that is passed through the kidneys to be processed and excreted in urine.
40.  Abnormally low level of phosphate in the blood.
41.  A form of renal disease.
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W levels, but the study drug was restarted in all these people. It has 
been reported that a large study is planned, to take place in North 
America and Europe, of Descovy® a new alternative to Truvada®®. 
This drug substitutes the old formulation of tenofovir, tenofovir 
disoproxil fumarate (TDF) with a new one, tenofovir alafenamide (TAF), 
in combination with emtricitabine. TAF is already licensed for HIV 
treatment and reaches higher intracellular levels and lower plasma 
levels requiring lower dosage, while producing fewer kidney and 
bone-related side-effects. Its efficacy as PrEP in humans is unknown 
but 15 centres in eight European countries have registered interest 
in joining the study: Austria, Denmark, France, Germany, Ireland, the 
Netherlands, Spain and the UK.[42];
2. In a sub-study of iPrEx a decrease in bone mineral density of −0.91% 
in the spine −0.61% in the hip was seen with Truvada® compared 
with placebo by 24 weeks. Among all participants in the iPrEx study 
there were fractures in 1.7% of the Truvada® group and 1.4% of the 
placebo group so the adverse effect is marginal but nonetheless 
noteworthy;
3. Chronic hepatitis B or C in people prescribed antiretroviral therapy 
(ART) poses an increased risk for severe and potentially fatal hepatic 
adverse reactions. The safety and efficacy of Truvada® for PrEP in 
people with hepatitis B or C has not been established;
4. The most frequently reported adverse reactions by people taking 
Truvada® are nausea (12%) and diarrhoea (7%). No new adverse 
reactions were identified from the iPrEx and Partners PrEP studies, 
and the most frequent adverse reaction reported in the Truvada® 
group in the iPrEx study was headache (1%). In both iPrEx and 
IPERGAY there were increased rates of gastrointestinal disturbance 
with Truvada® compared with placebo. In the Partners PrEP study, 
there were increased reports of gastrointestinal side effects and 
fatigue in the Truvada® group, mainly during the first month. In 
PROUD, 21/275 (8%) people in the immediate Truvada® group 
interrupted or missed doses because of adverse events.
WHO guidance recommends creatinine testing before starting  
PrEP and quarterly during PrEP use for the first 12 months, then annually 
thereafter; hepatitis B surface antigen (HBsAg) is preferred; support to 
optimise adherence, particularly through initial adverse effects including 
gastrointestinal disturbance; support is also required to ensure that PrEP 
users are fully informed about important aspects of taking PrEP including 
that it reaches protection after 7 doses and that full protection may 
require 4 doses for anal sex and 7 doses for vaginal sex. HIV testing is 
required before PrEP is offered and regularly with STI screening while  
PrEP is taken.[43] 
42.  PrEP Access in Europe Initiative (undated but circa 2016)
43.  WHO, Consolidated guidelines, 2016, p.57-59
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Six trials measured and reported cases of TDF or FTC drug resistance, 
with 8 (18%) HIV infections identified with resistance to TDF or FTC 
occurring among 44 trial participants acutely HIV-infected at enrolment. 
Additionally, 6 (2%) TDF or FTC drug-resistant infections occurred out 
of 533 cases of incident HIV infection postrandomization across study 
arms including five FTC mutations among participants randomised to PrEP 
and one mutation identified in a participant randomised to placebo[44]. 
The New England Journal of Medicine recently reported the case of a 
43-year-old man in Toronto who notwithstanding strict adherence to PrEP 
contracted a drug-resistant strain of HIV.[45]
3.2 PrEP and Key Populations: Efficacy, Adherence and Risk Compensation
The first edition of WHO’s Consolidated guidelines on the use 
of antiretroviral drugs for treating and preventing HIV infection, 
Recommendations for a public health approach in 2014 recommended, 
on the basis of the evidence then available, that PrEP be offered to MSM 
deemed to be at substantial risk for HIV. On the basis of further evidence 
of the effectiveness and acceptability of PrEP, WHO has now broadened 
the recommendation to include all population groups at substantial 
risk of HIV infection.[46] A systematic review and meta-analysis of PrEP 
which supports this recommendation illustrates that PrEP is effective in 
reducing the risk of acquiring HIV infection and that the level of protection 
did not differ by age, sex, regimen (TDF versus FTC + TDF) or mode of 
sexual acquisition of HIV (rectal, penile or vaginal exposure). Fonner 
et al’s 2016 systematic assessment of oral PrEP containing TDF across 
populations in 15 RCTs found PrEP to be effective in reducing risk of HIV 
acquisition across types of sexual exposure, sexes, PrEP regimens, and 
dosing schemes. [47] The review further reported that PrEP appears to 
present few significant safety risks, and no evidence of behavioural risk 
compensation in this collaborative, unbiased review and meta-analysis 
of the RCT evidence base, which was conducted by the John Hopkins 
Bloomberg School of Public Health in Maryland, Virginia, the Medical 
University of South Carolina, and the WHO. 
While the PrEP context-transferable evidence base appears more 
robust in the case of MSM as indicated by 3.1 – PROUD, IPERGAY, iPrEX - 
compared to other key populations affected by HIV as indicated by NICE 
and NHS Wales (see section 3.1 above), meta-analysis of all RCTs appears 
to suggest that PrEP is effective in terms of reducing HIV transmission in all 
key populations. However, as indicated above, real-world implementation 
44.  Fonner, Virginia A.; Dalglish, Sarah L.; Kennedy, Caitlin E.; Baggaley, Rachel; O’Reilly, Kevin R.; Koechlin, Florence 
M.; Rodolph, Michelle; Hodges-Mameletzis, Ioannis; Grant, Robert M. Effectiveness and safety of oral HIV 
preexposure prophylaxis for all populations, AIDS: 31 July 2016 - Volume 30 - Issue 12 - p 1973–1983 doi: 10.1097/
QAD.0000000000001145
45.  Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis N Engl J Med 2017; 376:501-502 February 2, 
2017DOI: 10.1056/NEJMc1611639 [accessed 5th April 2017]
46.  Substantial risk of HIV infection is provisionally defined as HIV incidence around 3 per 100 person-years or higher 
in the absence of PrEP. HIV incidence higher than 3 per 100 person-years has been identified among some groups 
of men who have sex with men, transgender women in many settings, and heterosexual men and women who have 
sexual partners with undiagnosed or untreated HIV infection (WHO, Consolidated Guidelines, 2016, p.53)
47.  Fonner, Virginia A.; Dalglish, Sarah L.; Kennedy, Caitlin E.; Baggaley, Rachel; O’Reilly, Kevin R.; Koechlin, Florence 
M.; Rodolph, Michelle; Hodges-Mameletzis, Ioannis; Grant, Robert M. Effectiveness and safety of oral HIV 
preexposure prophylaxis for all populations, AIDS: 31 July 2016 - Volume 30 - Issue 12 - p 1973–1983 doi: 10.1097/
QAD.0000000000001145
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scale-up of PrEP appears to be underway in a number of jurisdictions (see 
3.4.1), some implementation questions remain unanswered. For example, 
the extent to which PrEP may contribute to reductions in HIV incidence 
outside of clinical trial settings is largely unknown[48] although initial data 
are promising: sexual health clinics in London have recently reported a 
substantial decline in the number of new HIV infections among MSM and 
while PrEP may be contributing to that decline it is more likely to be as a 
result of combination prevention, which includes testing and treatment-
as-prevention (TasP). Speaking at the British HIV Association conference 
in Liverpool in April 2017, it is reported that Valerie Delpech from Public 
Health England acknowledged the possible contribution of PrEP and the 
fact that it may have more impact in the future[49]. The I Want PrEP Now 
campaign in the UK reports that 2000 men have been purchasing generic 
PrEP through its website, while services offered by some clinics to test 
for drug concentrations and adverse events related to PrEP have been 
well used. A Lancet Editorial reported that while the decline in infections 
cannot with certainty be linked to PrEP, “the temporal correlation is 
compelling.”[50] The government of New South Wales in Australia has also 
reported a drop to a five year low in HIV incidence which is attributed 
to the introduction in March 2016 of Expanded PrEP Implementation in 
Community, the EPIC trial.[51]
The efficacy of PrEP is dependent on multiple factors not least 
adherence with which it is strongly correlated. Emtricitabine 200 mg/
tenofovir disoproxil 245 mg; FTC/TDF appears efficacious to different 
degrees depending on biological, social and cultural factors – for example, 
stigma associated with taking PrEP has been highlighted by sex workers in 
countries where HIV is endemic and everybody knows that the brand name 
is a HIV drug, whereas this may be less of an issue in concentrated contexts.
Transgender women frequently report a disproportionate burden of HIV 
infection: Three RCTs assessing the efficacy of PrEP in men or transgender 
women who have sex with men, found that once-daily Truvada® 
(emtricitabine/tenofovir disoproxil 200 mg/245 mg) reduced the relative 
risk of acquiring HIV[52]. A subgroup analysis from the iPrEX trial focused on 
the experiences of 339 (14%) of participants who self-identified as “trans,” 
identified as female, or who used feminising hormones. Higher tenofovir 
concentrations after oral dosing were found in the rectum compared with 
the vagina, which may explain the near complete protection observed with 
PrEP dosing of 4–6 tablets per week among men and trans women who 
have sex with men, whose HIV exposure is primarily by anal intercourse. By 
contrast seroconversion was observed among several vaginally exposed 
48.    Wilton J, Senn H, Sharma M, Tan DHS, Pre-exposure prophylaxis for sexually-acquired HIV risk management: a 
review, 28 April 2015 Volume 2015:7 Pages 125—136
49.    Pebody, R. The large fall in HIV diagnoses in London gay men is real and thanks to combination prevention, not just 
PrEP, NAM AIDSMAP, 6th April 2017 
50.  Editorial www.thelancet.com/hiv Vol 4 February 2017 [accessed 6th April 2017]
51.   NSW Government. Health. HIV notifications fall to a five year low. http://www.health.nsw.gov.au/news/
Pages/20170304_00.aspx [accessed 6.4.2017]
52.   NICE, Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil), 2016, p.4
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non-trans women at this same level of PrEP use.[53] One review suggests 
that drug-drug interactions with feminising hormones may explain the 
lower doses of FTC or TDF concentrations.[54] Lower adherence levels 
were also observed among trans women but the reasons for this are not 
well understood. Qualitative research suggests that trans women tend to 
prioritise gender-affirming care over HIV prevention[55] 
In 18 PrEP-related studies - 15 RCTs and three observational OLE 
or demonstration projects - PrEP was found to be most effective in 
studies with high adherence, reducing infection risk by 70%. Fonner 
et al observed that the level of protection is strongly correlated with 
adherence to the extent that PrEP significantly reduced infection risk in 
studies with moderate adherence levels, but showed no effect in studies 
with low adherence.[56] A number of studies observed that younger 
participants had poorer adherence compared with older participants and 
while PrEP was found not to be effective in preventing HIV infection 
among women aged less than 25 years (FEM-PrEP) it reduced infection 
among women aged less than 30 years in Partners PrEP.[57] The ‘‘I Am 
Men’s Health’’ programme applied an innovative methodology involving 
co-location of PrEP services with community supports and weekly 
attendance to generate adherence to PrEP in 23 mostly young black MSM 
living below the poverty line. Despite multiple risk factors for HIV in the 
population, adherence to PrEP was 73%, with a median adherence of 82% 
for participants who had taken PrEP for at least 1 month.[58] Additional 
research is clearly needed on how to support adherence, especially 
for adolescents and young women although injectable formulations and 
(sustained release) implants, currently in development, offer the potential 
to mitigate current compliance challenges.[59] 
In women, some studies have suggested a possible biological 
mechanism for different rates of protection according to primary 
transmission route, in that higher rates of drug concentration have been 
found in rectal tissue compared with vaginal tissue.[60] Fonner et al’s 
systematic review and meta-analysis, however, did not find differences in 
the protective effects of PrEP between men and women. FEM-PrEP and 
Partners PrEP both reported that the effectiveness of contraception is 
53.  Grant, R.M., Jae M. Sevelius, Juan V. Guanira, Jana Villayzan Aguilar, Suwat Chariyalertsak, DrPH,k and Madeline 
B. Deutsch, Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis, J Acquir Immune Defic Syndr 
2016;72:S226–S229
54.  Mayer KH et al. - Antiretroviral pre-exposure prophylaxis implementation in the United States: a work in progress, 
Journal of the International AIDS Society 2015, 18(Suppl 3):19980
55.   Sevelius JM, Keatley J, Calma N, et al. ‘I am not a man’: Trans-specific barriers and facilitators to PrEP acceptability 
among transgender women. Glob Public Health. 2016:1–16. 16.
56.  Ibid.
57.   Liu AY, Vittinghoff E, Chillag K, Mayer K, Thompson M, Grohskopf L, et al. Sexual risk behavior among HIV-uninfected 
men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United 
States. J Acquir Immune Defic Syndr 2013; 64:87–94; Murnane PM, Heffron R, Ronald A, Bukusi EA, Donnell D, Mugo 
NR, et al. Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of 
hormonal contraception. AIDS 2014; 28:1825–1830.
58.   Giffin W. Daughtridge, S. CaitlinConyngham, Noel Ramirez, Helen C. Koenig, MD, MPH, ‘I Am Men’s Health’ Journal 
of the International Association of Providers of AIDS Care (JIAPAC) Vol 14, Issue 2, pp. 103 – 107 First published date: 
October-20-2014
59.   Hope, Thomas J. and Jeanne M. Marrazzo, ‘A shot in the arm for HIV prevention? Recent successes and critical 
thresholds’, AIDS Research and Human Retroviruses, xi, 31 (2015), 1055–1059
60.   Cottrell ML, Yang KH, Prince HMA, Kashuba ADM. Predicting effective Truvada PrEP dosing strategies with a novel 
PK-PD model incorporating tissue active metabolites and endogenous nucleotides (EN). HIV Research for Prevention 
(HIV R4P). Cape Town, South Africa. Abstract OA22.06 LB.; Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, 
Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 
transmission. Sci Transl Med 2011; 3: 112re114.
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W not altered by PrEP.[61] FEM-PrEP and Partners PrEP also evaluated the 
potential effects of PREP on adverse pregnancy-related events and the 
risk of adverse pregnancy-related events did not differ between PrEP 
and the placebo arms. Both FEM-PrEP and VOICE trials enrolled high-risk 
heterosexual women in sub-Saharan Africa, and demonstrated variable 
adherence with low levels of efficacy raising initial concerns that PrEP 
may not work for women. However, TDF-based oral PrEP was effective for 
women in the Partners PrEP and TDF2 studies[62]
Owing to differences in condom use and risk compensation 
measurement across studies, meta-analysis of trial data was not 
possible in Fonner et al’s systematic review. The literature does not 
provide a definitive consensus on risk compensation, but whether real 
or imagined, health care providers have reported concerns about risk 
compensation.[63] This finding was echoed in interviews conducted 
with Irish stakeholders in this study. A systematic review of behavioural 
outcomes from RCTs conducted by Koechlin et al (2016) reported that the 
majority of participants did not anticipate hypothetical PrEP use would 
lead to increased risk behaviours[64] and this is consistent with Fonnar 
et al’s meta-analysis of PrEP outcomes, which showed no significant 
effect on sexual behaviour with PrEP use.[65] No difference in condom 
use across arms was detected with some even showing increases in 
condom use throughout trial duration[66]. Similarly, in studies comparing 
PrEP with no-PrEP, which more accurately reflect real-life scenarios 
than RCTs, studies reported either no change in condom use across 
arms or slight increases in condom use over time.[67]  The PROUD trial 
used sexually transmitted infections (STIs) among MSM participants as a 
proxy for unprotected sexual intercourse and found similar rates across 
immediate and delayed PrEP arms.[68] A study in clinical practice in San 
Francisco, however, indicated a 40% drop-off rate in condom use among 
PrEP users.[69] In transgender people, one study in South America found 
anecdotally that condom use may decrease with PrEP[70].
61.  Callahan R, Nanda K, Kapiga S, Malahleha M, Mandala J, Ogada T, et al. Pregnancy and contraceptive use among 
women participating in the FEM-PrEP trial. J Acquir Immune Defic Syndr 2015; 68:196–203; Murnane PM, Heffron R, 
Ronald A, Bukusi EA, Donnell D, Mugo NR, et al. Pre-exposure prophylaxis for HIV-1 prevention does not diminish the 
pregnancy prevention effectiveness of hormonal contraception. AIDS 2014; 28:1825–1830.
62.  Wilton J, Senn H, Sharma M, Tan DHS, Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review, 
28 April 2015 Volume 2015:7 Pages 125—136
63.  Doblecki-Lewis, S. and Deborah Jones, Community Federally Qualified Health Centers as Homes for HIV Preexposure 
Prophylaxis: Perspectives from South Florida, Journal of the International Association of Providers of AIDS Care 2016, 
Vol. 15(6) 522–528
64.  Koechlin, F.M., Fonner, V.A., Dalglish, S.L. et al. Values and Preferences on the Use of Oral Pre-exposure Prophylaxis 
(PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature, AIDS Behav (2016). 
doi:10.1007/s10461-016-1627-z
65.  Fonner, Virginia A.; Dalglish, Sarah L.; Kennedy, Caitlin E.; Baggaley, Rachel; O’Reilly, Kevin R.; Koechlin, Florence 
M.; Rodolph, Michelle; Hodges-Mameletzis, Ioannis; Grant, Robert M. Effectiveness and safety of oral HIV 
preexposure prophylaxis for all populations, AIDS: 31 July 2016 - Volume 30 - Issue 12 - p 1973–1983 doi: 10.1097/
QAD.0000000000001145
66.  Ibid
67.  Liu AY, Vittinghoff E, Chillag K, Mayer K, Thompson M, Grohskopf L, et al. Sexual risk behavior among HIV-uninfected 
men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United 
States. J Acquir Immune Defic Syndr 2013; 64:87–94; Grohskopf LA, Chillag KL, Gvetadze R, Liu AY, Thompson M, 
Mayer KH, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected 
men who have sex with men in the United States. J Acquir Immune Defic Syndr 2013; 64:79–86.
68.  Fonner et al 2016
69.  Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a 
clinical practice setting [published online September 1, 2015]. Clin Infect Dis. 2015. pii: civ778
70.  Galea JT, Kinsler JJ, Salazar X, et al. Acceptability of preexposureprophylaxis as an HIV prevention strategy: 
barriers and facilitators to pre-exposure prophylaxis uptake among at risk Peruvian populations. Int J STD AIDS. 
2011;22(5):256–62.
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There is significant variability between groups and contexts with women 
in one US study indicating that taking PrEP would result in a decrease 
in condom use,[71] while women in a study in Ghana demonstrated a 
decrease in number of sexual partners and rate of unprotected sex 
acts.[72] One study found that 20% of young women expected to use 
condoms less frequently if they took PrEP.[73] 
In serodiscordant couples, 3% of Chinese partners said they would 
increase their number of partners if PrEP was available to them and 12% 
said they would decrease condom use.[74] However, in Kenya, 25% of 
respondents said they would stop using condoms if PrEP were available 
to them.[75] The longitudinal Partners PrEP analysis reported decreasing 
frequency of unprotected intercourse with HIV-positive study partners 
but also noted increased frequency of unprotected intercourse with 
outside partners over time[76].
 A study in Kenya and South Africa reported that female sex workers 
raised concerns that their colleagues might see PrEP as an opportunity 
to forego condoms to increase earnings[77] which reflects concerns 
also raised in interview by the Sex Workers Alliance Ireland (SWAI) for 
this research. SWAI argue that the recent introduction of the Criminal 
Law (Sexual Offences) Act 2017 which criminalises the purchase of sexual 
services will decrease sex workers’ income thus encouraging higher risk 
activity as sex workers strive to make a living. 
Two of the randomised trials were conducted in European MSM 
populations and while in both trials the HIV incidence in the control 
group was much higher than anticipated (9.0/100 person years in PROUD 
and 6.6/100 person years in IPERGAY) the reduction in HIV was also the 
highest reported to date (86% in both trials). PROUD also demonstrated 
the feasibility of delivering PrEP through sexual health clinics using simple 
and easy to apply inclusion criteria[78]. The PROUD study demonstrated 
high levels of adherence (86%) but these are estimates based on 
prescription records. While PROUD reported STIs during the study with 
slightly higher rates in the PrEP group compared to the placebo group 
(57% vs 50%) the study concluded that compared to HIV risk from 
condomless sex, the difference was not statistically significant. This is 
difficult to call not least because the background incidence of HIV in the 
PROUD study was so extraordinarily high, but given that STI rates were 
similar in both groups, it is reasonable to suggest that sexual behaviour 
may have been quite similar in each group. IPERGAY is a very different 
71.  Wingood GM, Dunkle K, Camp C, et al. Racial differences and correlates of potential adoption of preexposure 
prophylaxis: results of a national survey. J Acquir Immune Defic Syndr. 2013;63(Suppl 1):S95–101.
72.   Guest G, Shattuck D, Johnson L, et al. Acceptability of PrEP for HIV prevention among women at high risk for HIV.  
J Women’s Health. 2010;19(4):791–8.
73.   Rubtsova A, Wingood G, Dunkle K, Camp C, DiClemente R. Young adult women and correlates of potential adoption of 
preexposure prophylaxis (PrEP): results of a national survey. Curr HIV Res. 2014;11(7):543–8.
74.   Mijiti P, Yahepu D, Zhong X, et al. Awareness of and willingness to use oral pre-exposure prophylaxis for HIV prevention 
among HIV-serodiscordant heterosexual couples: a cross-sectional survey in Xinjiang, China. PLoS ONE. 2013;8(7): 
e67392.
75.   Fowler N, Arkell P, Abouyannis M, James C, Roberts L. Attitudes of serodiscordant couples towards antiretroviral-
based HIV prevention strategies in Kenya: a qualitative study. AIDS Patient Care STDs. 2015;29(1):33–42.
76.   Fonner et al 2016
77.   Mack N, Evens EM, Tolley EE, et al. The importance of choice in the rollout of ARV-based prevention to user groups in 
Kenya and South Africa: a qualitative study. J Int AIDS Soc. 2014;17(3 Suppl 2):19157.
78.   BHIVA–BASHH Position Statement on PrEP in the UK: Update 2016, p.3
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W study from PROUD, in that it studied ‘on-demand’[79] PrEP which is not 
licensed for use in the EU: this trial also reported good adherence (43% 
per cent reported that they had taken it according to the protocol; 29% 
had taken some doses; and 28% had not taken any) and there was no 
evidence of risk compensation identified by the study.
Finally, the context transferable data for PWID is perhaps weaker than 
for any other key population notwithstanding recommendations by the 
WHO[80] and CDC PrEP Guidelines.[81] The Bangkok Tenofovir Study[82], 
which underscores these recommendations, is the only large-scale study 
conducted with PWID. As previously outlined, the RCT reported that 
with optimal adherence a 70% reduction in HIV incidence is possible but 
overall effectiveness in terms of reducing HIV incidence rates was found to 
be 48.9% with once daily TDF without FTC. The social and policy context 
for this study differs significantly from the Irish context and as such, the 
high levels of adherence may not be relied upon. Evidence suggests 
that single interventions do not produce substantial and sustained 
reductions in HIV transmission among PWID but rather a high coverage 
of combination biomedical, harm reduction and structural approaches 
are required.[83] Coupled with the fact that HIV incidence is low among 
PWID in Ireland due to successful harm reduction interventions, the 
European Commission have only licensed Gilead’s Once-Daily Truvada® 
for reducing the risk of sexually acquired HIV-1 in August 2016. However, 
the European AIDS Clinical Society (EACS) guidelines from 2015 and WHO’s 
2016 guidelines recommend PrEP for people at high-risk of acquiring HIV 
infection in combination with other preventive interventions, including 
the use of condoms. As such, it is likely to be the case in practice that 
eligibility criteria informed by WHO and EACS guidance would extend PrEP 
to PWID and their sexual partners if all clinical requirements are met. 
It should be noted however that NHS England’s proposed eligibility and 
exclusion criteria of individuals whose injecting drug use is their only risk 
of HIV acquisition have been excluded from proposed PrEP provision, on 
the grounds that “current HIV incidence in this group in the UK is too low 
for PrEP to be cost effective”[84].
79.  Differs from daily dosage of one Truvada pill and instead prescribes two Truvada pills from one day to two hours 
before sex is anticipated.
80.  WHO, Consolidated Guidelines, 2016; US CDC 
81.  US Public Health Service, Pre-exposure Prophylaxis for the Prevention of HIV Infection in the United States: A Clinical 
Guideline, 2014. “PrEP is recommended as one prevention option for adult injection drug users (IDU) at substantial 
risk of HIV acquisition” p9
82.  Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, 
Natrujirote P, Kittimunkong S, Chuachoowong R. Antiretroviral prophylaxis for HIV infection in injecting drug users in 
Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. The 
Lancet. 2013 Jun 21;381(9883):2083-90. Available from: https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/
archive/prep-idu-factsheet- 508.pdf [accessed 4th April 2017]
83.  Marshall, B. D. L., and Milloy, M.-J. (2016) Improving the effectiveness and delivery of pre-exposure prophylaxis (PrEP) 
to people who inject drugs. Addiction, doi: 10.1111/add.13597
84.  NHS England, Clinical Commissioning Policy Proposition: Pre-exposure prophylaxis (PrEP) to prevent the acquisition of 
HIV in adults Reference: November 2016 [draft] 
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3.3 Cost Effectiveness
Cost effectiveness studies are context and epidemic-specific and as 
such few conclusions can be drawn from studies conducted in other 
jurisdictions. The cost-effectiveness of PrEP appears to be particularly 
sensitive to key variables such as HIV incidence, levels of adherence, 
willingness to use PrEP, risk behaviours, the cost of drugs and other 
clinical interventions required to support PrEP programmes. Presenting 
at the ECDC PrEP conference in 2016, modelling experts emphasised the 
challenges of cost effectiveness modelling in a situation where substantial 
short-term budget impact has a potential longer-term public health 
benefit and cost saving.[85] 
 Cost effectiveness studies have been undertaken in a number 
of countries and settings, including the Netherlands, Australia, Canada 
and the United Kingdom but there appears to be no clear indication that 
PrEP is cost-effective.[86] The Dutch study was based on mathematical 
modelling to predict the effectiveness and cost-effectiveness of PrEP in 
daily usage and ‘on-demand’ and demonstrated that ‘on-demand’ PrEP 
would be cost-saving if the price was reduced by 30-40% but daily PrEP 
would not[87]. The Canadian study found that targeting PrEP at the highest 
risk MSM is likely to improve cost-effectiveness,[88] and the Australian 
study found that cost-effectiveness is only achieved when targeted at 
all discordant MSM partnerships. Other scenarios did not generate cost-
effectiveness ratios that would constitute value for money.[89] 
In the United Kingdom – where the cost of drugs is generally lower than 
in Ireland – two studies have demonstrated that PrEP would not be cost-
effective unless the price of Truvada® is cut substantially[90]. The first of 
these conducted by Ong et al estimated the cost and cost effectiveness 
of a proposed daily oral PrEP programme covering 10,000 high-risk MSM 
attending genitourinary medicine clinics in England. Cambiano et al modelled 
85.  Jones, A., Couzins, Z., Preparing for PrEP – A Review of the Current Evidence for Pre-exposure Prophylaxis (PrEP) to 
prevent HIV infection in Wales, NHS Wales, 2017, p.13
86.  Cambiano V., Miners A., Dunn D., McCormack S., Ong K., Gill N., et al. Is PrEP for HIV prevention cost-effective in 
MSM in the UK? Glasgow: University College London; 2015; Ong KJ., Desai S., Desai M., Nardone A., Hoek AJ van., Gill 
ON. Cost and cost-effectiveness of an HIV pre-exposure prophylaxis (PrEP) programme for high-risk men who have 
sex with men in England: results of a static decision analytical model. The Lancet. 13 November 2015; Available at: 
http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(15)00854-5.pdf (Accessed: 6th April 2017); Nichols 
B. PrEP is Only Cost-Effective Among MSM in the Netherlands When Used on Demand. Conference on Retroviruses 
and Opportunisitc Infections (CROI) 2016; 25 February 2016; Boston, Massachusetts; Nichols BE., Boucher CAB., van 
der Valk M., Rijnders BJA., van de Vijver DAMC. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 
prevention in the Netherlands: a mathematical modelling study. The Lancet Infectious Diseases. September 2016; 
Available at: DOI:10.1016/S1473-3099(16)30311-5 (Accessed: 6th April 2017); Schneider K., Gray RT., Wilson DP. A Cost-
effectiveness Analysis of HIV Preexposure Prophylaxis for Men Who Have Sex With Men in Australia. Clinical Infectious 
Diseases. 4 January 2014; 58(7): 1027–1034. Available at: DOI:10.1093/cid/cit946 (Accessed: 6th April 2017); Ouellet E., 
Durand M., Guertin JR., LeLorier J., Tremblay CL. Cost Effectiveness of ‘On Demand’ Hiv Pre-Exposure Prophylaxis 
for Non-Injection Drug-Using Men Who Have Sex with Men in Canada. Canadian Journal of Infectious Diseases and 
Medical Microbiology. 2015; 26(1): 23–29. Available at: DOI:10.1155/2015/964512 (Accessed: 6th April 2017)
87.  Nichols B. PrEP is Only Cost-Effective Among MSM in the Netherlands When Used on Demand. Conference on 
Retroviruses and Opportunisitc Infections (CROI) 2016; 25 February 2016; Boston, Massachusetts; Nichols BE., 
Boucher CAB., van der Valk M., Rijnders BJA., van de Vijver DAMC. Cost-effectiveness analysis of pre-exposure 
prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. The Lancet Infectious Diseases. 
September 2016; Available at: DOI:10.1016/S1473-3099(16)30311-5 (Accessed: 6th April 2017)
88.  Ouellet E., Durand M., Guertin JR., LeLorier J., Tremblay CL. Cost Effectiveness of ‘On Demand’ Hiv Pre-Exposure 
Prophylaxis for Non-Injection Drug-Using Men Who Have Sex with Men in Canada. Canadian Journal of Infectious 
Diseases and Medical Microbiology. 2015; 26(1): 23–29. Available at: DOI:10.1155/2015/964512 (Accessed: 6th April 
2017)
89.  Schneider K., Gray RT., Wilson DP. A Cost-effectiveness Analysis of HIV Preexposure Prophylaxis for Men Who Have 
Sex With Men in Australia. Clinical Infectious Diseases. 4 January 2014; 58(7): 1027–1034. Available at: DOI:10.1093/cid/
cit946 (Accessed: 6th April 2017)
90.  Ong KJ., Desai S., Desai M., Nardone A., Hoek AJ van., Gill ON. Cost and cost-effectiveness of an HIV pre-exposure 
prophylaxis (PrEP) programme for high-risk men who have sex with men in England: results of a static decision 
analytical model. The Lancet. 13 November 2015; Available at: http://www.thelancet.com/pdfs/journals/lancet/
PIIS0140-6736(15)00854-5.pdf (Accessed: 6th April 2017)
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W the cost of PrEP to 5,000 gay men at risk of HIV infection.[91] The models 
have been criticised for relying on the observed HIV infection rates in 
sexual health clinic attendees, rather than the higher infection rates seen 
in those not taking PrEP in the PROUD study. However, the background HIV 
incidence rate in PROUD is extremely high and whether or not such rates 
may be witnessed beyond an RCT is open to question. Ong and Cambiano 
therefore base their models on the likely infection rate in the absence of 
PrEP which in the UK based on clinic attendees is 3.3% rather than the 9% 
seen in PROUD.[92] The models are also criticised for scenario assumptions 
of lower adherence and decreases in condom use over time, while operating 
on the premise that the cost of HIV treatment is likely to fall at a faster rate 
than the cost of PrEP. Cost effectiveness modelling studies are marked by 
limitations but so are RCTs and as such the true cost of an intervention like 
PrEP can never be accurately known until it is implemented and managed for 
results: as Nobel Prize winning physicist, Niels Bohr, commented somewhat 
ironically, “Prediction is very difficult, especially if it’s about the future.” 
Perhaps the most significant threat to both cost effectiveness and plans 
to upscale PrEP across Europe is Gilead Science, Inc. recent application 
for a Supplementary Protection Certificate (SPCs) for Truvada®. An SPC 
prolongs the term of patents for pharmaceutical products for a maximum 
of five additional years, which if granted in the case of Truvada® would 
extend the patent until 2022 thus preventing cheaper generics from 
acquiring licenses for PrEP in the European market. SPCs are governed by 
EU law and in early 2017 a UK court referred Gilead Science’s application 
to the Court of Justice of the European Union (CJEU), for further 
clarification on the SPC regulation. A decision is awaited at time of writing.
3.4 PrEP Guidelines 
PrEP is supported by a robust evidence base and implementation of PrEP 
programmes is supported by clinical guidance currently operationalised 
by key multilateral and national institutes for health. Primary guidance for 
PrEP implementation is presented here with review studies conducted in 
England, Scotland and Wales proposing PrEP implementation:
1. World Health Organisation, Consolidated guidelines on the use 
of antiretroviral drugs for treating and preventing HIV infection, 
Recommendations for a public health approach - Second  
edition (2016): 
 
Recommendation:  
Oral pre-exposure prophylaxis (PrEP) containing TDF should be 
offered as an additional prevention choice for people at substantial 
risk of HIV infection as part of combination HIV prevention 
approaches (strong recommendation, high-quality evidence);
91.  Cambiano V., Miners A., Dunn D., McCormack S., Ong K., Gill N., et al. Is PrEP for HIV prevention cost-effective in MSM 
in the UK? Glasgow: University College London; 2015
92.  AIDSMAP, Second Cost Effectiveness study finds that large PrEP programmes may need drug price cut to be 
affordable. http://www.aidsmap.com/Second-UK-cost-effectiveness-study-finds-that-large-PrEP-programmes-
may-need-drug-price-cut-to-be-affordable/page/3000951/ [accessed 6th April 2014]
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2. US Public Health Service, Pre-exposure Prophylaxis for the 
Prevention of HIV Infection in the United States, A Clinical Practice 
Guideline,2014 
 
Recommendation:  
Daily oral PrEP with the fixed-dose combination of tenofovir 
disoproxil fumarate (TDF) 300 mg and emtricitabine (FTC) 200 mg has 
been shown to be safe and effective in reducing the risk of sexual HIV 
acquisition in adults; therefore, 
• PrEP is recommended as one prevention option for sexually-active 
adult MSM (men who have sex with men) at substantial risk of HIV 
acquisition;
• PrEP is recommended as one prevention option for adult 
heterosexually active men and women who are at substantial risk of 
HIV acquisition;
• PrEP is recommended as one prevention option for adult injection 
drug users (IDU) at substantial risk of HIV acquisition;
• PrEP should be discussed with heterosexually-active women and men 
whose partners are known to have HIV infection (i.e., HIV-discordant 
couples) as one of several options to protect the uninfected partner 
during conception and pregnancy so that an informed decision can 
be made in awareness of what is known and unknown about benefits 
and risks of PrEP for mother and foetus.
3. European AIDS Clinical Society, 2017 
 
Recommendations:
• PrEP should be used in adults at high-risk of acquiring HIV infection 
when condoms are not used consistently. Before PrEP is initiated, 
HBV serology status should be documented;
• Recommended in HIV-negative men who have sex with men (MSM) 
and transgender individuals when condoms are not used consistently 
with casual partners or with HIV-positive partners who are not 
on treatment. A recent STD, use of post-exposure prophylaxis or 
chemsex may be markers of increased risk for HIV acquisition;
• May be considered in HIV-negative heterosexual women and men 
who are inconsistent in their use of condoms and have multiple 
sexual partners where some of whom are likely to have HIV infection 
and not being on treatment;
• PrEP is a medical intervention that provides a high level of protection 
against HIV acquisition but does not protect against other STDs and 
should be used in combination with other preventive interventions. 
PrEP should be supervised by a doctor, experienced with sexual 
health and use of HIV medicines, possibly as part of a shared care 
arrangement.
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4. British HIV Association (BHIVA) and British Association for Sexual 
Health and HIV (BASHH), Position Statement on PrEP, May 2016 
 
Recommendation:
• PrEP should be made available within a comprehensive HIV prevention 
package to:
• Men who have sex with men, trans men and trans women who are 
engaging in condomless anal sex;
• HIV-negative partners who are in serodiscordant heterosexual and 
same-sex relationships with a HIV-positive partner whose viral 
replication is not suppressed;
• Other heterosexuals considered to be at high risk.
5. National Health Service, England, Clinical Commissioning Policy 
Proposition: Pre-exposure prophylaxis (PrEP) to prevent the 
acquisition of HIV in adults [draft, 2016] 
 
Policy Statement: 
Policy Statement NHS England proposes to routinely commission Pre 
Exposure Prophylaxis for the treatment of adults at high risk of HIV 
acquisition in accordance with the criteria outlined in this document; 
 
Proposed Criteria for Commissioning: 
Prescribing of ARVs for HIV pre-exposure prophylaxis TDF/
emtricitabine will be prescribed as an intermittent regimen for MSM, 
trans women and trans men clinically assessed as being at high 
risk of HIV acquisition. Based on clinical assessment of individual 
clinical need, a daily regimen may be indicated and this will need 
to be fully documented. Daily TDF/emtricitabine will be prescribed 
for heterosexuals clinically assessed as being at high risk of HIV 
acquisition.
6. Nandwani R and Valiotis G, on behalf of the Scottish HIV Pre-
Exposure Prophylaxis Short Life Working Group. PrEP in Scotland. 
Scottish Health Protection Network (SHPN) October 2016
 Recommendations:
• The HIV PrEP Short Life Working Group strongly recommends that 
people at the highest risk of HIV in Scotland are provided with 
the option of PrEP as part of a wider targeted national prevention 
programme delivered by the NHS in sexual health services, subject 
to delivery of the programme at a cost effective price and reflecting 
SMC advice where applicable;
• Pending a decision on the availability of NHS-funded PrEP medication, 
the HIV PrEP Short Life Working Group recommends that the Executive 
Leads endorse specialist sexual health services targeting support to 
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provide advice and clinical monitoring to individuals who have either 
self-purchased PrEP medication or are considering doing so. 
7. Jones, A., Couzins, Z., Preparing for PrEP? – A Review of the 
Current Evidence for Pre-exposure Prophylaxis (PrEP) to prevent 
HIV infection in Wales, NHS Wales, 2017 
 
Recommendation:
• Pending the outcome of the decision from the All Wales Medicines 
Strategy Group (AWMSG) regarding NHS provision of PrEP medication, 
the HIV Expert Group recommends that the specialist sexual 
health services provide advice and clinical monitoring to individuals 
who have accessed PrEP medication outside of the NHS or are 
considering doing so;
• Additional funding will be required for specific support and 
monitoring of PrEP in specialist sexual health services;
• Formal structures should be in place centrally to monitor and 
evaluate the use of PrEP in Wales, to include: the outcomes regarding 
infection (HIV and other STIs); usage of PrEP (length of use, on 
demand or continual); behavioural changes (perceived risk of activity 
and condom use);
• Information regarding PrEP should be produced centrally, in 
collaboration with key stakeholders, as part of a revised HIV 
prevention programme;
• PrEP should not be considered in isolation but be seen as part of 
a comprehensive package of HIV prevention. Support needs to be 
given to allow for earlier diagnosis and linkage to other interventions 
that may reduce the incidence of STIs;
• Information regarding PrEP is constantly evolving, therefore central 
oversight needs to continue with updates being provided to services 
on a regular basis and public messaging revised accordingly. 
8. Australian National PrEP Guidelines, 2016: The Australian 
Commentary outlines the ASHM recommendations on how to 
effectively implement the US Public Health Service Guidelines in 
Australia. This Commentary is embedded in the US Public Health 
Service Clinical Practice Guidelines. 
 
Recommendation:
• PrEP is indicated for HIV-negative adults who are at ongoing high risk 
for HIV infection. HIV-negative status should be confirmed as close 
to initiation of PrEP as possible, ideally on the same day but not more 
than 7 days before the prescription is given, by using the standard-
of-care testing procedures. 
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W 9. NICE, Pre-exposure prophylaxis of HIV in adults at high risk: 
Truvada® (emtricitabine/tenofovir disoproxil), 2016 
 
There is no NICE guidance on pre-exposure prophylaxis for HIV 
but this evidence summary provides a comprehensive overview of 
evidence appropriate to population characteristics, health system 
and the policy context in the UK.
3.4.1 PrEP implementation in other jurisdictions
Taking PrEP to scale i.e. national implementation programmes, has been 
slow to evolve, which is surprising given the quality of the evidence 
supporting PrEP efficacy. PrEP is currently not available on the NHS in 
England, Scotland or Wales notwithstanding evidence reviews which have 
been undertaken in each jurisdiction, referred to throughout this chapter. 
NHS England announced in December 2016 that it will fund an extension 
to national HIV prevention programme with the aim of supporting those 
most at risk and reducing the incidence of HIV infection[93]. Following 
the recent Court of Appeal ruling that NHS England in collaboration with 
local authorities, has the power, but not the obligation, to fund PrEP a 
large scale clinical trial which will include 10,000 participants over the next 
three years at a cost of £10 million will be rolled out in 2017. NHS England 
emphasises that while the evidence supporting the clinical effectiveness 
of PrEP is strong, implementation questions that they claim should be 
answered before PrEP is rolled out on a national basis, should be answered. 
While not specified, evidence reviews from England, Scotland and Wales 
suggest that these questions pertain to the cost effectiveness of PrEP 
including the cost of clinical management, adherence, uptake, and levels 
of risk compensation/disinhibition.[94] While unstated, Gilead Science’s 
application for an SPC, which effectively prevents cheaper generic 
manufacturers from seeking marketing authorisation for their equivalent 
products, is likely to be a factor here as the cost of the NHS rises to almost 
10% of GDP[95]. Some NHS sexual health clinics – the most well known of 
which is 56 Dean Street in London – provides free HIV testing, STI screening 
and follow up to people who have purchased generic PrEP online.
It was reported at the 21st International AIDS Conference in Durban in 
2016 that more than 79,000 people in the United States have commenced 
PrEP in the last four years as widely advocated and endorsed by the 
CDC (see below). In New York City, a blueprint to reduce the incidence 
of HIV from 3000 new diagnoses per annum to 750 by the end of 2020 
includes statewide implementation of PrEP with collaboration among 
a wide range of clinical providers, HIV testing, primary prevention and 
93.  NHS England, NHS England announces major extension of national HIV prevention programme with Public Health 
England and funding for ten new specialised treatments, 4th December 2016. https://www.england.nhs.uk/2016/12/
hiv-prevention-pregramme/ [accessed 7th April 2017]
94.  Jones, A., Couzins, Z., Preparing for PrEP? – A Review of the Current Evidence for Pre-exposure Prophylaxis (PrEP) 
to prevent HIV infection in Wales, NHS Wales, 2017; European AIDS Clinical Society; NICE, Pre-exposure prophylaxis 
of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil), 2016; Nandwani R and Valiotis G, on behalf 
of the Scottish HIV Pre-Exposure Prophylaxis Short Life Working Group. PrEP in Scotland. Scottish Health Protection 
Network (SHPN) October 2016
95.  World Bank, Global Health Expenditure, http://data.worldbank.org/indicator/SH.XPD.TOTL.ZS [accessed 7th April 
2017]
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support services.[96] At a Conference on Retroviruses and Opportunistic 
Infections (CROI) in Seattle in February, 2017, Demetre C Daskalakis from 
NYC Department of Health and Mental Hygiene, New York, presented 
compelling evidence that the provision of PrEP as part of a broader HIV 
treatment and prevention package can make overarching objecting of the 
blueprint, Ending the Epidemic, appear achievable. NYC’s approach to 
HIV prevention is system wide and engages multiple stakeholders in PrEP 
delivery including STI clinics and community centres to operate a ‘status 
neutral’ model in which HIV testing is the gateway to a system of either 
HIV treatment or HIV prevention (see figure 3.4.1).
PrEP is widely available on the health system in France and on 11th 
April 2017, Scotland announced that PrEP would shortly be available on 
the NHS[97]. Many countries in Western Europe have either developed 
guidance for PrEP or made provision for PrEP in existing treatment 
guidelines. At present, the lower-income countries of central and Eastern 
Europe are showing very little interest in PrEP notwithstanding the 
emergence of generalised epidemics in this region. At time of writing, 
France is the only country providing PrEP through its public health service. 
The National Agency for Drug Safety has authorised a Recommendation 
for Temporary Use (RTU) of Truvada® for PrEP for three years, which can 
be renewed. As of July 2016, 1,077 people were reported to be receiving 
PrEP through the public health system, with 90 clinics offering PrEP 
assessment and prescription[98]. PrEP eligibility criteria are as follows:
• Anal sex without a condom with at least two different sexual partners 
in the last 6 months;
• Episodes of STIs in the past 12 months;
• Multiple PEP treatments in the last 12 months;
• Use of drugs during sex.
A PrEP demonstration project (PROUD) is completed in the UK and 
demonstration projects are ongoing in Belgium, Italy and the Netherlands, 
all of which are being implemented in healthcare settings. The target 
populations are MSM at high risk of HIV in Belgium, MSM and transgender 
people at high risk of HIV in the Netherlands, and sero-discordant 
heterosexual couples in Italy.
In Europe and Central Asia, PrEP demonstration projects are planned in 
a further 15 countries. National policy and clinical guidelines for PrEP are 
under development in Ireland, Romania and Ukraine as reported under 
the Dublin Declaration.[99]
The Danish Society for Infectious Diseases recommended in 2015 
that PrEP should be considered for MSM who are not HIV-infected 
and who regularly have condomless anal intercourse with different 
96.  New York State, Department of Health, Get tested, Treat Early, Stay Safe: End AIDS, 2015
97.  Boseley, Sarah, People at risk of HIV in Scotland to be given PrEP drug on NHS, The Guardian Newspaper. https://
www.theguardian.com/society/2017/apr/10/people-risk-hiv-scotland-prep-drug-nhs-aids [accessed 11th April 2017]
98.  European Centre for Disease Prevention and Control. Evidence brief: Pre-exposure prophylaxis for HIV prevention in 
Europe. Stockholm: ECDC; 2016.
99.  Ibid, p.2
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W partners. Repeated STIs are also a proxy for PrEP. However, PrEP is not 
recommended for heterosexuals on the basis that transmission among 
heterosexuals in Denmark has not reached a degree that justifies the use 
of PrEP. Danish guidelines provide for both daily dosage and ‘on demand’ 
regimens. In Spain the GeSIDA group of the Spanish Society of Infectious 
Diseases and Clinical Microbiology released Guidelines on PrEP in June 
2016, which recommend that PrEP should be offered to MSM and trans 
women who have had condomless sex in the last six months, and who have 
had more than two partners OR an STI diagnosis OR have sought PEP OR 
have had “chemsex”. These guidelines also recommend that PrEP may be 
considered for people who are not MSM or trans women where a person, 
a) is in a serodiscordant relationship with an HIV-positive person with an 
unsuppressed viral load; b) injects drugs and has shared equipment; c) 
has had transactional sex for food or shelter; or d) is otherwise socially 
vulnerable and at high risk of HIV.
3.4.2 Barriers to PrEP implementation in Europe 
An ECDC Evidence Brief on PrEP in Europe reported in October 2016 
that the cost of Truvada®, the cost of service delivery and feasibility are 
the main obstacles to PrEP implementation[100]. Thirty-one countries 
identified the cost of drugs as the primary issue preventing or limiting 
PrEP implementation, and 24 of these countries rated the issue of 
high importance. A further 23 countries identified the cost of service 
delivery as an issue of high or medium importance, and 19 countries 
identified feasibility as an issue of high or medium importance. A 
number of countries also expressed concerns about the impact of PrEP 
on transmission of other STIs, on condom use, eligibility criteria, and 
adherence and compliance with dosing regimens.[101] Gilead Science, 
Inc. recent application for a SPC for Truvada® will potentially reinforce 
obstacles to PrEP rollout on a wider scale in Europe not least in terms of 
extending the duration of the cost barrier.
100.  European Centre for Disease Prevention and Control. Evidence brief: Pre-exposure prophylaxis for HIV prevention in 
Europe. Stockholm: ECDC; 2016.
101. Ibid, p.6
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Chapter Summary
• A high quality, robust evidence base supports PrEP efficacy, with 
two RCTs demonstrating that once-daily Truvada® may reduce the 
relative risk of acquiring HIV infection in MSM and trans women by 
86% and by 75% in sero-discordant heterosexual couples compared 
with placebo ;
• The World Health Organisation recommends that oral PrEP should 
be offered as an additional prevention choice for all people at 
substantial risk of HIV as part of a combination of prevention 
approaches;
• The Bangkok Tenofovir Study is the only large-scale study conducted 
with PWID demonstrating a 48.9% reduction in HIV incidence but its 
findings may not be transferable to an Irish context; 
• PrEP efficacy is strongly correlated with adherence; 
• Implementation research is needed in diverse settings to support 
optimal adherence and to assess how PrEP may affect behavioural 
and social outcomes in the medium to long term;
• Six trials measured and reported low levels of drug resistance;
• The cost-effectiveness of PrEP appears to be particularly sensitive to 
key variables such as HIV incidence, levels of adherence, willingness 
to use PrEP, risk behaviours, the cost of drugs and other clinical 
interventions required to support PrEP programmes: as such cost-
effectiveness studies conducted in other jurisdictions are of limited 
value to the Irish context;
• PrEP programmes are supported by clinical guidance currently 
operationalised by key multilateral and national institutes for health in 
Europe and the USA;
• France is the only country in Europe currently providing PrEP 
through the public health service, but a number of countries are 
implementing or planning to implement PrEP demonstration projects;
• The cost of Truvada®, the cost of service delivery and feasibility are 
the main obstacles to PrEP implementation in Europe;
• Gilead Science’s application for an SPC for Truvada® is a significant 
threat to taking PrEP to scale in Europe.
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Figure 3.4.1 
Source: Department of Health and Mental Hygiene  
https://www1.nyc.gov/assets/doh/downloads/pdf/ah/neutral- 
prevention-treatment-cycle.pdf [accessed 7th April 2017]
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4. Findings: PrEP in the Irish Context
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the findings from key informant interviews conducted with a range of 
stakeholders including civil society activists, policy makers, health care 
providers, pharmaco-economists, international development specialists, 
and two focus group discussions (FGD) undertaken with MSM and HIV 
positive people between March and April 2017. Queries put to a range 
of sources including pharmacists and national health insurers are also 
included here where responses were issued either by telephone or 
email. Given the paucity of data available on the potential or rationale 
for introducing PrEP in Ireland, opportunities to verify or triangulate 
information were limited. Therefore, in order to present a clearer picture 
of the Irish-specific landscape, data from this research is presented so as 
to reinforce existing grey literature and academic sources where possible, 
with outlier issues and/or data corresponding to ToR requirements 
presented in section 4.6. This Chapter also includes analysis in the context 
of the evidence base presented in Chapter 3 or additional sources of 
evidence with recommendations for consideration or policy dialogue 
presented in bold. This is not an unbiased sample, however, and as such, 
findings must be interpreted with some caution.
4.1 Multiple risk behaviours for HIV and STIs 
The Men who have sex with men Internet Survey Ireland (MISI) 2015 
captures the sexual health knowledge, attitudes, needs and behaviour of 
over 3,000 men in the Republic of Ireland. A small number of respondents 
- 2% - said they were using PrEP even though it is not available in Ireland 
through the Health Service Executive.[102] Thirty-seven per cent of men in 
this survey had never tested for HIV and 61% had not tested for HIV in the 
last year, while 67% of respondents were definite about their HIV status, 
the remaining third were unsure with 29% believing that it was ‘probably 
negative’, 0.2% ‘probably positive’ and 4% ‘didn’t know’. Seventy nine 
percent of HIV positive respondents reported that they were on ART 
and of those on ART, 91% were virally suppressed. Nine percent of men 
reported having a newly diagnosed STI in the last 12 months and among 
those who reported testing for STIs within the last 12 months, 21% had a 
newly diagnosed STI. Seventy-one per cent of men who ever had sex with 
a man had condomless anal intercourse (CAI), 55% had CAI in the last 12 
months and 47% reported CAI within the last 6 months. Men most likely 
to report CAI with a non-steady partner were men with a lower level 
of education, men who were unemployed and HIV positive men. When 
steady and non-steady partners were combined 69% of men reported sex 
with more than one partner, and 25% had CAI with more than one partner 
in the last 12 months. Seventy-seven percent of HIV positive men reported 
more than one CAI partner[103].
102.  Kate O’Donnell, Margaret Fitzgerald, Peter Barrett, Mick Quinlan and Derval Igoe, MISI 2015 –  
Findings from the men-who-have-sex-with-men internet survey, Health Service Executive, 2016, p.91
103.  Ibid, p.VIII
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Seven percent of men reported using drugs associated with chemsex 
(sex under the influence of psychoactive drugs) during the last year, 
with usage more common among respondents living in Dublin, and 
those who were HIV-positive. These findings are consistent with a similar 
study conducted by the Dean Street Clinic in London in which chemsex 
behaviour tended to accelerate after a HIV diagnosis[104]. The Dean Street 
research also found higher rates of chemsex episodes in the aftermath of 
relationship break-up, and following migration to London. Sexually active 
episodes while under the influence of drugs tended to last from between 
12 and 48 hours and while 45% reported between 4 and 10 partners per 
episode, 11% reported 10 or more partners per episode.[105] Data in the 
initial stages of collection by the Gay Men’s Health Service (GMHS) in Dublin 
points to a significantly higher proportion of recreational drug use among 
men attending the service compared to the Dean Street cohort[106].  This 
data which is capturing a higher risk profile among men attending 
the GMHS will help to inform the Sexual Health and Crisis Pregnancy 
Programme Working Group on PrEP and the national multidisciplinary 
multisectoral group in their assessment of MSM PrEP eligibility. 
A study to assess the prevalence of chemsex among attendees at 
Ireland’s only dedicated sexual health clinic for MSM presented at the 
Society for the Study of Sexually Transmitted Diseases in Ireland (SSSTDI) 
Autumn Meeting in November 2016 reported that of 486 convenience 
sampling questionnaires included in analysis, 27% had engaged in chemsex 
reporting use of crystal meth, G, ketamine, mephedrone, NPS, cocaine, 
ecstasy or other stimulants during sex.[107] Use of drugs during sex was 
more likely to be reported by 25-39 yr olds (31%) compared to men aged 
18-24 and the over 40 age groups (20%). Gamma-Hydroxybuteric Acid or 
‘G’ is a central nervous system depressant that produces a stimulant effect 
at lower doses, was the most commonly used drug reported by men in this 
study. Half of these men had used 2 or more drugs at last chemsex episode 
and 9% had ever injected drugs for/during a chemsex episode. Of the 27% 
who reported engaging in chemsex, they were almost two and a half times 
more likely to have had more than 10 sexual partners within the previous 12 
months. Of 486 men participating in the study, 1 in 3 did not use a condom 
at last anal sex but those who reported engagement in chemsex were more 
likely to have engaged in CAI at last anal intercourse. In excess of two thirds 
(71%) of those who had engaged in chemsex had ever been diagnosed with 
an STI, compared with 56% of those who had not engaged in chemsex[108]. 
While this study is limited by the fact that it is only representative of men 
attending an MSM health service, it reinforces initial data emerging from 
this service (referred to above) which suggests that there is a cohort of 
MSM in Ireland demonstrating high and multiple risk behaviours for HIV.
104.  Stuart, D. Nneka Nwokolo, Alan McOwan, Margherita Bracchi, Marta Boffito, ChemSex: Data on Recreational Drug Use 
and Sexual Behaviour in Men Who Have Sex with Men (MSM) from a Busy Sexual Health Clinic in London, UK, Chelsea 
and Westminster Hospital Trust, 2016
105.  Ibid
106.  Email communication with Siobhán O’Dea, Gay Men’s Health Service, 15th March 2017. This data will be presented 
when analysed at a later date.
107.  Glynn, R., Chemsex use among MSM attending a sexual health clinic in Dublin, SSSTDI Autumn Meeting, 26th November 
2016
108.  Ibid, slides 9-14
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in the MISI Ireland study, the most common drug of choice being 
cannabis, ecstasy and cocaine. Recreational drug use was found to be 
more common among younger men, students, and those living in Dublin 
peaking among 20-24 year olds and HIV positive men.[109] These MISI 
data appears to reinforce these findings – and in fact suggests - a slightly 
higher prevalence of chemsex among MSM in Ireland compared to survey 
data recently published by Squirt.org, an online platform for MSM sex that 
surveyed 22,248 members in 2016. This survey found that chemsex had 
been practiced by 30% of survey respondents while 39% of respondents 
said they would consider engaging in chemsex and 61% said they would 
not. The drug of choice for study participants was crystal meth (36%), 
followed by marijuana (19%), cocaine (13%), and MDMA, better known as 
ecstasy (11%)[110]. Of relevance here, the survey also inquired about safe 
sex practices for those who engage in chemsex: 93% of respondents 
said that they don’t use protection for oral sex, while 51% said they don’t 
use protection for penetration. Eighty-nine per cent reported that they 
knew their current HIV status, 63% said they knew the HIV status of their 
partner, and 45% said they disclose their HIV status to their partners. A 
further 37% said they don’t know their HIV status. Twenty-three per cent 
of survey participants reported that they were HIV positive, with 19% 
saying they were positive, but undetectable and 68% who reported that 
they were HIV negative. Slightly higher percentages – 3% - were taking 
PrEP in this survey compared to the MISI cohort. 
 In the Dean Street study[111] 64% reported zero condom use, 
while initial data emerging from the GMHS appears to suggest that a 
slightly higher proportion of men who have completed an anonymous 
behavioural questionnaire, report that they do not use condoms for either 
insertive or receptive anal intercourse.[112] 
 In 2016 a national multidisciplinary multisectoral group was 
established with representation from the Sexual Health and Crisis 
Pregnancy Programme, STI and Infectious Disease services, Public Health 
Departments, the Health Protection Surveillance Centre, Laboratory 
services, the Gay Health Network, HSE Gay Men’s Health Service (GMHS), 
and Positive Now, an all-Ireland network of HIV positive people, in 
response to increasing trends in HIV and STIs amongst MSM in Ireland. As 
outlined in section 1.1 between 2014 and 2015, HIV notifications among 
MSM increased by 21%, while early infectious syphilis (EIS) increased by 
53%.[113] As indicated by figure 4.1 below, the number of MSM testing HIV 
positive in Ireland has been increasing exponentially since 2013 with 223 
cases, 58% of all new diagnoses, where the probable mode of transmission 
was known, reported in MSM in 2015.
109. Ibid, p.74
110.  Squirt.org. Prevalence of Drug-fuelled sex or Chemsex in the gay community, http://www.squirt.org/press/chemsex 
[accessed 10th April 2017]
111.  Stuart, D. Nneka Nwokolo, Alan McOwan, Margherita Bracchi, Marta Boffito, ChemSex: Data on Recreational Drug Use 
and Sexual Behaviour in Men Who Have Sex with Men (MSM) from a Busy Sexual Health Clinic in London, UK, Chelsea 
and Westminster Hospital Trust, 2016
112. Email communication with Siobhán O’Dea, Gay Men’s Health Service, 15th March 2017
113.  Health Service Executive, Epi-Insight: Disease Surveillance Report of the National Disease Surveillance Centre, volume 
17 issue 5 May 2016
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Figure 4.1: Number of HIV notifications in Ireland by reported probable  
route of transmission, 2012-2015
Source: Epi-Insight: Disease Surveillance Report of the  
National Disease Surveillance Centre, volume 17 issue 5 May 2016
 
There has also been a steady increase in EIS in MSM with 214 cases 
notified among this group in 2015, an increase of 53% on 2014. In the 
same year, MSM accounted for 87% of diagnoses of EIS – see Figure 4.2:
Figure 4.2: Number of notifications of EIS in Ireland by probable mode 
of transmission, 2012-2015
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Source: Epi-Insight: Disease Surveillance Report of the  
National Disease Surveillance Centre, volume 17 issue 5 May 2016
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to establish as the same level of behavioural surveillance is not available 
in Ireland. Provisional data from the HPSC illustrates that 29 cases of 
heterosexually acquired Syphilis and 402 cases of Gonorrhoea were 
notified in 2016 but 45% of all STIs where gender is known were acquired 
by women.[114] In addition, some level of risk is indicated by the Healthy 
Ireland 2015 survey in which a large number of respondents (87%) 
answered questions about their sexual health. As identified by the HPSC 
for this research, the Healthy Ireland instrument may provide an entry 
point for gathering a more complete behavioural surveillance dataset. The 
2015 data currently tells us very little about who is at risk for HIV but it 
points to high risk sexual behaviours in the general population with only 
24% reporting that they had used a condom when they last had sex, and 
47% reporting that they did not use any form of contraception the last 
time they had sex. Seventeen per cent of those were having sex outside 
a steady relationship and not using contraception.[115] The perspectives 
of representatives or health care providers working with key populations 
other than MSM have contributed to this research but few conclusions 
may be drawn due to the very small size of the sample. 
4.2 Comparing results with the Flash! PrEP in Europe: Ireland Report
The Flash! PrEP in Europe online survey which is conducted by the 
French HIV organisation, AIDES and the University of Amsterdam was 
officially launched on 15th June 2016. Initial results for Ireland revealed 
a high level of PrEP awareness with 92% (n=335) of MSM demonstrating 
awareness of PrEP, 72.5% of which demonstrated correct knowledge, 
and 27.5% incorrect or partially correct knowledge.[116] Sixty-six per 
cent of MSM reported a probable or definite intention to use PrEP if and 
when it becomes officially available[117] with only 15% reporting that they 
would probably or definitely not use PrEP if it were available in Ireland. 
Reflecting the findings of the focus group discussion in this study, 62% 
of MSM believed that PrEP should be available either free-of-charge or 
covered by health insurance, while 32% expressed the view that those 
who use it should pay some of the costs. Community health centres, STI 
clinics and General Practitioners were favoured by survey participants 
as the ‘best places to prescribe PrEP’.[118] In this study however, the 
MSM FGD overwhelmingly preferred to access PrEP in a specialist clinic/
hospital where staff are sensitive to and understand MSM lifestyles. Some 
men pointed to extremely negative experiences of accessing PEP in 
non-specialist centres where junior doctors were found to be unfamiliar 
with the treatment. General Practitioners (GPs) were also considered 
unsuitable to administer PrEP given that fees are likely to be charged and 
114.  Health Protection Surveillance Centre, Sexually Transmitted Infections (STIs) in Ireland, 2016 Provisional Data
115.  Healthy Ireland Survey, 2015, (Dublin: Stationary Office), p.57
116.  University of Amsterdam, AIDES, Plus. Flash! PrEP in Europe Country Report Ireland. Early Results. 2017, p.7
117.  This may be due to the sampling method, which distributed flyers through drug-related organisations in Dublin, HIV-
related organisations, LGBT-related organisations, migrants-related organisations, and provided regular information 
about the survey on Facebook® and twitter® HIV Ireland pages. The survey organisers also sponsored posts and 
adverts on Facebook® with a website banner posted on drugs.ie
118   Ibid, p.9
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similar to non-specialist centres, men reported a lack of understanding of 
gay lifestyles among some GPs.
Forty-five per cent of those ‘maybe, probably or definitely’ interested 
in using PrEP in the Flash! PrEP in Europe study reported that they 
‘somewhat or strongly agreed’ with the statement that ‘they would 
rather have condomless sex’ while 38% somewhat or strongly disagreed 
with this statement. This ambiguity and general lack of consensus on 
risk compensation was also reported by 90% (n=11) of MSM focus group 
participants in this study. One participant said that “The only reason 
I would want to go on PrEP is so that I would no longer need to use 
condoms.” and this view was shared by a number of men, and a significant 
range of civil society and health care professionals who participated in this 
study. However, this view was not unanimous with other FGD participants 
suggesting that for them PrEP provides “an opportunity to add another 
layer or prevention.” or similarly, “I want it for those times when I might 
make a stupid mistake.” The diversity of views around risk compensation in 
the context of PrEP reflects wider ambiguity around this issue not least in 
the evidence base which provides no definitive consensus. 
The Flash! PrEP in Europe study reported that ninety-eight per cent of 
men ‘maybe, probably or definitely’ interested in using PrEP said that it 
would make them feel safer and 89% that they would feel more in control, 
views also expressed by men participating in the FGD. Sixty-nine per cent 
‘somewhat or strongly agreed’ that they would have a more satisfying sex 
life if PrEP were available, which was a view also shared by men in the FGD, 
and 60% self-identified themselves at risk of acquiring HIV. The significant 
minority (n=61) who ‘probably or definitely’ would not take PrEP were for 
reasons including that they do not want to take medication every day (1 
participant in the FGD); concerned about side effects; do not want to pay 
for PrEP, or were afraid of being seen in a negative light, of acquiring STIs 
or do not perceive themselves to be at risk for HIV. Ten men (2.7%) said 
they are or have been participating in a PrEP study and of the remainder 
(N=355) 12 (3.4%) were informal PrEP users. It has not been possible to 
confirm the existence of a PrEP study at the GUIDE clinic in St. James’s 
Hospital but this Flash! PrEP report supports anecdotal evidence which 
emerged in the MSM FGD. A number of men who participated in the FGD 
at Outhouse on 22nd March 2017 said that they were using PrEP which 
they had purchased in generic form online at a cost of $150 for three 
months supply using guidance provided by the UK-based I want PrEP Now 
website. One participant said “The biggest concern for me as a PrEP user 
is that I am breaking the law by buying PrEP online.” a concern shared by 
a number of men in the FGD. Men importing PrEP in the FGD reported 
that they knew of people who had provided an address in Northern 
Ireland where online purchase of up to 3 months supply of medication 
online is permitted. The men had not experienced themselves or knew 
of anyone who had had the PrEP supply seized by customs and one 
participant reported that at least one clinician has advised that in the 
event that an import of generic PrEP is seized, he/she would be prepared 
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W to provide a retrospective prescription to satisfy customs officials. Men 
participating in this focus group and a FGD with HIV+ people expressed 
fears and concerns around the lack of clinical monitoring and support 
for people using generic PrEP that they have purchased online: one 
participant reported that he has but one functioning kidney following a 
cancer diagnosis, while others raised concerns about the impact of PrEP 
on haemochromatosis and/or potential interactions with performance 
enhancing drugs, which had been raised by health care personnel in one 
dedicated sexual health clinic. 
The ambiguity surrounding PrEP access, the lack of knowledge, 
information and clinical monitoring was raised by many as the greatest 
cause for concern currently. Drug resistance was highlighted by a number 
of HIV+ contributors to this study, who argued that drug resistant strains 
of HIV are a threat to the safety of positive and negative people. While as 
the evidence in chapter 3 highlights, these risks are low but concerns are 
nonetheless valid. Finally, the risks of purchasing medication online from 
unknown sources are well established, not to mention illegal under Irish 
law. The obvious health risks raised by men in the MSM FGD around the 
lack of clinical support for PrEP is a real cause for concern in terms of 
personal safety, the negative consequences of drug interactions, and pre-
existing health complications. Equally, the potential side effects of taking 
once-daily Truvada® or a generic alternative as outlined in section 3.1.1 
highlight the potentially serious consequences of self-administration of 
PrEP. The potential to increase resistant strains of HIV is increased by the 
risk that a person who is unaware of an existing HIV infection commences 
PrEP. One dedicated sexual health clinic said in interview that they are 
providing HIV testing and clinical monitoring to men who are taking PrEP 
but this is unofficial and neither funded nor supported by the HSE. As 
such, this service which is based on the goodwill of the people providing 
it is dependent on word of mouth and constrained by lack of capacity and 
resource limitations. As also advocated by the HIV PrEP Short-life Working 
Group in Scotland and while acknowledging that such interventions are 
not cost neutral, the safety concerns posed by the online purchase 
and self-administration of PrEP in Ireland must immediately prompt the 
funding and establishment, within existing specialist sexual health clinics, 
of information, advice and clinical monitoring services until such time as 
PrEP is made available through the HSE.
4.3 Comparing results with the PrEP Access in Europe Report
The PrEP Access in Europe Report published by the PrEP in Europe 
Initiative (PiEi) reported anecdotal evidence that some doctors are 
currently prescribing Truvada®® off label to HIV-negative individuals in 
at least ten countries in Europe. This report largely reinforces the findings 
of the Flash! PrEP in Europe Study with regard to the ways in which MSM 
are accessing PrEP, findings which are also validated by disclosures by 
MSM in the FGD undertaken by this study. The PrEP Access in Europe 
Report suggests that in the vast majority of these cases, access to PrEP is 
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through private practice where clients pay the full cost of the drug, which 
in Ireland is €700 for one box of 30 pills[119], which is also confirmed by 
this study. The report includes an anonymous quotation, which incorrectly 
cites the cost of Truvada®® and also incorrectly claims that PrEP is only 
available through the pharmacy in St. James’s Hospital: “IRELAND: “PrEP 
is only available to be dispensed from one pharmacy, based in the Sexual 
Health clinic (GUIDE) at St. James’ Hospital and comes at the full price 
(around €400 for a month). I would also imagine there would be extra cost 
involved for liver [and] renal function tests and regular HIV tests if in the 
private system.””[120]
It is also reported that people in Ireland are accessing PrEP through 
HIV-positive friends, who either share the Truvada®® pills that are no 
longer needed by them for treatment, or by going back to clinics for more, 
claiming that they have lost the prescription or the bottle.[121] 
Generic versions of PrEP are available from online pharmacies and while 
supply of prescription medicines by mail order (including the internet) is 
prohibited in Ireland, the PrEP Access in Europe report claims that this 
method of acquiring PrEP is increasingly prevalent in Ireland as outlined 
above.[122] While imports may potentially be seized by customs officials, 
it is claimed that customers are using parcel forwarding options based in 
countries that do allow generic drug importation. The UK, for example, and 
consequently Northern Ireland, permits three months’ supply of medicine 
for personal use. At least one pharmacy offers customers south of the 
border, the opportunity to direct medicines purchased online to Newry, 
where they may be collected.[123] Some clinics in Europe are offering 
unofficial drug-level testing to ensure that people are acquiring the 
correct levels of emtricitabine and tenofovir disoproxil fumarate as one 
specialist sexual health clinic confirmed is also occurring in Ireland. The 
PrEP Access in Europe report confirms – as raised by MSM in the FGD - 
that Ireland is one of a number of countries in which people are accessing 
PrEP in this way: “Ireland: “It is possible for people to order generic 
Truvada® online to a UK address which is then redirected. Anecdotally, 
this passes through customs and VAT is applied before delivery with no 
further issues””[124]
119.  Confirmed in correspondence with Miriam Moriarty, Chief II Pharmacist, Genito-Urinary Medicine and Infectious 
Diseases, St. James’s Hospital on 10th April 2017. It should also be noted, however, that a prescription issued privately 
by an Infectious Diseases specialist would be brought to a community pharmacy to be dispensed, where the actual 
costs may be higher. 
120.  PrEP in Europe Initiative, PrEP Access in Europe, October 2016, p.13
121.  Ibid, p.14
122.  Ibid, p.15
123  McNally’s Pharmacy, Newry, Co. Down - http://www.mcnallyspharmacy.com/index.php?option=com_
content&view=article&id=45&Itemid=109 [accessed 10th April 2017]
124  Ibid, p.15
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W 4.4 Comparing Results with Towards preparedness for PrEP: PrEP 
awareness and acceptability among MSM at high risk of HIV transmission 
who use socio-sexual media in four Celtic nations: Scotland, Wales, 
Northern Ireland and The Republic of Ireland: an online survey
The Social Media, Men who have Sex with Men and Sexual Health 
(SMMASH) survey collected anonymous, online self-completion 
questionnaires with MSM in Scotland, Wales, Northern Ireland and the 
Republic of Ireland in 2013. SMMASH sought information on socio-
demographic factors, sexual health and sexual behaviours in the previous 
12 months with HIV-negative/status unknown high-risk men (n=386) 
drawn from Scotland (44%, n=170), Wales (22%, n=85), the Republic of 
Ireland (19.9%, n=73) and Northern Ireland (14%, n=54). Participation 
generally reflected the relative population size of each country although 
Scotland was over-represented (+7%) and the Republic of Ireland under-
represented (−9.5%)[125]. 
The survey found that participants were more likely to be aware of 
PrEP if they lived in Northern Ireland (compared with Wales or Republic 
of Ireland), reported frequent (daily or more often) gay social media use, 
lived near the commercial gay scene, reported an HIV test or an STI test 
in the last year, reported regular HIV testing at least every 6 months or 
regular STI testing at least every year. The multivariate regression model 
revealed that only regular (at least every 6 months) HIV testing remained 
independently associated with PrEP awareness. Participants reporting 
≥10 anal and ≥5 CAI partners in the last year demonstrated significantly 
increased likelihood that they would use PrEP if it were available. Notably, 
an almost twofold difference between the Republic of Ireland and 
Northern Ireland in terms of PrEP awareness prompted the authors to 
recommend local health promotion initiatives for new HIV prevention 
technologies[126]. MSM FGD participants in this study were all PrEP-aware 
but some younger participants attended in anticipation of learning about 
PrEP which was not the focus of the discussion. FGD participants involved 
in outreach to MSM said that they are experiencing constant requests for 
information about PrEP – where it may be purchased, how it works etc – 
and this increasing demand for education and information on PrEP was 
raised by both civil society and health care providers in this study. 
125  Frankis, J, Young, I, Lorimer, K, Davis, M, & Flowers, P., Towards preparedness for PrEP: PrEP awareness and 
acceptability among MSM at high risk of HIV transmission who use sociosexual media in four Celtic nations: Scotland, 
Wales, Northern Ireland and The Republic of Ireland: an online survey, Sexually Transmitted Infections, 2016, 92, 4, p. 
279, Publisher Provided Full Text Searching File, EBSCOhost, viewed 27 February 2017.
126  Ibid, 282
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 4.5 Comparing Results with Antiretroviral Therapy (ART) for HIV 
Prevention: Attitudes and practice amongst healthcare providers  
in HIV and STI care in Ireland[127]
A cross sectional survey of attitudes to PrEP, TasP and Post-Exposure 
Prophylaxis (PEP) among HIV and STI health care providers presented at 
the Autumn meeting of the Society for the Study of Sexual Transmitted 
Diseases in Ireland (SSSTDI) in November 2016, revealed that 100% of 
medical, nursing and pharmacists who completed the self administered 
anonymous online questionnaire had heard of PrEP. A further 83% ‘agreed 
or strongly agreed’ with the statement that “PrEP should be available in 
Ireland to individuals at high risk for HIV”, while 91% indicated that they 
were ‘likely or very likely’ to recommend PrEP to high risk individuals. 
In excess of 90% ‘agreed or strongly agreed’ that PrEP should only be 
implemented as part of an overall HIV prevention programme, while up 
to 70% believed that the use of PrEP will encourage patients to engage 
in riskier behaviours. Less than 40% believed that the use of PrEP may 
disseminate ARV drug resistance, and circa 35% believed that the use of 
PrEP will result in less funding for general sexual health services. Less than 
40% expressed concern about side effects and less than 10% that PrEP 
may not be efficacious.
While the methods deployed to collect data in the Garvey et al (2016) 
study[128] (self-administered anonymous online questionnaire) presented 
at the SSSTDI conference were entirely different to the qualitative 
methods used in this study, a number of the same themes reported in 
Garvey et al also arose in semi-structured key informant interviews used 
here with a range of health care professionals working in HIV and sexual 
health in Ireland. 
Each of the themes raised by health care providers in Garvey et al 
(2016) study[129] will be explored here in light of the more in-depth 
qualitative data collected by this process:
1. “Who is going to look after this cohort, the services are already 
bursting at the seams.”[130] 
Health care providers interviewed in this study raised similar concerns 
identifying the capacity of the health care system to respond to HIV-
negative people at risk as one of the barriers to PrEP implementation 
in Ireland. Sexual health services were described by one participant as 
‘crisis managing’ clients requiring PEP and fails to envisage how PrEP might 
be incorporated into the treatment-to-prevention continuum of care. 
One dedicated sexual health centre reported an increasing number of 
MSM are requesting clinical support for PrEP, which they have purchased 
in generic form online. With significant capacity constraints, including 
127   Garvey P, Kiernan J, O’Leary A, Hurley C, Lyons F, Antiretroviral Therapy (ART) for HIV Prevention: Attitudes and 
practice amongst healthcare providers in HIV and STI care in Ireland, SSSTDI Autumn Meeting, 26th November 2016
128   Ibid
129   Ibid
130  Ibid, slide 18
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the radar’ as there is neither the staffing nor the resources to support 
a system of expansion. This clinic emphasised that their client base 
frequently present with a very high risk profile, with increasing episodes 
of chemsex reported, but that PrEP taken to scale needs to be supported 
by adequate resources. It was argued by this and many other providers 
contributing to this study that an implementation trial needs to be the first 
step so that feasibility issues may be addressed and the best way to make 
PrEP available to everyone who needs it identified (see below for further 
discussion). One health researcher argued that capacity issues should not 
outweigh the need for prioritisation of a prevention intervention like PrEP 
that promises such significant public health gains.  
2. “The non availability of PrEP is hugely concerning and is impacting on 
new HIV infection rates. The gay sex landscape has changed... Unsafe 
sex is now routinely part of the sexual repertoire and the use of 
recreational drugs have impacted on MSM sexual practises”[131] 
 
As indicated by section 1.1 increases in the number of MSM testing 
positive for HIV is an international phenomenon, not just an Irish 
one. Notwithstanding, both civil society and health care professional 
participants in this study echoed this concern with one dedicated sexual 
health centre pointing to an increasing number of MSM with multiple 
levels of risk including CAI and chemsex episodes attending the service. 
A significant number of health care providers argued that Ireland has 
largely failed to control the HIV epidemic with rising rates of HIV and STIs 
annually prompting the question as to whether Ireland needs to start 
viewing the epidemic as a public health emergency? One dedicated sexual 
health service pointed to a 44% increase in requests for PEP between 
2015 and 2016, while it was also reported that a number of MSM are taking 
performance enhancing drugs, which coupled with illicit drug use requires 
prompt intervention. One provider argued that from a public health 
perspective, there is a duty of care to those – very often women - who 
may unknowingly be at risk of HIV. A number of men attending the FGD 
in Outhouse also raised the fact that Ireland has become a ‘sex positive’ 
culture in recent years with an ever increasing number of sex parties 
available: as such, the sexual health service needs to evolve in parallel with 
changes in culture and society.  
3. “I do not consider it to be an appropriate use of taxpayers’ money. 
Condoms are a cheaper alternative” [132] 
This view was not expressed or shared by any participant in this 
study. While a small number of health care providers said that they may 
initially have had doubts about PrEP when factoring the competition for 
131   Ibid, slide 18
132   Ibid, slide 18
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health priorities within an already constrained health system, all of these 
reported that they had now reversed that view in favour of PrEP given 
the public health benefits and overwhelming evidence for PrEP efficacy. 
All participants expressed the view that PrEP should be seen as one 
prevention intervention among an arsenal of measures that are targeted 
and appropriate to the needs of the individual, but should not replace the 
emphasis on condom use to prevent HIV and STIs. 
If at its most basic, the principles of public health are understood to 
be rooted in the prevention of disease, the promotion of health and 
prolonging life then the evidence appears to suggest that PrEP is an 
appropriate public health intervention in the context of the risk profile 
of the community it serves. While there are multiple ways in which 
the evidence may be interpreted – for example, economic or political 
perspectives - policy options from a public health perspective are largely 
limited to one: PrEP is an effective public health intervention and while 
some participants in this study expressed reservations or concerns around 
how PrEP should be implemented, all contributors to this study supported 
the implementation of PrEP on public health grounds. 
4. “Politically, supplying PrEP free of charge would cause difficulty in the 
context of rationing of healthcare” [133] 
That PrEP should be provided free-of-charge at the point of delivery 
was contested in this study. A significant number of health care personnel 
did not believe that PrEP should be provided free-of-charge on the basis 
that a significant number of prevention interventions in others areas of 
healthcare are not free to those who need them. Meningococcal B is a 
serious life-threatening illness that primarily affects children under the 
age of 5 years: it is prevented by a vaccine that was only made available 
through the General Medical Service (GMS) to children born after 
1st October 2016. No rationale, it was argued, can advocate that PrEP be 
free-of-charge when antibiotics, contraception, the vaccine for chicken 
pox and Orlistat, a drug for treating obesity, are some of the numerous 
examples of prevention interventions in other areas of healthcare that 
are not funded by the GMS[134] scheme. People on low incomes will have 
access to PrEP if they are medical card holders. A FGD with HIV+ people 
mirrored this view suggesting that medical card holders should pay 
prescription charges and those who can pay should be obliged to make 
a contribution towards the cost of PrEP on the basis that it is a short-
term intervention rather than chronic condition requiring treatment for 
life. MSM participating in the FGD entirely disagreed with this position, 
unanimously arguing that PrEP should be entirely free at the point of 
access: “It’s back to us as a community – we are entitled to it [PrEP free-
of-charge]” while others suggested that some people would be prepared 
to pay for PrEP – “Some people would be willing to pay but I don’t think 
133   Ibid, slide 18
134   Either cost-limited or free-of-charge to medical card holders and refundable to tax payers above €144 per month 
limit
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W we should have to pay.” This tension between the provider perspective 
and the end-user perspective is not unusual, but in light of prevention 
interventions in other areas of healthcare that are comparable to PrEP 
it seems improbable that PrEP will be made available free-of-charge if 
implementation is taken to scale.
 This study contacted both VHI and Laya Health Insurance seeking 
conformation as to whether or not PrEP is now or may be covered in the 
future. Only VHI responded on 29th March as follows: 
Thank you for your e-mail of 20/3/17 below enquiring if Vhi cover Pre-
exposure Prophylaxis (PrEP). We confirm Pre-exposure Prophylaxis (PrEP)  
is not covered under our Member Rules Terms and Conditions. We are sorry 
our reply cannot be more favourable on this occasion.
4.6 New Findings
This study explored a number of issues relating to PrEP that are not explored 
by previous studies focusing on Ireland. These findings are as follows:
1. Reasons why PrEP should be introduced into the health care  
system in Ireland 
As already indicated, while this is far from an unbiased exercise in that 
all participants were directly or indirectly associated with HIV and sexual 
health services, that PrEP should be introduced into Ireland was almost 
unanimously supported. There were 2 participants who qualified their 
support for PrEP implementation, with one preferring to see the evidence 
from implementation trials in other jurisdictions before committing to PrEP 
in Ireland, and a second who, while not opposed in principle, advocated 
greater emphasis on testing and TasP rather than PrEP. The evidence base 
for PrEP efficacy is irrefutable, it was argued, which coupled with the high 
risk profile of some MSM in particular (see section 4.1), warrants immediate 
implementation. It was argued by a number of health care providers that 
Ireland has failed to control the HIV epidemic and while PrEP is not a silver 
bullet, it provides a significant contribution to the range of HIV prevention 
interventions that currently exist. Behavioural surveillance data strongly 
supports PrEP roll-out to MSM in Ireland but the evidence in terms of 
demand for PrEP, the risk profile or evidence of self-administration of 
PrEP is not available for other key populations affected by HIV.  
2. Barriers to PrEP implementation 
The most significant barrier to PrEP implementation in Ireland by 
participants in this study is Gilead Science, Inc.’s application for a 
Supplementary Protection Certificate (SPCs) for Truvada®. If granted, the 
term of the patent for Truvada® may be extended up to 2022 preventing 
cheaper generics from acquiring licenses for PrEP in the European 
market. This will have a knock-on effect on both cost effectiveness and 
budget impact (see below) which may delay introduction of PrEP not 
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only in Ireland but also in Europe. Other barriers to PrEP implementation 
raised by participants include the potential for other areas of the health 
service to object to PrEP among the competition for health priorities, and 
national debate which is bound to become emotive and argued along axes 
of morality and values rather than public health objectives.
3. Who should get PrEP? 
Responses to this question appear to have been determined by sector-
alignment: health care providers were more likely to advocate that PrEP 
should be made available to those in greatest need and/or at highest 
risk of HIV as part of a broader prevention and treatment package as 
per WHO, BHIVA, and CDC guidelines, while civil society actors and the 
focus group discussion with MSM argued primarily that PrEP should be 
available to anyone who wishes to take it. The FGD in particular made 
the point that HIV is a special concern for LGBTI communities and as 
such PrEP must be central to a national HIV and sexual health response. 
Some men entirely rejected the notion of eligibility criteria on the basis 
that the health system should respect an individual’s self-assessment of 
their own risk. This is understandable if unrealistic, however, as the health 
system, at least in the initial stages, is more likely to opt for a low-risk, 
lower budget-impact option which makes PrEP available to people of high 
risk of acquiring HIV as advocated by the WHO. While this level of caution 
is undoubtedly required to get PrEP over the policy line, the unintended 
consequences of limiting access to PrEP may prompt some men to put 
themselves at risk in order to meet the required criteria but only an 
implementation trial will determine the detail in this regard. The SHCPP 
Working Group for PrEP appears to favour eligibility criteria selected by 
the French health system as most appropriate to Ireland. These criteria 
are indicated in France for all persons over the age of 18 who do not 
routinely use condoms during sexual intercourse and who are at high risk 
of contracting HIV. In particular, gay men and transgender people who 
have sex with men and at least one of the following criteria:
• Anal sex without a condom with at least two different sexual partners 
in the last 6 months;
• Episodes of STIs in the past 12 months;
• Multiple PEP treatments in the last 12 months;
• Use of drugs during sex[135]. 
As outlined above, while some behavioural surveillance is available for 
MSM, this same level of data is not available for other groups at risk of HIV, 
prompting calls by a number of participants in this study for increased 
behavioural surveillance investment to help identify and better off-set 
risk by early intervention as also advocated by WHO Europe. Improved 
surveillance is required to enable Ireland to both achieve and report 
135  Provided by Dr. Fiona Lyons in personal email communication dated 10th March 2017.
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W against its 90-90-90 targets (by 2020, 90% of all people living with HIV will 
know their HIV status, 90% of all people with diagnosed HIV infection will 
receive sustained antiretroviral therapy, and 90% of all people receiving 
antiretroviral therapy will have achieved viral suppression).
A small number of outliers argued that PrEP should not be extended to 
non-citizens of Ireland. This may be valid in cost-effectiveness terms, but 
it is almost certainly problematic in public health terms given that at least 
55% of HIV cases diagnosed in Ireland originate from other countries. [136] 
Additionally, 35% (n=94) of people testing HIV+ in Ireland in 2015 were 
born in sub-Saharan Africa, and over half (53%) of female cases were 
born in sub-Saharan Africa. To fail to provide PrEP to non-Irish citizens 
may potentially offset any HIV prevention gains. HIV is a policy priority for 
Ireland’s overseas aid programme at the Department of Foreign Affairs 
and Trade, and the HSE has articulated a commitment to working in global 
solidarity with developing countries to fulfil its responsibility to achieving 
a universal ‘right to health’. Healthy Ireland: A framework for improved 
health and wellbeing (2013-2025) is explicitly committed to the principle of 
‘solidarity’ with resource poor countries[137] and the Irish government’s 
policy emphasis on a ‘whole-of-Government’ approach to realise policy 
coherence between departments and sectors means that any suggestion 
that non-Irish citizens may not access PrEP would contravene those policy 
commitments at national and international levels.
As outlined in section 3.2, WHO’s Consolidated guidelines on the 
use of antiretroviral drugs for treating and preventing HIV infection, 
Recommendations for a public health approach in 2016 recommend 
that PrEP be offered to all population groups at substantial risk of HIV 
infection. PrEP has been found to be effective in reducing the risk of 
acquiring HIV infection and that the level of protection does not differ by 
age, sex, regimen or sexual mode of acquiring HIV (rectal, penile or vaginal 
exposure).[138] However, the risk profile of key populations affected by 
HIV other than MSM is sadly lacking in an Irish context and as such it is 
virtually impossible to determine with any degree of accuracy the number 
of people likely to benefit from PrEP were it made available in Ireland. The 
MISI 2015 data is currently supporting an estimate of the number of MSM 
eligible for PrEP using the French health system eligibility criteria, but no 
such data exists for other population groups at risk of HIV. As such, only 
an implementation study will fill this gap in information. The scope of this 
research precluded in-depth assessment of key populations other than 
MSM in Ireland, and as such no firm conclusions may be drawn, but some 
interviews were conducted with key stakeholders from the Sex Workers 
Alliance Ireland (SWAI), a FGD with PositiveNow was conducted on behalf 
of this research, one interview conducted with a health care provider in 
the drugs sector and email communication was established with Ireland’s 
136. Geographic origin is unknown in 15% of cases (HPSC, 2015, p.12-13)
137. Health Service Executive, Healthy Ireland: A Framework for Improved Health and Wellbeing, 2013-2025, p.51
138.  Substantial risk of HIV infection is provisionally defined as HIV incidence around 3 per 100 person-years or higher 
in the absence of PrEP. HIV incidence higher than 3 per 100 person-years has been identified among some groups 
of men who have sex with men, transgender women in many settings, and heterosexual men and women who have 
sexual partners with undiagnosed or untreated HIV infection (WHO, Consolidated Guidelines, 2016, p.53)
5
5
-
5
6
F
I
N
D
I
N
G
S
:
 
P
R
E
P
 
I
N
   
T
H
E
 
I
R
I
S
H
 
C
O
N
T
E
X
T
embassy in Uganda where PrEP is currently being rolled out on a  
national scale.
SWAI welcomed PrEP and felt it would provide sex workers with an 
added layer of protection, which, it was argued, has become more 
important since the introduction of the Criminal Law (Sexual Offences) 
Act 2017 which criminalises the purchase of sexual services. SWAI said 
that there is anecdotal evidence which suggests that this new legislation 
is resulting in a decrease in income which in turn encourages higher risk 
activity as women and men strive to make a living. SWAI also raised the 
fact that women from traditional societies are more likely than Irish sex 
workers to engage in condomless sex.
The Bangkok Tenofovir Study[139] as reported in Chapter 3 is the only 
large-scale study conducted with PWID and its findings cannot be said to 
be transferable to an Irish context. Equally, while the US CDC highlights 
that a 70% reduction in HIV incidence was found in this trial,, a closer look 
at the data reveals that this level of protection was only achieved with 
optimal adherence and so the overall reduction was found to be 48.9%. 
It is clear from this research that PrEP has not featured in policy dialogue 
within the drugs sector and is certainly not a policy priority. The one 
health care professional who did participate in this study from the drugs 
sector cautiously welcomed PrEP in principle, but felt that real-world 
implementation evidence is lacking with regard to PWID. This participant 
further argued that PWIDs cannot access methadone programmes, 
while frontline and proven interventions like needle exchange services 
have experienced cutbacks. As such, it was argued that funds for the 
injecting population may be better spent on improving access to proven 
interventions, while waiting to see the evidence for PrEP emerge from 
other jurisdictions. The NHS Clinical Commissioning Policy Proposition: 
Pre-exposure prophylaxis (PrEP) to prevent the acquisition of HIV in adults 
argued cogently that: “Compared to many countries, the prevalence of 
HIV among people who inject drugs (PWID) is low in the UK, largely due 
to highly successful needle exchange programmes....There is insufficient 
evidence to support routine commissioning for this sub-population.”[140] 
The FGD with HIV+ MSM and women from sub-Saharan Africa welcomed 
PrEP but highlighted a paucity of information and knowledge among 
non-MSM key populations. This group argued that anyone who felt they 
were at risk should be in a position to request an eligibility assessment, 
and highlighted important concerns around the PEP[141] to PrEP nexus in 
which anecdotal evidence suggests that some people are clinic-hopping 
to acquire PEP in order to use it as PrEP without medical supervision. The 
FGD raised valid concerns about the emergence of drug resistant strains 
of HIV which also would affect the treatment options for HIV+ people.
As outlined in Chapter 3, the Partners PrEP study was a double-blind RCT 
139.  Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, 
Natrujirote P, Kittimunkong S, Chuachoowong R. Antiretroviral prophylaxis for HIV infection in injecting drug users in 
Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. The 
Lancet. 2013 Jun 21;381(9883):2083-90. Available from: https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/
archive/prep-idu-factsheet- 508.pdf [accessed 4th April 2017]
140.  NHS England, 2016, p.17
141.  Post Exposure Prophylaxis (see Introduction) 
H
I
V
 
I
R
E
L
A
N
D
 
R
E
P
O
R
T
P
R
E
-
E
X
P
O
S
U
R
E
 
P
R
O
P
H
Y
L
A
X
I
S
 
(
P
R
E
P
)
  
S
C
O
P
I
N
G
 
A
N
D
 
P
O
L
I
C
Y
 
O
P
T
I
O
N
S
 
R
E
V
I
E
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individuals in a heterosexual serodiscordant relationship in Kenya and 
Uganda. This trial reported a relative risk reduction of 75% compared with 
placebo. While it was not possible to interview serodiscordant heterosexual 
couples for this research, communication with the Irish Aid programme in 
Uganda reported that PrEP is a policy priority targeting people who have 
multiple sexual partners; engage in transactional sex including sex workers; 
use or abuse injectable drugs and alcohol; have had more than one episode 
of an STI within the last twelve months; are part of a discordant couple, 
especially if the HIV positive partner is not on ART or has been on ART for 
less than six months; are recurrent users of PEP (3 consecutive cycles of 
PEP);engage in anal sex or are members of key populations who are unable 
or unwilling to achieve consistent use of condoms.[142] It is, however, too 
early to assess demand for PrEP or to comment on the level of acceptability 
of PrEP in this sub-Saharan African context.
 While there is a paucity of behavioural surveillance data supporting 
an estimate of key populations – other than MSM - eligible for PrEP using 
the French health system eligibility criteria, participants in this study 
– with the exception of the drugs sector health care provider for valid 
reasons outlined above – overwhelmingly supported WHO 2016 guidance 
that PrEP be offered to all population groups at substantial risk of HIV 
infection in Ireland. In the absence of behavioural surveillance for key 
populations other than MSM, the Scottish HIV PrEP Short Life Working 
Group estimated that 5% or less are likely to be eligible for PrEP.[143] In 
practice, it is likely that MSM engaging in high risk behaviours will be more 
likely to meet the eligibility criteria than others. 
4. Implementation/demonstration study 
The vast majority of contributors to this research argued for an 
implementation or demonstration study as a first step before national 
implementation is considered. The rationale underscoring this 
recommendation was two pronged: in the first instance, a number of 
participants felt that were too many unknowns with regard to PrEP in 
Ireland to justify wholesale national implementation not least in terms of 
the capacity of the health system to respond to an additional cohort of 
HIV-negative patients; the level of demand for PrEP; operationalisation of 
eligibility criteria; levels of adherence; risk compensation, and unforeseen 
or unanticipated circumstances of this intervention in an Irish context. 
Secondly, it was argued that a trial would limit the immediate budget 
impact of making PrEP available until such time as generic and cheaper 
formulations are available, which are more likely to contribute to cost 
effectiveness. On the other hand, some contributors argued against an 
implementation study believing that the evidence is robust enough: if we 
are truly committed to evidence-based medicine, one participant argued, 
142.   Email communication with Denis Busobozi, HIV Advisor, Irish Embasy, Uganda.
143.  Nandwani R and Valiotis G, on behalf of the Scottish HIV Pre-Exposure Prophylaxis Short Life Working Group. PrEP in 
Scotland. Scottish Health Protection Network (SHPN) October 2016
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PrEP should be introduced without delay. One service provider from the 
drugs sector argued that Ireland might be best served by waiting to see 
the evidence arising from implementation research conducted elsewhere 
before investing in an intervention whose evidence–base is built on data 
from RCTs with limited real world application.
Policy tends to be developed in incremental steps[144] and while the 
concept of evidence-based medicine seems entirely rational, the power 
of experts, and indeed evidence itself, is almost always contingent on 
alignment with political priorities.[145] The evidence for public health 
policy suggests that a new and potentially controversial intervention like 
PrEP will not be taken to scale immediately but will commence with an 
implementation trial targeting those most at risk. This is not least because 
the budget impact can be contained, any untended consequences more 
easily offset and outstanding questions about PrEP implementation in 
Ireland more easily answered. 
5. Cost effectiveness of PrEP in Ireland 
As outlined in section 3.3 above, cost effectiveness studies are context 
and epidemic-specific and as such few conclusions can be drawn from 
studies conducted in other jurisdictions. The cost-effectiveness of PrEP 
is particularly sensitive to key variables such as HIV incidence, levels of 
adherence, willingness to use PrEP, risk behaviours, the cost of drugs and 
other clinical interventions required to support PrEP programmes. As no 
cost-effectiveness study has been conducted in Ireland, no definitive 
claims can be made as to whether PrEP is likely to be cost effective in 
Ireland. As described in Chapter 3, two studies conducted in the UK - 
where HIV incidence is higher (based on 2015 data), the cost of once-daily 
Truvada® is lower, the overall epidemiology of HIV and the risk profile 
of MSM is similar (see section 4.1) to Ireland - have demonstrated that 
PrEP would not be cost-effective unless the price of Truvada® is cut 
substantially[146]. Consequently, it seems reasonable to extrapolate that 
once-daily Truvada® for PrEP is unlikely to be cost effective in Ireland 
either. Health care professionals from a range of sectors who contributed 
to this study pointed to the fact that budget impact tends to be more 
important than cost effectiveness. Budget Impact Analysis (BIA) is a tool 
to predict the potential financial impact of the adoption and diffusion 
of a new technology or intervention into the healthcare system[147]. 
144.  Kingdon, J.W., Agendas, Alternatives, and Public Policies - second edition. 2003, New York, London: Longman; Kraft, 
M.E., Furlong, S., Public Policy: Politics, Analysis and Alternatives. 2013, London and Thousand Oaks California: Sage 
Publications; Stone, D., Policy Paradox: The Art of Political Decision Making - Revised Edition. 2002, New York: WW 
Norton & Company.
145.  Nathanson, C.A., Sember, R., Parker, R., Contested Bodies: The Local and Global Politics of Sex and Reproduction, in 
Sex Politics: Reports from the Front Lines, R. Parker, Petchesky, R., Sember, R., Editor. 2007, Sexuality Policy Watch: 
Rio de Janeiro. 
Nathanson, C.A., The Contingent Power of Experts: Public Health Policy in the United States, Britain, and France. 
Journal of Policy History, 2007. 19(1): p. 71-94.
146.  Ong KJ., Desai S., Desai M., Nardone A., Hoek AJ van., Gill ON. Cost and cost-effectiveness of an HIV pre-exposure 
prophylaxis (PrEP) programme for high-risk men who have sex with men in England: results of a static decision 
analytical model. The Lancet. 13 November 2015; Available at: http://www.thelancet.com/pdfs/journals/lancet/
PIIS0140-6736(15)00854-5.pdf (Accessed: 6th April 2017)
147.  Health Information and Quality Authority, Guidelines for Budget Impact Analysis, https://www.hiqa.ie/reports-and-
publications/health-technology-assessments/guidelines-budget-impact-analysis [accessed 12.4.2017]
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W It addresses the affordability of the intervention in terms of the net 
annual financial cost of adopting the technology for a fixed number of 
years, whereas cost effectiveness evaluates whether an intervention 
provides value relative to health outcome (see example)[148].
A significant number of health care providers including two pharmaco-
economists interviewed for this research argued that Gilead Sciences 
Inc need to make Truvada® available at an affordable price and that 
there is a need to negotiate a lower price for potential PrEP users in 
Ireland. As highlighted above, one of the most significant barriers to PrEP 
implementation was considered to be Gilead’s application for an SPC for 
Truvada® potentially preventing access to cheaper generics regimens for 
up to five more years. There has been some reluctance, however, among 
health care providers to use generic ARVs for HIV treatment with one 
study demonstrating that while generic substitution would be acceptable 
to the majority of patients and health care providers in an Irish sample, 
the potential increase in pill burden and dosing frequency were identified 
as concerns or barriers to generic substitution.[149] The authors argue that 
the potential saving to the health service which could be redirected into 
the HIV service or indeed new prevention interventions like PrEP merits 
some consideration. The introduction of generic substitution has resulted 
in significant cost savings to the Irish health service in recent years but 
generic substitution for ARVs has not been considered. It has been 
estimated by the NHS that substitution with generic ARVs would result in 
a cost saving of £1.25 billion but there are clearly other implications that 
need to be factored with regard to ARV generic substitution.[150] While it 
has not been articulated by senior policy makers in health, the potential 
cost of PrEP is perceived to be the barrier to implementation in Ireland, 
a finding also reported by Garvey et al’s study of health care providers 
discussed above.[151] Should costs appear to remain a barrier to PrEP 
implementation, there is a role for advocacy in challenging the HSE to 
explore the cost-saving potential of generic substitution of ARVs which 
have been found to be acceptable to the majority of patients and HIV 
health care providers in Kieran et al’s (2017) study[152].
Other contributors to this research argued that the decision to 
implement PrEP or otherwise should be informed by multi-factor analysis 
and not just cost or budget impact. The New York State blueprint for 
ending the HIV epidemic by 2020 adopted a return on investment (ROI) 
analysis rather than either a cost effectiveness or budget impact analysis. 
The strategy argues that “The state’s expenditures on efforts to end AIDS 
148.  Example: A cost-effectiveness analysis may indicate that Drug A is a good value relative to Drug B, because it has 
an incremental cost-effectiveness ratio (ICER) of €40,000 per Quality-Adjusted Life Year (QALY).  This means that 
per person, the health system needs to spend €40,000 additional Euro to provide each patient with Drug A.  If 
there are 3,000 patients within a health system that need this drug, the healthcare system will have to spend 
an additional €120 million Euro to treat these patients, which may not be affordable.
149.  Kieran, J.A., O’Reilly, E., O’Dea, S., Bergin, C., O’Leary, A., Generic substitution of antiretrovirals: 
patients’ and health care providers’ opinions, International Journal of STD & AIDS 0(0) 1–8
150.  Hill A, Hill T, Jose S, et al. Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 
2014–2018. J Int AIDS Soc 2014; 17: 19497.
151.  Garvey P, Kiernan J, O’Leary A, Hurley C, Lyons F, Antiretroviral Therapy (ART) for HIV Prevention: Attitudes and 
practice amongst healthcare providers in HIV and STI care in Ireland, SSSTDI Autumn Meeting, 26th November 2016
152.  Kieran et al, 2017, p.7
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as an epidemic should be viewed as investments rather than costs”[153] 
Estimating the lifetime HIV-related medical care cost as $357,498, while 
achieving the goal of reducing new HIV infections from 3,000 to 750 
per year by the end of 2020 would, it is estimated, result in a saving of 
$804.4 million. In relation to testing, New York State assessed the return 
on the public health investment of a large-scale HIV testing programme 
which demonstrated a return of $1.95 for every dollar invested.[154] ROI 
analysis should be considered in conjunction with budget impact and cost 
effectiveness analysis[155] which may prove to be a more propitious cost 
benefit benchmark for PrEP implementation in Ireland.
6. The Role of Advocacy 
The role of advocacy in supporting PrEP implementation was contested 
and perceived quite differently across sectoral lines although this divide 
was not consistently held. Health care providers welcomed HIV advocacy 
in general on the basis that every heath care issue requires champions 
without which very little traction would be gained particularly in areas like 
HIV and sexual health which tend not to be policy priorities. Specifically in 
relation to PrEP however, some argued that in light of serious constraints 
in the health system which have been receiving significant media focus, 
overt-PrEP campaigns may not be helpful in taking – as a first step at 
least – an implementation/demonstration study over the policy line. On 
the other hand some civil society groups and MSM participants in the 
FGD were of the view that the failure to provide PrEP to MSM who wish 
to avail of it constitutes “homophobia, this is stigma” and were “very 
uncomfortable” with any suggestion that overt public discussion involving 
the media is likely to be debated along axes of values and morality rather 
than public health which may risk or delay PrEP implementation.
The Terrence Higgins Trust (THT) in the UK has already faced this 
dilemma in terms of Public Health England’s reluctance to implement a 
PrEP programme. While engaging politicians in advocacy, THT found it 
efficacious to link political support with decision makers in the health 
services rather than engage them in public and/or controversial media 
debate. As is the case in Ireland, prominent politicians were not inclined 
to become involved in the debate in England, rather back-benchers and 
elected representatives not in government. THTs campaigns are factually 
based focusing on the public health benefits of PrEP in the context of a 
HIV epidemic that is spiralling in the UK with push back against narratives 
that seek to compare one disease with another. There has been some 
conservative backlash in the UK but it is a minority platform that has not 
gained significant traction. No backlash has been identified in Scotland 
since announcing that PrEP would be available on the NHS, however.
153.  New York State, 2015 Blueprint, p.14
154.   Ibid
155.  Ireland is currently not in a position to report against these targets
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Policymaking for sexual health and other contested domains in Ireland 
tends to favour a covert and ambiguous approach[156]. The divisive and 
polarising nature of debate on moral issues in Irish life has rendered policy 
and law reform in these areas highly problematic for politicians and civil 
servants, with changes driven and frequently successfully implemented 
from the ground up[157]. Given Ireland’s relatively cautious and sometimes 
conservative social and political culture, advocacy platforms for PrEP 
might be best served by campaigns targeting key policy makers, while 
mobilising political champions to engage stakeholders in dialogue to help 
remove some of the barriers to PrEP implementation. Furthermore, civil 
society representatives need to be prepared for media interest in PrEP 
with a factually based public health narrative that is devoid of emotive 
arguments and rests on sound science.
It emerged in the course of this research that some groups are using 
the system of PQs (Parliamentary Questions) as a way of acquiring 
information on the status of PrEP from the Sexual Health and Crisis 
Pregnancy Programme’s Working Group on PrEP. PQs are usually reserved 
as the final stage in a process of advocacy if at all not least because they 
tend to yield extremely cautious and benign answers from government 
representatives, while placing a significant administrative burden on key 
civil servants. The perceived need for PQs may be better met by improved 
channels of communication between community representatives on the 
Working Group and their constituency.
156.  Butler, S. and Mayock, P. ‘An Irish solution to an Irish problem’: Harm reduction and ambiguity in the drug policy of 
the Republic of Ireland, in International Journal of Drug Policy, 16:6 (2005), p. 421; Shane Butler, Alcohol, Drugs and 
Health Promotion in Modern Ireland (Dublin: Institute of Public Administration, 2002)
157.  Nolan, A., Larkan, F, Vectors of transnationality in the adoption of a liberal public health response to HIV and AIDS in 
Ireland, Global Social Policy 16(3) · December 2015 DOI: 10.1177/1468018115620458; Nolan, A. (forthcoming May 2018), 
Covert policy: the Church, the State and the gay community response to the emergence of AIDS in Ireland, Journal of 
Policy History; Nolan, A., (forthcoming 2018) Transforming School-based Sex Education Policy in the Initial Era of AIDS 
in Ireland, Irish Educational Studies 
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4.7 Chapter Summary & Conclusions
• All participants expressed the view that PrEP should be seen as one 
prevention intervention among an arsenal of measures that are 
targeted and appropriate to the needs of the individual, and should 
not replace the emphasis on condom use to prevent HIV and STIs;
• PrEP is an effective public health intervention and while some 
participants in this study expressed reservations or concerns around 
how PrEP should be implemented, all contributors to this study 
supported the implementation of PrEP on public health grounds;
• The safety concerns posed by the online purchase and self-
administration of PrEP in Ireland must immediately prompt the 
funding and establishment, within existing specialist sexual health 
clinics, of information, advice and clinical monitoring services until 
such time as PrEP is made available through the HSE.
• Data in the initial stages of collection by the Gay Men’s Health 
Service (GMHS) in Dublin points to a significantly higher proportion 
of recreational drug use and other high risk behaviours among men 
attending the service compared to the Dean Street Clinic in London;
• The risk profile of other groups affected by HIV is virtually impossible to 
establish as the same level of behavioural surveillance is not available in 
Ireland although high STI incidence rates among women and patterns 
of risk behaviour are evident in general populations surveys;
• MSM interviewed for this study argued that Ireland has become a ‘sex 
positive’ culture in recent years with an ever increasing number of 
sex parties available: as such, sexual health services need to evolve in 
parallel with changes in culture and society; 
• In light of prevention interventions in other areas of healthcare that 
are comparable to PrEP, it seems improbable that PrEP will be made 
available free-of-charge if implementation is taken to scale;
• A number of participants in this study raised the need for increased 
behavioural surveillance investment to help identify and better off-
set risk by early intervention. Improved surveillance is also required 
to enable Ireland to both achieve and report against its 90-90-90 
commitments: by 2020, 90% of all people living with HIV will know 
their HIV status, 90% of all people with diagnosed HIV infection 
will receive sustained antiretroviral therapy, and 90% of all people 
receiving antiretroviral therapy will have achieved viral suppression;
• To fail to provide PrEP to non-Irish citizens may potentially offset  
any HIV prevention gains. HIV is a policy priority for Ireland’s overseas 
aid programme at the Department of Foreign Affairs and Trade, and 
the HSE has articulated a commitment to working in global solidarity 
with developing countries to fulfil its responsibility to achieving a 
universal ‘right to health’. Healthy Ireland: A framework for improved 
health and wellbeing (2013-2025) is explicitly committed to the 
principle of ‘solidarity’ with resource poor countries. The Irish 
government’s policy emphasis on a ‘whole-of-Government’ approach 
to realise policy coherence between departments and sectors means 
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would contravene those policy commitments at national and 
international levels;
• Participants in this study overwhelmingly supported WHO 2016 
guidance which advocates that PrEP be offered to all population 
groups at substantial risk of HIV infection in Ireland;
• The potential cost of PrEP is perceived to be a barrier to 
implementation in Ireland. There is a role for advocacy in challenging 
the HSE to explore the cost-saving potential of generic substitution 
of ARVs which have been found to be acceptable to the majority of 
patients and HIV health care providers;
• Return on Investment analysis should be considered in conjunction 
with budget impact and cost effectiveness analysis in the context 
of the 90-90-90 targets[158] - 90 per cent of people living with 
HIV must know their status; 90 per cent of people with diagnosed 
HIV infection must be on sustained antiretroviral therapy; and 90 
per cent of people receiving antiretroviral therapy must have viral 
suppression – which may prove to be a more propitious cost benefit 
benchmark for PrEP implementation in Ireland;
• Advocacy platforms for PrEP might be best served by campaigns 
targeting key policy makers, while mobilising political champions to 
engage stakeholders in dialogue to help remove some of the barriers 
to PrEP implementation. Civil society representatives need to be 
prepared for media interest in PrEP with a factually based public 
health narrative, that is devoid of emotive arguments and rests on 
sound science;
• The perceived need for PQs may be better met by improved 
channels of communication between community representatives on 
the Working Group and their constituency.
158   Ireland is currently not in a position to report against these targets
6
3
-
6
4
F
I
N
D
I
N
G
S
:
 
P
R
E
P
 
I
N
   
T
H
E
 
I
R
I
S
H
 
C
O
N
T
E
X
T

H
I
V
 
I
R
E
L
A
N
D
 
R
E
P
O
R
T
P
R
E
-
E
X
P
O
S
U
R
E
 
P
R
O
P
H
Y
L
A
X
I
S
 
(
P
R
E
P
)
  
S
C
O
P
I
N
G
 
A
N
D
 
P
O
L
I
C
Y
 
O
P
T
I
O
N
S
 
R
E
V
I
E
W
6
5
-
6
6
P
O
L
I
C
Y
 
O
P
T
I
O
N
S
5. Policy Options
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has been to provide evidence-based guidance to both HIVI and the GHN 
on PrEP efficacy, while establishing the views of key populations affected 
by HIV, and stakeholders directly and indirectly involved in the provision 
of HIV services throughout Ireland. It is intended to enable an informed 
policy platform to realise effective advocacy for PrEP and as such this 
chapter will commence with an overview of the policy framework for 
PrEP at global, regional and national levels before concluding with policy 
options as determined by this review. Section 5.2 spotlights a combination 
of evidence-based findings from Chapter 3 combined with Irish-
specific findings presented in Chapter 4 to present policy options and 
considerations for PrEP policy dialogue and advocacy. Detailed findings are 
contained in the body of this paper with highlights summarised here.
5.1 Global, Regional and National Policy Framework for PrEP
The transnational dimensions of health, in particular, are facilitated 
and realised through governance structures which emphasise global 
and local connectivity[159]. Transnationalism and the multidimensionality 
of policy transfer intensifies the global-local nexus for HIV and AIDS 
policy. Ireland emphasises on an all-of-government approach with policy 
coherence prioritised between the HSE and Irish Aid’s global health and 
HIV partnership portfolio, illustrating the extent to which health policy 
is increasingly perceived to be international in scope. PrEP is already 
governed – directly and indirectly - by international policy instruments 
that have been ratified by Ireland. The most recent of these, the 2016 
United Nations Political Declaration on HIV and AIDS: On the Fast-Track to 
Accelerate the Fight against HIV and to End the AIDS Epidemic by 2030, 
was adopted at the United Nations General Assembly High-Level Meeting 
on AIDS in June 2016, and mandated UNAIDS to support countries in 
reporting on the commitments in the Political Declaration[160]. Paragraph 
48 is explicit in its endorsement of PrEP:
48. (We) Welcome the important progress achieved in research for 
new biomedical tools for prevention, notably regarding treatment 
as prevention, pre-exposure prophylaxis and antiretroviral-based 
microbicides and voluntary medical male circumcision, but also 
recognize that research and development must be accelerated, 
including for long-acting formulations of pre-exposure prophylaxis, 
preventive and therapeutic HIV vaccines and curative interventions;
159.  Obinger, H., Schmitt, C., Starkea, P., Policy Diffusion and Policy Transfer in Comparative Welfare State Research, 
Social Policy & Administration, Vol. 47, NO. 1, February 2013, PP. 111–129; Browne, T., Craddock, S., Ingram, A., Critical 
Interventions in Global Health: Governmentality, Risk, and Assemblage, Annals of the Association of American 
Geographers, 102(5) 2012, pp. 1182–1189; Kanbur, R., Sumner, A., Poor Countries or Poor People? Development 
Assistance and the New Geography of Global Poverty, Journal of International Development J. Int. Dev. 24, 686–695 
(2012); Dolowitz, D., Marsh, D., Learning from Abroad: The Role of Policy Transfer in Contemporary Policy-Making, 
Governance: An International Journal of Policy and Administration, Vol. 13, No. 1, January 2000; Yeates, N., Social 
Politics and Policy in an Era of Globalization: Critical Reflections, Social Policy and Administration, 1999, 33 (4): p372-
389;
160.  This Political Declaration was built on three previous political declarations: the 2001 Declaration of Commitment on 
HIV/ AIDS, the 2006 Political Declaration on HIV/AIDS and the 2011 Political Declaration on HIV and AIDS. Member 
States unanimously adopted the 2001 Declaration at the United Nations General Assembly Special Session on HIV/
AIDS in 2001. The 2001 Declaration reflected global consensus on a comprehensive framework to achieve Millennium 
Development Goal 6: halting and beginning to reverse the HIV epidemic by 2015.
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While four sub-paragraphs of paragraph 62 directly and indirectly 
endorse PrEP interventions, particularly in areas of high incidence, 
paragraph 62g is explicit in its commitment to the adoption of evidence-
based prevention measures “that reflect the specific nature of each 
country’s epidemic by focusing on geographic locations, social networks 
and populations that are at higher risk of HIV infection.” However, this 
paragraph also places particular emphasis on the need for each country 
to ensure that “resources for HIV prevention are spent as cost-effectively 
as possible and to ensure that particular attention is paid to those 
populations at highest risk, depending on local circumstances.” this is 
likely to affect those who believe that PrEP should be available to anyone 
who wishes to take it (see section 4.6 – Who should get PrEP?) 
UNAIDS is a key partner in Ireland’s Global Health and HIV Portfolio 
to which overseas development assistance commits €2.7 million per 
annum[161] and is therefore committed to 90-90-90 targets by 2020: 90% 
of all people living with HIV will know their HIV status, 90% of all people 
with diagnosed HIV infection will receive sustained antiretroviral therapy, 
and 90% of all people receiving antiretroviral therapy will have achieved 
viral suppression. To fast track actions to achieve the 2020 targets, the 
new Action plan for the health sector response to HIV in the WHO European 
Region 2017-2022 emphasises the need for member states to optimise 
prevention efforts through the prioritisation of evidence-based HIV 
prevention urging a particular focus on key populations, ‘with inclusion of 
novel approaches such as pre-exposure prophylaxis (PrEP) for populations 
at substantial risk of HIV acquisition’[162]
The Dublin Declaration, 2004 commits member states in Europe 
and Central Asia to act collectively in tackling the HIV/AIDS epidemic, 
setting out a number of actions to accelerate the achievement of this 
commitment. The countries also committed to closely monitor and 
evaluate the implementation of the actions outlined in the Declaration, 
along with those of the Declaration of Commitment of the United Nations 
General Assembly Session on HIV/AIDS. As such, the most recent special 
report under the Dublin Declaration 2016 particularly emphasises the 
need to reduce HIV infections in Europe as “Coverage of key prevention 
interventions, including condom promotion and distribution, behaviour 
change interventions, pre-exposure prophylaxis (PrEP) and harm 
reduction for people who inject drugs remains too low in many countries 
to make a real impact.”[163] 
At national level, policy provision for PrEP is contained in the National 
Sexual Health Strategy 2015-2020 under action 3.29: “Develop and 
implement guidelines for the appropriate use of antiretroviral therapy in 
HIV prevention.”
161.  2015 budget allocation
162.  WHO Europe, Action plan for the health sector response to HIV in the WHO European Region,  
2017-2022, Geneva
163.  ECDC, The status of the HIV response in the European Union/European Economic Area, Dublin  
Declaration report, 2016
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W 5.2 Policy options for PrEP Advocacy in Ireland: key recommendations 
and conclusions
This exploratory exercise has proved to have commenced with a 
misnomer in that policy options for the introduction of PrEP into Ireland 
as indicated by the evidence base governing PrEP efficacy; the global, 
regional and national policy context; the high risk profile of most at-risk 
populations; the epidemiology of HIV in Ireland, which reflects broader 
European trends; the views of health care providers and key stakeholders 
working directly and indirectly in HIV, and the views of potential end users, 
all point to one policy option: This review finds overwhelming evidence 
supporting the introduction of PrEP for populations at substantial risk 
of HIV in Ireland as part of a comprehensive package of HIV prevention 
interventions.
The evidence presented in Chapter 4 points to an albeit limited level of 
self-administered PrEP use among MSM, but which nonetheless requires 
urgent intervention by statutory services in collaboration with civil society 
who may be well placed to provide immediate information, education and 
guidance for PrEP users. It is recommended as a first step, that the safety 
concerns posed by the online purchase and self-administration of PrEP 
in Ireland must immediately prompt the funding and establishment, within 
existing specialist sexual health clinics, of information, advice and clinical 
monitoring services until such time as PrEP is made available through 
the HSE.
The evidence base, while currently dependent on RCTs and a small 
number of implementation studies, which are increasing in number, 
clearly demonstrates PrEP efficacy particularly for MSM and transsexual 
women. Two RCTs (PROUD and IPERGAY) demonstrated that once-daily 
Truvada® may reduce the relative risk of acquiring HIV infection in MSM 
and trans women by 86%. As indicated in Chapter 4, data in the initial 
stages of collection by the GMHS in Dublin points to a high proportion of 
recreational drug use while a significant proportion of men are reporting 
that they do not use condoms for either insertive or receptive anal 
intercourse. In sero-discordant heterosexual couples, the relative risk 
of HIV was reduced by 75%: it should be borne in mind; however, that 
the Partners’ trial funded by the Bill and Melinda Gates Foundation was 
conducted in Kenya and Uganda which are countries characterised by 
generalised epidemics and as such may not be transferable to an Irish 
context. Equally, the Bangkok Tenofovir Study is the only large-scale study 
conducted with PWID demonstrating a 48.9% reduction in HIV incidence 
but its findings may also not be transferable to an Irish context, where HIV 
incidence is low among PWID due to generally successful harm reduction 
interventions. Contributors to this study from the drugs sector were 
reluctant to endorse PrEP for PWID due to the paucity of implementation 
evidence. It should be noted that NHS England’s proposed eligibility and 
exclusion criteria of individuals whose injecting drug use is their only risk 
of HIV acquisition have been excluded from proposed PrEP provision, on 
the grounds that “current HIV incidence in this group in the UK is too low 
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for PrEP to be cost effective”[164]. While the risk profile of other groups 
affected by HIV is virtually impossible to establish as the same level of 
behavioural surveillance is not available in Ireland, high STI incidence 
rates among women and patterns of risk behaviour are evident in general 
population surveys. Consequently notwithstanding the absence of 
context-transferable evidence for key populations other than MSM and 
trans women, the World Health Organisation recommends that oral PrEP 
should be offered as an additional prevention choice for all people at 
substantial risk of HIV as part of a combination of prevention approaches, 
which is widely supported by contributors to this review, while recognising 
that the primary beneficiaries of potential PrEP introduction will be MSM 
in practice.
PrEP in practice is marked by a number of unknowns with regard to 
adherence levels, the potential for risk compensation, and of particular 
concern to health care providers interviewed in this study, the capacity 
of an already over-stretched sexual health service to absorb a cohort 
of HIV-negative clients. Implementation research is needed in diverse 
settings not least in terms of supporting adherence and the capacity of 
already over-stretched health systems to respond effectively to increased 
demand. It is also largely unknown how PrEP may affect behavioural and 
social outcomes in the medium to long term. The RCTs described here 
noted few changes in terms of sexual behaviours but trials provide a high 
level of psycho-social support that may not be replicated in real-world 
settings. WHO notes that while daily dosing was the preferred choice for 
the majority of users, implementation research is required to establish 
how best to adapt PrEP to diverse and changing sexual practices. It is also 
required to establish whether frequent HIV and renal monitoring could be 
reduced; how best to maximise support for PrEP users while minimising 
cost, while integrating PrEP into existing services. 
The vast majority of contributors to this review favoured an 
implementation or demonstration study as a first step not least because 
the budget impact can be contained, any unintended consequences more 
easily offset and issues resolved before PrEP is taken to scale. Concerns 
about the cost of PrEP were frequently cited as a perceived barrier to 
PrEP implementation: this is a Europe-wide concern, not just an Irish one. 
Clinical interventions are not cost-neutral and the actual cost of once-
daily Truvada® for PrEP is likely to impact significantly on the budget 
for HIV and sexual health. An implementation trail would facilitate cost-
containment until such time as generic substitutions are licensed for PrEP 
in Europe. As a first step, it is recommended that GHN and HIVI support 
the introduction of an implementation study, which may be more easily 
and speedily sanctioned, until such time as PrEP may be taken to scale.
The cost-effectiveness of PrEP appears to be particularly sensitive to 
key variables such as HIV incidence, levels of adherence, willingness to use 
PrEP, risk behaviours, the cost of drugs and other clinical interventions 
164.  NHS England, Clinical Commissioning Policy Proposition: Pre-exposure prophylaxis (PrEP) to prevent the acquisition of 
HIV in adults Reference: November 2016 [draft] 
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conducted in other jurisdictions are of limited value to the Irish context. 
The potential cost of PrEP is perceived to be a barrier to implementation 
in Ireland. In the medium to long term, there is a role for advocacy in 
challenging the HSE to explore the cost-saving potential of generic 
substitution of ARVs which have been found to be acceptable to patients 
and HIV health care providers, while Return on Investment analysis should 
be considered in conjunction with budget impact and cost effectiveness 
analysis which may prove to be a more propitious cost benefit benchmark 
for PrEP implementation in Ireland.
Coupled with concerns about the cost of PrEP and the capacity 
of the health system to respond to the clinical requirements of PrEP 
introduction, some participants raised questions as to whether PrEP 
should be made available to non-Irish citizens. This is problematic in public 
health terms given that at least 55% of HIV cases diagnosed in Ireland 
originate from other countries. [165] Additionally, 35% (n=94) of people 
testing HIV+ in Ireland in 2015 were born in sub-Saharan Africa, and over 
half (53%) of female cases were born in sub-Saharan Africa. To fail to 
provide PrEP to non-Irish citizens may potentially offset any HIV prevention 
gains. HIV is a policy priority for Ireland’s overseas aid programme at the 
Department of Foreign Affairs and Trade, and the HSE has articulated a 
commitment to working in global solidarity with developing countries to 
fulfil its responsibility to achieving a universal ‘right to health’. Healthy 
Ireland: A framework for improved health and wellbeing (2013-2025) is 
explicitly committed to the principle of ‘solidarity’ with resource poor 
countries. Importantly, the Irish government’s policy emphasis on a 
‘whole-of-Government’ approach to realise policy coherence between 
departments and sectors means that any suggestion that non-Irish citizens 
may not access PrEP would contravene those policy commitments at 
national and international levels. It is recommended that policy advocacy 
must ensure that PrEP implementation does not operate eligibility on the 
basis of citizenship but works to ensure inclusiveness on public health 
terms and in the interests of a ‘whole-of-government’ approach. 
Europe’s Action plan for the health sector response to HIV in the WHO 
European Region, 2017-2022 urges member states to “collect and analyse 
timely and high-quality epidemiological data to understand how, where 
and among whom new HIV infections are occurring, develop HIV estimates, 
monitor risk behaviours and estimate the size of key populations in need 
of services.”[166] Ireland’s failure to prioritise and invest in the collection 
of epidemiological data is a significant risk to cost-effectiveness, budget 
impact and service planning estimates for PrEP and other interventions, 
while also precluding full engagement and reporting against high profile 
international commitments, including 90-90-90 targets. A number of 
participants in this study raised the need for increased behavioural 
surveillance investment to help identify and better off-set risk by early 
165. Geographic origin is unknown in 15% of cases (HPSC, 2015, p.12-13)
166. WHO Europe, 2016, p.8
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intervention. Part of the challenge to the statutory services in responding 
to new technologies like PrEP is that reliable estimates of the number of 
people likely to be eligible are wanting due to lack of epidemiological data 
and evidence supporting implementation. There is a role for civil society to 
champion improved surveillance systems in Ireland so that new technologies 
(like PrEP) are supported by robust epidemiological data and evidence.
Civil society advocacy is central to the realisation of particularly 
contested policy issues, and plays a key role in holding government 
and statutory service providers to account. While advocates for PrEP 
implementation are an important part of the process, Ireland’s relatively 
conservative political culture points to a generally cautious approach to 
policy change for sexual health. Views were divided on the best approach 
to policy advocacy for PrEP but it is herein suggested that advocacy 
platforms for PrEP might be best served by campaigns targeting key policy 
makers, while mobilising political champions to engage stakeholders in 
dialogue to help remove some of the barriers to PrEP implementation. 
Civil society representatives need to be prepared for media interest 
in PrEP with a factually based public health narrative that is devoid of 
emotive arguments and rests on sound science. 
It is a flawed rationale that renders the statutory services ever the 
subject of complaint when private interests like Gilead Science Inc are the 
primary reason why PrEP is not likely to be affordable. Gilead’s application 
for an SPC for Truvada® is the single most significant threat to taking PrEP 
to scale in Europe not just in Ireland and this issue requires strong civil 
society engagement.
Conclusion
A combination of the evidence for PrEP efficacy coupled with the 
risk profile of key populations in Ireland, increasing incidence of HIV 
reflecting broader European trends, PrEP’s policy coherence with 
Ireland’s international policy position, and a high level of support for 
PrEP implementation among key stakeholders and potential end-users, 
points to the need for immediate steps to be taken to make PrEP 
available to key populations at substantial risk of HIV acquisition as part 
of a comprehensive package of HIV prevention measures. At an absolute 
minimum, the failure to provide HIV testing and clinical monitoring to MSM 
who are self-purchasing and administering PrEP is a risk to the individual 
and broader public health. While multidrug resistance levels are generally 
low, the risks are increased if people with an undiagnosed HIV infection 
are acquiring PrEP online. The global, regional and national policy context 
actively advocates PrEP implementation and the requirements to prioritise 
HIV prevention in member states of the European Union where sexually 
acquired HIV incidence rates are raising exponentially must render PrEP a 
policy priority in Ireland. 
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[accessed 7th April 2017] 
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Terms of Reference provided by HIV Ireland Ltd and the Gay Health Network to 
guide Pre-exposure Prophylaxis (PrEP) Scoping and Policy Options Review
a. We need guidance on PrEP!
b. Your paper will help inform the decision making and future position of HIVI on 
PrEP.
c. The paper will be of sufficient integrity to be accepted and respected by 
external stakeholders in debates on the pros and cons of PrEP and its 
introduction into Ireland.
d. The paper will explore the main issues for and against PrEP and the 
experience of introducing PrEP in other jurisdictions.
e. The paper in particular will identify barriers to PrEP, both actual and 
perceived, and provide responses to these barriers.
f. The paper will explore PrEP within an Irish context i.e. any unique Irish factors 
relative to international experience of introducing PrEP.
g. The paper will explore PrEP and MSM but also other target groups where PrEP 
would be relevant (e.g. IVDU’s, Sex Workers).
h. The paper will aim to engage with end users.
i. The paper will provide an objective and informed voice that can influence 
Government policy.
7
7
-
7
8
A
P
P
E
N
D
I
X
 
A
Appendix B: PrEP Desk Review Synthesis
Research 
Parameters
Themes 
Public health effectiveness Adherence Feasibility/knowledge/ 
willingness to take PrEP
Risks/Risk Compensation Cost/cost 
effectiveness
Guidance 
on PrEP
1.  WHO: Oral PrEP containing
TDF should be offered as an
additional prevention choice for
people at substantial risk of HIV
infection167 as part of combination
HIV prevention approaches. This
is a strong recommendation,
supported by high-quality
evidence;
2.  PrEP should not displace or
threaten the implementation of
effective and well-established HIV
prevention interventions, such as
condom programming and harm
reduction (WHO, 2016);
3.  There is a need for synergy & a
broad approach to harm reduction
programming to include the offer
of PrEP to address both sexual
and injection-related health risks
(Coleman et al 2016);
4.  On 22 August 2016, the European
Commission officially granted
marketing authorisation for once
daily Truvada® in combination
with safer-sex practices to reduce
the risk of sexually acquired
HIV-1 infection among uninfected
adults at high risk. The marketing
authorization allows for the
marketing of Truvada® for PrEP in
all 28 countries of the European
Union, subject to national
regulatory authority approval
of required pharmaco vigilance
materials in each country.
1.  Level of protection is strongly
correlated with adherence. 12
trials on the effectiveness of
oral PrEP have been conducted
among serodiscordant couples,
heterosexual men, women, MSM,
Trans & PWID-all demonstrate that
when adherence is high, significant
levels of efficacy have been
achieved.
2.  Perfect compliance is not required 
to obtain benefits of PrEP but 
timing relative to HIV exposure is NB
1.  A number of studies note high
levels of acceptability and
willingness to use PrEP but low
levels of uptake;
2.  PrEP is recommended for those
facing a genuinely high risk of
acquiring HIV. The benefit to be
obtained from PrEP depends on
the incidence rate of HIV and this
factor has to be balanced against
the (small) risks of the medication.
Adverse events are infrequent,
the benefits of treatment for
those living with HIV are very high,
whereas the benefits of PrEP
to those who are HIV-negative
depend entirely on their chance of
acquiring infection;
3.  Koechlin et al, 2016 systemmatic
review identified strong interest
& support for PrEP use amongst
most populations at risk of HIV
infection, and lesser (though still
fairly high) interest among people
who inject drugs. Notably, literature
on heterosexual men, transgender
people, adolescent girls and young
women, and people who inject
drugs is limited, thus calling for
more research;
1.  Literature does not provide
a definite consensus on risk
compensation but accurate to
state that there is no conclusive
evidence to support the claim that
PrEP leads to risk compensation in
sexual practices, such as decreased
condom use or more sexual
partners;
2.  Given concerns about risk
compensation, normative bodies
continue to maintain that PrEP
should be used together with
condoms;
1.  The HIV incidence threshold for
cost-saving implementation of PrEP
will vary, depending on the relative
costs of PrEP versus treatment for
HIV infection and the anticipated
uptake & effectiveness of PrEP.
PrEP costs are not limited to the
cost of drugs and include costs
for clinic staff, laboratory testing,
pharmacy services, community
education, provider education and
monitoring and evaluation;
2.  A systematic review of 13 cost-
effectiveness studies found that
key considerations to address in
assessing cost-effectiveness of
PrEP are cost, epidemic context,
individual adherence level,
PrEP programme coverage and
prioritization strategy.
[1]
167   Substantial risk of HIV infection is provisionally defined as HIV incidence around 3 per 100 person-years or higher in the absence of PrEP (measure 
of incidence rates – result of events divided by time, in this case possibly 3 infections in group of 100 people in one year) HIV incidence higher 
than 2 per 100 person-years considered sufficient to warrant offering oral PrEP in the recommendations issued by the International Antiviral 
Society – USA expert panel in 2014 . Thresholds for offering PrEP may vary depending on a variety of considerations, including epidemiological 
context or trends, available resources and the relative costs, feasibility and demand for PrEP.
HIV IRELAND REPORT PRE-EXPOSURE PROPHYLAXIS (PREP) 
SCOPING AND POLICY OPTIONS REVIEW
Research 
Parameters
Themes 
Public health effectiveness Adherence Feasibility/knowledge/ 
willingness to take PrEP
Risks/Risk Compensation Cost/cost  
effectiveness
Pros/in favour 
of PrEP
1.  Stepping stone to the ultimate goal 
of HIV vaccine;
2.  Low level of adverse events 
reported;
3.  The risk of drug resistance is 
low but in case of large-scale 
implementation is unknown;
4.  Access provides opps for accessing 
sexual health services, & people 
at substantial HIV risk often slip 
through gaps & have fewer HIV 
prevention options;
5.  New infections among MSM in 
UK are down 40% - Lancet 2017 
suggests that while, “The decline 
in infections cannot with certainty 
be linked to PrEP, the temporal 
correlation is compelling.”
1.  Different effectiveness findings 
between studies can be explained 
by differing adherence levels;
2.  Low adherence levels in the 
efficacy trials raised concerns 
about the feasibility of PrEP 
as a public health strategy but 
recognised that real-life adherence 
to a product of demonstrated 
effectiveness would probably 
be different from adherence 
in a placebo-controlled trial, 
where participants are told that 
intervention efficacy is still unclear 
and that half of them are receiving 
a placebo.
1.  The impact of PrEP on sexual 
practices may vary according 
to social & cultural contexts 
but may also provide opps for 
understanding how PrEP influences 
sexual practices leading to 
improved SH outcomes.
1.  Koechlin et al 2016 systematic 
review found no significant effect 
on sexual behaviour with PrEP use – 
funded by WHO
1.  Some trials find PrEP favourable 
in terms of cost-effectiveness 
but this finding is not transferable 
as CE is particularly context and 
epidemiologically dependent.
Cons/
opposition  
to PrEP
1.  Neither cost nor value neutral;
2.  Several studies noted subclinical 
declines in renal functioning and 
bone mineral density among PrEP 
users which reversed when PrEP 
discontinued;
3.  Stigma is a driver of HIV and 
could be decreased or increased 
depending on how PrEP is 
implemented;
4.  Resistance among some health 
care providers – ID staff do not 
manage HIV neg populations;
5.  Destabilized the social norm of 
‘‘100% condom use,’’;
6.  Few side-effects reported - Mild 
nausea, diarrhoea, bloating and 
headache were reported in the 
first month by less than 1 in 10 
people. These side effects then 
usually cease.
1.  Studies with low adherence show 
no effect on reducing HIV;
2.  Social & behavioural factors critical 
to compliance;
3.  Younger populations have poorer 
adherence;
4.  two people have become HIV 
positive even though they were 
adhering to PrEP. This was because 
they caught HIV from a partner who 
was already resistant to the drugs in 
PrEP. This is a very rare event. 
1.  The impact of PrEP may also realise 
adverse behavioural & social 
outcomes although trials have not 
brought any to light as yet;
2.  Issues of equality & access are 
raised by PrEP;
3.  Low levels of PrEP awareness 
reported across Celtic nations. 
Only one-third of high-risk MSM 
had heard of PrEP but over one-
half would be willing to take a daily 
pill to prevent HIV infection. 
1.  IPERGAY trial, provided intensive 
counselling on the importance of 
safe sex and condom distribution 
& moreover, trail participants are 
selected assuming that they do not 
use condoms consistently and have 
multiple partners => an increased 
cost implication to minimise risk 
compensation.
1.  Cost implications of M&E, HIV 
testing, STI screening, renal, HBV 
monitoring, adherence support etc.
2.  Cost effectiveness relative to low 
incidence rate? 
79-80APPENDIX B
Research 
Parameters
Themes 
Public health effectiveness Adherence Feasibility/knowledge/ 
willingness to take PrEP
Risks/Risk Compensation Cost/cost  
effectiveness
Experience  
of introducing 
PrEP in other 
jurisdictions
1.  Confining to MSM is more 
stigmatizing;
2.  Australian guidance differs from 
guidelines in the US, SA, & EU in its 
approach to determining eligibility 
for PrEP-targets daily PrEP to those 
at high and ongoing risk of HIV 
infection, which in the Australian 
context is mainly MSM-considering 
expansion to those at moderate 
risk of HIV as access to PrEP 
improves.
1.  Data from clinical trials and others 
indicate that most participants did 
not take oral PrEP as prescribed. 
Although adherence observed 
in clinical trials is likely to vary 
considerably from levels in the 
‘‘real world,’’ trial results suggest 
that implementation programmes 
need to greatly increase adherence 
levels in order to maximize the 
likelihood that PrEP will have a 
population-level impact;
2.  Despite the initial reports of PrEP 
efficacy, concerns were raised 
because of the less-than-optimal 
adherence in iPrEx (approximately 
51% had detectable drug levels 
in their blood) and two PrEP 
studies in African women that did 
not demonstrate protection; US 
community-based clinics have 
reported high levels of patient 
adherence to PrEP.
1.  Much of the data on the 
acceptability of PrEP is based 
on willingness to take PrEP (i.e., 
hypothetical receptivity) rather 
than actual intentions (i.e., planned 
behavioral action). 
2.  Intending to begin PrEP in US most 
common among men most at risk 
for HIV. 
3.  PEP used for PrEP – evidence of 
clinic hopping in EU countries & pill 
sharing;
4.  Purchasing online at full cost/
or generic without medical 
supervision is widespread across 
Europe;
5.  Some EU clinics offering drug 
testing to ensure quality of product 
purchased online;
1.  In generalized epidemics, priority 
for the use of PrEP to people at 
substantial risk of acquiring HIV 
infection increases impact but 
some studies found PrEP to be 
cost–effective within the context of 
ART expansion only & others found 
no benefit;
2.  In concentrated epidemics 
results vary widely. Studies have 
found PrEP to be cost–effective, 
depending on the cost of the drug 
and delivery systems when PrEP 
uptake is higher among people at 
substantial risk;
3.  Canadian study concluded that 
‘on demand’ (as opposed to 
continuous) PrEP strategy ranges 
from cost saving to largely cost-
effective;
HIV IRELAND REPORT PRE-EXPOSURE PROPHYLAXIS (PREP) 
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Research 
Parameters
Themes 
Public health effectiveness Adherence Feasibility/knowledge/ 
willingness to take PrEP
Risks/Risk Compensation Cost/cost  
effectiveness
Barriers to 
PrEP, both 
actual and 
perceived 
1.  Many of the issues raised in argument 
against PrEP are identical to those 
invoked against female contraception, 
namely, cost, safety, the potential 
impact on sexual behaviour and the 
potential for unforeseen health risks 
associated with longterm use- not 
new or specific to HIV;
2.  Lack of data for targeting high-risk 
populations;
3.  Advocates of prevention among SWs 
& PWIDs in some jurisdictions have 
argued that authoritarian states 
could implement mandatory PrEP 
programmes for KPs, resulting in 
human rights violations, or simply 
in the neglect of other effective 
prevention interventions,;
4.  Current media focus on PrEP and 
MSM, encourages assumption that 
MSM should ‘‘be responsible and  
just use condoms,” & fails to take  
into account of the fact that for  
many MSM, condoms are not a  
feasible option;
5.  More nuanced discussion is missing 
about the potential benefits of PrEP 
for women, including female sex 
workers and transwomen, for whom 
PrEP offers a prevention strategy that 
is under their control;
6.  PrEP will ‘‘medicalize’’ what should 
properly be regarded as a structural 
and social issue ;
7.  PrEP exemplifies global economic and 
health disparities in an intervention 
that caters to affected communities 
in rich countries when over half the 
people with HIV in the world still 
cannot get treatment;
8.  A key challenge for Europe is to meet 
the needs of other high-risk groups, 
particularly migrants, for whom 
the links with community-based 
organizations and the healthcare 
system are much lower than for MSM
Perception of poor adherence levels. 1.  In US men intending to begin  
PrEP were those with the least 
access to it;
2.  US studies found barriers based 
on financial, insurance, and 
immigration status;
3.  Knowledge of PrEP is low outside 
clinical trials;
1.  Several studies with health care 
personnel capture concerns about 
risk compensation. For several 
participants, this discussion took on 
a moralistic tone;
2.  One study with non-specialist 
healthcare providers found that 
the need to discuss sexual activity 
to assess risk and determine 
whether PrEP was appropriate was 
perceived as a major barrier to 
PrEP;
3.  Perception that PrEP will increase 
behavioural disinhibition, resulting 
in new HIV transmissions, whether 
it will promote the development 
of resistant strains of HIV, and/or 
increase rates of STDs. 
4.  Concerns raised regarding rates 
of toxicity of the medications, 
because side effects may be less 
acceptable for individuals who are 
otherwise healthy than for people 
at risk of developing HIV without 
medication.
1.  A common problem for all 
countries is the cost of the 
drug which makes large-scale 
national PrEP programmes look 
unaffordable. This is the underlying 
reason that the PrEP policy has 
stalled in England and Wales, where 
the National Health Service is only 
willing to contribute £2M to the 
early implementation activities 
(McCormack et al 2016);
2.  Cambiano et al 2015 concluded 
that in UK the use of PrEP for MSM 
during periods of condomless sex 
is not cost effective at current 
antiretroviral prices, but it would 
become cost-effective if drug 
prices are reduced after patent 
expiry date.
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Research 
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Themes 
Public health effectiveness Adherence Feasibility/knowledge/ 
willingness to take PrEP
Risks/Risk Compensation Cost/cost  
effectiveness
PrEP within an 
Irish context 
1.  IRELAND: “PrEP is only available to 
be dispensed from one pharmacy, 
based in the Sexual Health clinic 
(GUIDE) at St. James’ Hospital and 
comes at the full price (around 
€400 for a month).
1.  Perception is likely to have 
penetrated Irish health service 
providers 
1.  PrEP Access in Europe Initiative: 
“It is possible for people to order 
generic Truvada® online to a UK 
address which is then redirected. 
Anecdotally, this passes through 
customs and VAT is applied before 
delivery with no further issues.”
2.  Frankis et al 2017 identified low 
levels of PrEP awareness across 
these Celtic nations. Euro Prep 
92% of sexually active MSM in 
Ireland are PrEP aware with 72% 
correctly knowledgeable.
1.  Offering PrEP in situations where 
the incidence of HIV is higher than 
3 per 100 person years is expected 
to be cost saving in many situations 
– HPSC input required.
2.  Transaction costs involved for liver, 
renal function tests, STI screening 
and regular HIV tests;
3.  Asked if PrEP should be free 
of charge & covered by health 
insurance, 62% of respondents said 
yes and 3% said no. 32% felt that 
people who use it should pay some 
of the cost.
PrEP  
& MSM 
1.  PrEP in the form of daily oral 
tenofovir(TDF)/emtricitabine 
(FTC) offers 90% reduction in HIV 
infection with adherence. The 
level of protection does not differ 
by age, sex, regimen & mode of 
acquiring HIV (rectal, penile or 
vaginal exposure)
1.  In one US study with extremely 
vulnerable black young MSMs 
used innovative methodology to 
generate adherence: no participant 
seroconverted to HIV while in 
the program, & despite very high 
risk factors in the population, 
adherence to PrEP was excellent;
2.  Concerns about adherence for 
MSM abating.
1.  Feasibility & high levels of 
awareness, knowledge and 
willingness to take PrEP are 
reported in multiple studies.
1.  The PROUD study, in the UK 
demonstrated that PrEP is feasible 
and effective and is not associated 
with significant changes in 
behavioural risk.
2.  Data from regular clinical practice 
in San Francisco indicated a 40% 
drop-off rate in condom use 
among PrEP users;
3.  Initial data from demonstration 
studies in MSM show that people 
who choose to take PrEP are those 
who report episodes of UAI & 
reported PrEP adherence is already 
high, with no subsequent risk 
compensation or change from their 
present condom use. 
4.  Among MSM, PrEP may become a 
choice among people at risk due to 
condomless anal sex, who feel that 
a daily pill may suit them better 
than condoms;
5.  Increases in STIs predate PrEP-in 
the UK rates of other STIs have 
been increasing for the last decade, 
driven largely by infections in HIV-
positive MSM but accompanied 
by a steady increase in syphilis, 
gonorrhoea and chlamydia in HIV-
negative MSM
1.  A mathematical modelling study 
on the cost-effectiveness of PrEP 
concluded that PrEP could prevent 
a significant number of infections 
among high-risk MSM (Desai 
2008). Another mathematical 
modelling study that evaluated 
the cost-effectiveness of PrEP 
in South Africa showed that 
the cost-effectiveness of PrEP 
relative to ART decreases rapidly 
as ART coverage increases beyond 
three times its coverage in 2010 
(Pretorius 2010).
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Themes 
Public health effectiveness Adherence Feasibility/knowledge/ 
willingness to take PrEP
Risks/Risk Compensation Cost/cost  
effectiveness
PrEP & Trans 1.  More information is needed 
about interactions between PrEP 
and hormone therapy used by 
transgender people;
2.  Because a relatively low percent of 
iPrEx participants were transgender 
women, there are insufficient data 
regarding PrEP safety, acceptability 
and efficacy for them. The iPrEx 
OLE study found that TDF/FTC 
concentrations were, on average, 
lower among transgender women 
compared with MSM. 
3.  Although suboptimal medication 
adherence is thought to explain 
some of the differences, the 
possibility that drug-drug 
interactions of exogenous 
feminizing sex hormones could 
alter intercellular FTC or TDF 
concentrations is under study. 
4.  Further studies of PrEP for 
transgender women are needed.
1.  Additional research is needed 
on how to support adherence, 
especially for adolescents, young 
women and transgender people;
1.  The iPrEx OLE project and 
the Partners Demonstration 
Project both show that PrEP 
implementation is feasible for 
different populations, including 
men and women.
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willingness to take PrEP
Risks/Risk Compensation Cost/cost  
effectiveness
PrEP & 
Women incl 
FSW
1.  Of 10 randomized PrEP trials 
reporting HIV outcomes, women 
were included in six studies and 
men in seven studies. PrEP was 
effective for both men and women. 
The level of protection does not 
differ by age, sex, regimen & mode 
of acquiring HIV (rectal, penile or 
vaginal exposure);
2.  Vaginal rings – potential for 
negative effects from sustained 
release forms;
3.  Potential risk of occult infection168 - 
variable distribution of antiretroviral 
drugs at exposed mucosal sites- 
PrEP does not get into the vaginal 
tissues as well as rectal tissues;
4.  Tenofovir DF as a single drug is 
supported by several studies for 
reducing risk from heterosexual 
(vaginal) sex;
5.  PrEP does not appear to affect 
the effectiveness of hormonal 
contraception;
6.  If PrEP is to be introduced FSWs it 
should only be done after adequate 
capacity building, awareness 
building, & within the trusted 
spaces of CSOs.
1.  Adherence among women has 
been high when open-label PrEP is 
provided;
2.  Additional research is needed 
on how to support adherence, 
especially for adolescents, young 
women and transgender people;
3.  Despite high levels of interest in 
PrEP in studies in Kenya & Sth India, 
concerns were expressed regarding 
the potential stigma associated 
with being recognized as someone 
who takes pills every day; privacy 
around the administration of 
PrEP; the possibility of being 
identified as being HIV positive; 
potential adverse effects of a new 
medication; and challenges with 
daily drug adherence;
4.  Long-acting agents that 
combine PrEP with hormonal 
contraceptives), may offer 
an additional motivation for 
adherence. Preclinical or early 
clinical studies are already under 
way for such strategies in women;
1.  Two placebo-controlled trials 
among women found significant 
barriers to uptake and adherence, 
including the social stigma of being 
identified as living with HIV because 
of taking the medication, cultural 
barriers and lack of family or social 
support. 
2.  The iPrEx OLE project and 
the Partners Demonstration 
Project both show that PrEP 
implementation is feasible for 
different populations, including 
men and women;
1.  Koechlin et al systematic review 
2016 found some sex workers 
raised concerns that their 
colleagues might see PrEP as an 
opportunity to forego condoms to 
increase earnings;
2.  Adolescent Girls/Young Women 
One study found 20% of young 
women expected to use condoms 
less frequently if they took PrEP
1.  A recent study in US designed 
to assess the predictors of HIV 
incidence among at-risk women 
found an annualized HIV incidence 
of 0.25%. This low level of HIV 
incidence would make it very 
difficult to conduct an efficacy 
trial to evaluate the benefit of 
PrEP for high-risk US women, 
because thousands would 
need to be enrolled in order to 
demonstrate efficacy. Given the 
low HIV incidence in US women, 
concerns have been raised about 
the chronic use of PrEP (given costs 
and toxicities) to prevent the rare 
likelihood that individual women 
would become HIV-infected – also 
issue for Ireland
PrEP  
& PWID
1.  Daily PrEP reduces risk by 70% with 
adherence. The level of protection 
does not differ by age, sex, regimen 
& mode of acquiring HIV (rectal, 
penile or vaginal exposure);
2.  PrEP is recommended for PWID by 
the American Centres for Disease 
control & the WHO;
1.  Poor adherence to ARV’s well 
documented for this KP;
2.  Once study found high level of 
adherence among prisoners & 
those who self-identify as high-risk 
(Martin, 2017);
3.  Adherence unclear in Bangkok 
study (further research)
1.  The iPrEx OLE project and 
the Partners Demonstration 
Project both show that PrEP 
implementation is feasible for 
different populations, including 
men and women;
2.  No interaction is expected 
between PrEP and heroin, 
methadone or methamphetamine.
1.  Shrestha (2017) study of 400 opioid 
dependent drug users, willingness 
to initiate PrEP was high and 
correlated with being at elevated 
risk for HIV, but anticipated higher 
risk behaviors in PWID group even 
while on PrEP.
168  An infection recognised by secondary manisfestation. In HIV when the virus establishes a beachhead at the 
site of mucosal transmission but does not become detectable as systemic infection.
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PrEP & hetero 
and/or sero-
discordant
1.  The level of protection does not 
differ by age, sex, regimen & mode 
of acquiring HIV (rectal, penile or 
vaginal exposure);
2.  The Partners Demonstration 
Project, showed an overall relative 
risk reduction of 96% in an interim 
analysis suggesting that the use of 
PrEP as a bridge in serodiscordant 
couples whereby the HIV-negative 
partner takes PrEP for protection 
while waiting for the HIV-positive 
partner to start treatment and 
minimize viral load is efficacious;
3.  PrEP has the potential to confer 
agency and control on HIV-
uninfected persons who heretofore 
have had to depend on willingness 
of partners to use condoms or 
ARV as their primary prevention 
strategies;
4.  1460 heterosexual HIV infections 
were estimated as acquired in the 
UK by migrants living in the UK or 
by those born in the UK but it is 
not yet clear how to identify the 
heterosexuals at risk who would 
benefit from PrEP;
1.  The iPrEx OLE project and 
the Partners Demonstration 
Project both show that PrEP 
implementation is feasible for 
different populations, including  
men and women.
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Outlier/
implementation 
Issues
1.  Provider training, linking PrEP to 
other health & community services 
recommended;
2.  PrEP as part of combination 
prevention; HIV testing; renal 
function testing; Hep B, adherence 
& pregnancy monitoring; 
3.  Active surveillance during PrEP 
scale-up is warranted;
4.  PrEP reshaping the sexual 
landscape eg online dating sites 
for MSM now offer an expanding 
variety of options for characterizing 
one’s HIV status - HIV-negative 
& on PrEP; HIV-positive & not on 
treatment; HIV-positive with an 
undetectable viral load and I don’t 
know;
5.  Governments may need to see a 
demonstration of partnerships 
to be convinced that it is easy to 
accommodate PrEP within existing 
reconfigured services (McCormack 
et al, 2016)
1.  Additional research is needed on 
how best to integrate PrEP with 
other services. PrEP is compatible 
with HIV testing, HIV treatment 
services, sexual health services, 
condom provision, behavioural 
counselling, harm reduction, 
empowerment programmes, 
contraceptive services, 
reproductive health services and 
primary health care. For e.g., PEP 
started after recent exposure to 
HIV can be transitioned to PrEP 
after 28 days if there is continuing 
substantial risk. 
2.  How best to integrate PrEP into 
existing services is not known and 
may vary in different settings;
3.  The CDC released clinical 
guidelines in May 2014 state that 
data on the efficacy and safety 
of PrEP for adolescents are 
insufficient, & the risks & benefits 
of PrEP for adolescents should be 
weighed carefully in the context of 
local laws and regulations.
1.   A compromise in PrEP messaging 
suggested by Ca´ceres CF et al 2015 
could include stating 1) PrEP does 
not intend to replace condoms 
but to add to condom protection; 
2) PrEP does not protect against 
bacterial STIs; 3) PrEP can become 
especially useful for those who 
have difficulties with consistent 
condom use, as long as it is taken 
as prescribed.
1.  Across all trials, PrEP was provided 
in the context of a package of HIV 
prevention interventions, including 
regular HIV testing and counselling, 
provision of condoms, screening 
and treatment for STIs, adherence 
counselling and other options 
relevant to the study population, 
such as access to contraception 
for women and methadone 
maintenance therapy for people 
who inject opioids – transaction 
costs?
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Appendix C – List of Participants 
 
Face-to-face interviews:  
Research Participant Contribution Status
Dr. Fiona Lyons
Clinical Lead in Sexual Health
HSE Sexual Health and Crisis Pregnancy Programme
Participated
Dr. Paddy Mallon
Infectious Disease Specialist
Mater Misericordiae University Hospital, Dublin
Participated
Dr. Jennifer Kieran
Consultant in Clinical Pharmacology and Therapeutics  
& Adjunct Professor in Clinical Pharmacology and Therapeutics**
St James Hospital & Trinity College, Dublin
Participated
Dr. Anne Marie Liddy
Specialist Registrar in General Medicine and Clinical Pharmacology  
and an Assistant Professor within the Department of Pharmacology and 
Therapeutics, Trinity College
Trinity College, Dublin
Participated
Dr. Derval Igoe
Specialist in Public Health Medicine
Health Protection Surveillance Centre
Participated
Ms. Siobhán O’Dea
Manager
Gay Men’s Health Service
Participated
Lorraine Gallagher
Development Specialist
Irish Aid Programme
Dept of Foreign Affairs and Trade
Participated
Andrew Leavitt
Activist
ACT UP Dublin
Participated
Ms. Helen Deely
Head 
Sexual Health & Crisis Pregnancy Programme
Dr. Fiona Lyons on behalf  
of SH&CPA
Ms. Breda Gahan
Global HIV and AIDS Programme Advisor
Dochas and Concern Worldwide, Dublin
Participated
Dr. Derek Freedman MD, FRCPI
Specialist in Sexual Health, STD and HIV
STD Clinics, Dublin
Unavailable to participate
Dr. Austin M O’Carroll 
General Practitioner 
Mountjoy St Medical Practice, Dublin
Participated
Dr. Eamon Keenan
Consultant Psychiatrist in Substance Misuse & Clinical Leader
The HSE National Addiction Services, Dublin
Unavailable to participate
Dr. Cillian De Gascun
Consultant Virologist & Laboratory Director National Virus Reference 
Laboratory, University College Dublin
Participated
Dr. Gabriel Fitzpatrick
Department of Public Health, HSE East
Did not respond to invitation  
to interview
8
7
-
8
8
Telephone interviews:
Research Participant Participant Status
Alex Phillips
Campaign & Parliamentary Officer
Terrence Higgins Trust, London
Participated
Denis Busobozi
HIV Advisor
Embassy of Ireland, Uganda
Participated by email
Maureen Ndawana
African Policy Network 
Unavailable for interview
International Network of People Who Use Drugs Unavailable for interview
Kate McGrew
Coordinator
Sex Workers Alliance Ireland, Dublin
Participated
AIDS West, Galway Did not respond to invitation  
to interview
Deirdre Seery 
CEO
Sexual Health Centre Cork
Participated
Richard Carson
CEO
ACET Ireland, Dublin
Participated by email
Anne Mason
Manager
GOSHH (Gender Orientation Sexual Health HIV), Limerick
Did not respond to invitation  
to interview
Dr. Helen Tuite
Specialist in Infectious Diseases
University Hospital, Galway
Did not respond to invitation 
 to interview
Catherine Fleming
Clinical Lecturer
Dept of Medicine NUI, Galway
Did not respond to invitation  
to interview
Professor Mary Horgan
Dean
School of Medicine, University College Cork 
Did not respond to invitation  
to interview
James O’Connor
HIV Advocacy and Learning
Participated
Dr. Joe Barry
Professor & Head of Department Professorial Chair in Population Health 
Medicine
Trinity College, Dublin
Unavailable for interview
Miriam Moriarty
Chief II Pharmacist
Genito-Urinary Medicine and Infectious Diseases
St James’s Hospital
Participated by email
VHI Participated by email
Laya Health Care No response to query 
received.
Dean Street Clinic, London (invitation to interview with follow-up calls) Did not respond to invitation  
to interview
New York Clinics Did not respond to invitation  
to interview
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Research Participant Contribution Status
MSM organised by Outhouse and GHN 11 men participated
Positive Now (convened on behalf of the study by Dr. Erin Nugent) 4 men/2 women
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HIV IRELAND
70 ECCLES STREET
DUBLIN 7
IRELAND
WWW.HIVIRELAND.IE
INFO@HIVIRELAND.IE
+353 (0) 1 873 3799
HIV Ireland is a registered charity operating at local, 
National and European level. The principal aim of the organisation 
is too improve, through a range of support services, conditions 
for people living with HIV and AIDS and/or Hepatitis, their families 
and their caregivers while further promoting sexual health in the 
general population.
Our mission and vision is to 
contribute towards a signifi cant 
reduction in the incidence and 
prevalence of HIV in Ireland and 
towards the realisation of an AIDS-
free generation by advocating 
for individuals living with HIV, 
preventing new HIV infections 
and combating HIV-related 
stigma and discrimination.
Since 1987 HIV Ireland has 
been pioneering services in sexual 
health education and promotion, 
and has consistently engaged 
in lobbying and campaigning in 
the promotion of human rights. 
Our approach broadly refl ects a 
harm minimisation model which 
emphasises practical rather 
than idealised goals. In relation 
to practical service provision 
we currently operate under 
two headings:
Community Support
· Counselling
· 1-1 Support
· Advocacy
· Community Outreach Work
· HIV & STI Community Testing
·  Capacity Building with People 
Living with HIV
 
Prevention, Education & Training
·  One day workshops on HIV, 
STI’s and Sexual Health
·  Sexual Health Training for Trainers 
Programme 
(Let’s Talk About… Safer Sex)
·  Free Condom Service 
(Just Carry One Campaign)
·  Social Media work 
and campaigning
·  Network Involvement
